



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Targeted next generation sequencing makes new molecular diagnoses and expands genotype-phenotype relationship in Ehlers-Danlos syndrome

Citation for published version:

Weerakkody, R, Vandrovcsa, J, Kanonidou, C, Mueller, M, Gampawar, P, Ibrahim, Y, Norsworthy, PJ, Biggs, J, Abdullah, A, Ross, D, Black, H, Ferguson, DJP, Cheshire, N, Kazkaz, H, Grahame, R, Ghali, N, Vandersteen, A, Pope, FM & Aitman, TJ 2016, 'Targeted next generation sequencing makes new molecular diagnoses and expands genotype-phenotype relationship in Ehlers-Danlos syndrome', *Genetics in Medicine*. <https://doi.org/10.1038/gim.2016.14>

Digital Object Identifier (DOI):

[10.1038/gim.2016.14](https://doi.org/10.1038/gim.2016.14)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Genetics in Medicine

Publisher Rights Statement:

Author's final peer-reviewed manuscript as accepted for publication

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Genetics in Medicine

Targeted next generation sequencing makes new molecular diagnoses and expands genotype-phenotype relationship in Ehlers-Danlos syndrome.

--Manuscript Draft--

Manuscript Number:	GIM-D-15-00205R2
Article Type:	Original Research Article
Section/Category:	Clinical Genetics
Keywords:	Ehlers-Danlos syndrome, High-throughput DNA sequencing, Hereditary Disorders of Connective Tissue, Aortic diseases, Collagen
Corresponding Author:	RUWAN ALWIS WEERAKKODY, MA, MRCS Imperial College London London, UNITED KINGDOM
First Author:	RUWAN ALWIS WEERAKKODY, MA, MRCS
Order of Authors:	RUWAN ALWIS WEERAKKODY, MA, MRCS Jana Vandrovcova, PhD Christina Kanonidou, MSc, MBBS Michael Mueller, PhD Piyush Gampawar, MSc, MBBS Yousef Ibrahim, MBBS Penny Norsworthy, BSc Jennifer Biggs, MSc Abdulshakur Abdullah, BSc. David Ross, BSc. Holly A Black, PhD David Ferguson Nicholas J. Cheshire, MD, FRCS Hanadi Kazkaz, FRCP, PhD Rodney Grahame, FRCP, PhD Neeti Ghali, MRCP, PhD Anthony Vandersteen, MRCP, PhD F Michael Pope, FRCP, PhD Timothy J. Aitman, FRCP, FMedSci, PhD
Manuscript Region of Origin:	UNITED KINGDOM
Abstract:	<p>Purpose: Ehlers-Danlos syndrome (EDS) comprises a group of overlapping hereditary disorders of connective tissue with significant morbidity and mortality, including major vascular complications. We sought to identify the diagnostic utility of a next-generation sequencing (NGS) panel in a mixed EDS cohort.</p> <p>Methods: We developed and applied PCR-based NGS assays for targeted, unbiased sequencing of 12 collagen and aortopathy genes to a cohort of 177 unrelated EDS patients. Variants were scored blind to previous genetic testing and were then compared to results of previous Sanger sequencing.</p>

Results:

Twenty-eight pathogenic variants in COL5A1/2, COL3A1, FBN1 and COL1A1, and four likely pathogenic variants in COL1A1, TGFB1/2 and SMAD3 were identified by the NGS assays. These included all previously detected single nucleotide and other short pathogenic variants in these genes, and seven newly detected pathogenic or likely pathogenic variants leading to clinically significant diagnostic revisions. Twenty-two variants of uncertain significance (VUS's) were identified, seven of which were in aortopathy genes and require clinical follow-up.

Conclusion:

Unbiased NGS-based sequencing made new molecular diagnoses outside the expected EDS genotype-phenotype relationship and identified previously undetected clinically actionable variants in aortopathy susceptibility genes. These data may be of value in guiding future clinical pathways for genetic diagnosis in EDS.

Targeted next generation sequencing makes new molecular diagnoses and expands genotype-phenotype relationship in Ehlers-Danlos syndrome.

Ruwan A Weerakkody^{*1,2,3,4}, Jana Vandrovcova^{*2}, Christina Kanonidou^{2,4,5}, Michael Mueller², Piyush Gampawar^{2,4}, Yousef Ibrahim², Penny Norsworthy², Jennifer Biggs², Abdulshakur Abdullah², David Ross^{2,4}, Holly A Black⁴, David Ferguson⁶, Nicholas J Cheshire³, Hanadi Kazkaz⁵, Rodney Grahame⁵, Neeti Ghali¹, Anthony Vandersteen^{1,a}, F Michael Pope¹, Timothy J Aitman^{2,4}

*Equal contribution

1. National Ehlers-Danlos Syndrome Diagnostic Service, Northwick Park Hospital, UK; 2. Department of Medicine / Institute of Clinical Sciences, Imperial College London, UK; 3. Vascular Unit, St Mary's Hospital, Imperial College London, UK; 4. Institute of Genetics and Molecular Medicine, University of Edinburgh, UK; 5. Department of Rheumatology, University College Hospital, London, UK; 6. Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, UK.

a. Present address for AV: Maritime Medical Genetics Service, IWK Health Centre & Dalhousie University, Nova Scotia, Canada

Correspondence to:

Prof Timothy J Aitman, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, Crewe Road South, Edinburgh EH4 2XU, UK;

tim.aitman@ed.ac.uk

+44 (0) 131 651 8021

ABSTRACT

Purpose:

Ehlers-Danlos syndrome (EDS) comprises a group of overlapping hereditary disorders of connective tissue with significant morbidity and mortality, including major vascular complications. We sought to identify the diagnostic utility of a next-generation sequencing (NGS) panel in a mixed EDS cohort.

Methods:

We developed and applied PCR-based NGS assays for targeted, unbiased sequencing of 12 collagen and aortopathy genes to a cohort of 177 unrelated EDS patients. Variants were scored blind to previous genetic testing and were then compared to results of previous Sanger sequencing.

Results:

Twenty-eight pathogenic variants in *COL5A1/2*, *COL3A1*, *FBN1* and *COL1A1*, and four likely pathogenic variants in *COL1A1*, *TGFBR1/2* and *SMAD3* were identified by the NGS assays. These included all previously detected single nucleotide and other short pathogenic variants in these genes, and seven newly detected pathogenic or likely pathogenic variants leading to clinically significant diagnostic revisions. Twenty-two variants of uncertain significance (VUS's) were identified, seven of which were in aortopathy genes and require clinical follow-up.

Conclusion:

Unbiased NGS-based sequencing made new molecular diagnoses outside the expected EDS genotype-phenotype relationship and identified previously undetected clinically actionable variants in aortopathy susceptibility genes. These data may be of value in guiding future clinical pathways for genetic diagnosis in EDS.

Key words

Ehlers-Danlos syndrome, High-throughput DNA sequencing, Hereditary Disorders of Connective Tissue, Aortic diseases, Collagen

INTRODUCTION

Ehlers-Danlos syndrome (EDS) is a group of overlapping hereditary disorders of connective tissue (HDCT).[1, 2, 3] Predominant clinical phenotypes include skin fragility, easy bruising and joint hypermobility.[2] Due to generalised connective tissue fragility, blood vessels and internal organs may also be affected to a variable extent. Vascular EDS patients can present as early as the first two weeks of life with aneurysm or rupture of large blood vessels, or sudden spontaneous rupture of the bowel or other intra-abdominal organs.[2, 3, 4]

EDS is classified clinically by the 1997 Villefranche nosology.[1] The three major groups are classical, vascular and hypermobility type EDS, whilst others, including kyphoscoliosis, dermatosparaxis, arthrochalasia are extremely rare.[1, 2] The central pathological abnormality affects collagen packing or stability, mechanisms traditionally based upon certain microscopic, biochemical and genetic abnormalities in collagen types I, III, and V. Most classical EDS cases are caused by mutations in one of two genes encoding collagen type V (*COL5A1*, *COL5A2*); vascular EDS is largely caused by mutations in *COL3A1*, encoding collagen type III, whilst the genetics of hypermobility type EDS remains largely unresolved and is predicted to be heterogeneous.[2, 4] A number of other genes encoding extracellular matrix proteins (*PLOD1*, *CHST14*, *FKBP14*; *RIN2*; *PRDM5*, *ZNF469*, *B4GALT7*, *SLC39A13*) are reported as causes of additional very rare EDS presentations.[2, 4] Because of phenotypic heterogeneity and clinical overlap between EDS types, clinical evaluation alone is often not definitive and even after genetic testing, the majority of EDS cases remain without a molecular diagnosis.[1, 2]

Next generation sequencing (NGS) technologies offer the potential for genetic testing in a range of disorders including EDS.[5] Using a newly developed NGS-based panel, we screened a mixed cohort of EDS patients for variants in key collagen genes and certain other genes known to cause EDS or related connective tissue disorders. We sought to ascertain whether this approach would increase the proportion of genetic diagnoses and improve understanding of the relationship between genotype and phenotype in EDS by

comparing the results obtained by NGS with previous genetic testing of individual genes by Sanger sequencing.

MATERIALS AND METHODS

Selection of cases with Ehlers-Danlos syndrome

177 unrelated patients with suspected EDS referred by specialist (tertiary) clinicians to the National EDS Diagnostic Service (London, UK) were recruited to the study. The patients were predominantly female (67%) and Caucasian (89%). The mean age of the cohort was 33.6 years (range 2-78). Since the service studied complex EDS phenotypes and because of their prognostic importance, patients with vascular complications were preferentially recruited to the study. Clinical diagnoses upon first interview, based only on clinical features, were as follows: classical EDS (or overlapping syndrome) 12%, vascular EDS (or overlapping syndrome) 12%, EDS hypermobility type or benign joint hypermobility syndrome (BJHS) 43%, kyphoscoliotic EDS 2%. 7% of cases had a phenotype overlapping multiple EDS types, not falling into one specific EDS type and will be described hereafter as Complex EDS. 24% of cases had features predominantly outside the EDS spectrum, here termed "Other hereditary disorder of connective tissue (HDCT)." This term was used for patients with non-specific features of HDCT, where criteria for a specific EDS type were not adequately fulfilled and the patient did not have an arterial complication (for example osteogenesis imperfecta, myopathies). A further group not falling into a specific EDS type but with prior history of arterial complication (defined as one or more of: aortic or peripheral arterial aneurysm, dissection or rupture, cerebral aneurysm/subarachnoid haemorrhage) was designated "Other HDCT (vascular)".

Clinical categorisation was based upon 1997 Villefranche criteria[1] by specialist EDS clinicians (FMP, AV, NG – combined experience 51 years). 76 relatives were phenotyped and recruited to the study for segregation analysis. All study subjects were recruited

according to Ethics Protocol Reference 11/LO/0883 (West London Research Ethics Committee).

Characterisation of clinical, biochemical, histological and ultrastructural phenotype

Phenotypic data were derived from clinical notes, including diagnostic scores (according to Beighton system, Villefranche criteria, Ghent nosology and Sillence criteria), [1, 6] light and electron microscopy (LM, EM) and collagen protein analysis carried out at the National EDS Diagnostic Service, London. Genetic testing results (by conventional Sanger sequencing) in the UK National Health Service were recorded for comparison.

Skin biopsies taken from patients' upper inner arm were used for Collagen protein analysis and microscopy. Fibroblasts were cultured from skin biopsies, with collagen labelling and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis performed as described. [7] LM: Dermal tissue blocks stained with Haematoxylin & Eosin / Elastin Van Gieson, were assessed to determine changes in dermal thickness and collagen: elastin ratio. EM: skin biopsies were placed directly into 4% glutaraldehyde in 0.1M phosphate buffer and processed for routine EM as described previously. [8] Thin sections (stained with uranyl acetate and lead citrate) were examined for ultrastructural abnormalities of collagen fibril size and arrangement and appearance of fibroblast endoplasmic reticulum.

DNA extraction and targeted exon sequencing

Saliva samples were collected using the Oragene DNA kit (Genotek, Ontario, Canada). DNA from whole blood samples was extracted using the QIAamp DNA Blood Midi kit (Qiagen, Venlo, Netherlands). Two NGS assays were designed, to sequence the exons and exon-intron boundaries of genes commonly associated with EDS and overlapping phenotypes: (1) Collagen NGS panel: 375 primer-pairs for *COL1A1*, *COL1A2*, *COL3A1*, *COL5A1* and *COL5A2*; and (2) Aortopathy NGS panel: 363 primer-pairs for *FBN1*, *TGFBR1*, *TGFBR2*, *MYH11*, *ACTA2*, *SMAD3* and *MYLK* (Tables S1 & S2; Supplementary materials). Both NGS panels were used on every patient.

Multiplex PCR was performed using the Access Array (Fluidigm, South San Francisco, USA) in batches of 47 test samples and one negative control (water blank) as described.[9] Ninety-six purified samples were pooled and sequenced on the MiSeq sequencer (Illumina, San Diego, USA) generating 150bp paired-end reads.

Read mapping, variant calling and annotation

The quality of sequencing reads was assessed with FastQC.[10] Reads were mapped to the GRCh37/hg19 human reference sequence using BWA-MEM v0.7.2.[11] Sequence reads were realigned around insertions/deletions and base call quality scores recalibrated with GATK v2.6-5.[12] Single-nucleotide variants (SNVs) and short insertions/deletions (up to 20 nucleotides) were called with GATK UnifiedGenotyper. Variants were hard filtered to achieve minimum coverage at a variant of ≥ 100 reads and allele balance > 0.25 . Variant annotation was carried out with ANNOVAR version 2013aug23[13]. Reference transcripts of genes are shown in Table S3.

Pathogenicity assignment

Synonymous variants, intronic variants located outside exon/intron boundaries and SNVs with minor allele frequency $> 0.1\%$ in 1000 genomes project (phase 2 release) or the NHLBI exome sequencing project data-sets (as available in 2013Aug23 version of Annovar) were excluded from further analysis. Splice site-disrupting variants, nonsense and frameshift coding variants with allele frequency $< 0.1\%$ were considered pathogenic. Substitutions of glycine residues at GlyXY repeats within collagen triple helical domains were considered pathogenic, as well as other variants previously reported as pathogenic in established variant databases (LOVD[14] and HGMD[15]) unless biochemical (collagen protein analysis), phenotype and/or segregation data suggested otherwise. Missense variants were classified according to American College of Medical Genetics and Genomics (ACMG) guidelines [16] with the special additional case of Glycine-substitutions in Collagen helical domains, which have the effect of disrupting helix formation and are therefore generally considered to be pathogenic owing to loss of function conferred by these variants. All other

variants were classified as variants of uncertain significance (VUS's) which were further categorised, based on available evidence, according to ACMG criteria.[16] Filtered variants were validated by Sanger sequencing and submitted to the LOVD database.[14] A single false positive variant was found in exon 1 of *SMAD3* (ID 382) and was removed from further analysis.

Statistical analysis

χ^2 and Fisher's exact tests were used to test for significant differences in categorical variables between individuals in different genotype or phenotype groups. The Mann-Whitney test was used to assess statistical differences between in silico prediction scores.

RESULTS

Clinical phenotype

Table 1 summarises the clinical phenotype spectrum tabulated by initial clinical diagnosis. There was wide phenotypic heterogeneity within each diagnostic group, with patients frequently possessing overlapping Villefranche criteria suggestive of more than one diagnostic category. Eighteen patients, distributed across diagnostic groups had marfanoid features (of which two had Ghent Marfan systemic scores ≥ 7). Four patients diagnosed as Other HDCT had signs consistent with osteogenesis imperfecta (OI) or an overlapping phenotype.

Results of previous genetic testing by Sanger sequencing

The traditional route to genetic testing by Sanger sequencing is phenotype-driven, usually by sequencing one or two of the most likely causative genes, based on clinical and laboratory data.

The frequency of a detected pathogenic variant in the anticipated gene was 33% for cases initially diagnosed as classical EDS or an overlapping phenotype (7 pathogenic variants in *COL5A1/2* of 21 patients tested) although the frequency increased to 58% if those with

overlapping classical/hypermobility phenotypes were excluded. The frequency of pathogenic variants in *COL3A1* in patients initially diagnosed as vascular EDS was 50% (11 of 22 patients tested). In the 4 patients with a clinical phenotype of EDS/OI the frequency of *COL1A1/2* pathogenic variants was 75% (Table 2). Outside of the anticipated gene, further testing revealed a specific pathogenic DNA variant in only 7.8% (12/155). In addition to short variants (SNV's and short indels) in collagen genes that were considered pathogenic, a complex rearrangement was identified causing complete allelic loss of *COL3A1* & *COL5A2* (ID 444) and pathogenic variants were identified in *TNXB* (ID 67), *FBN2* (ID 1125) and *FKBP14* (*homozygous*, ID 822) (Table S4). Pathogenic or likely pathogenic variants were also identified in three other patients: in *FBN1* (ID 66), *TGFBR1* (ID 706), and *SMAD3* (ID 382) (Table S4). Several incidental genetic abnormalities not considered to be contributory to EDS phenotype were also observed: a heterozygote VUS in *TNXB* (ID 79), *FLNA* variant (ID 538) and 0.1Mb polymorphic deletion identified by karyotyping (ID 801) (Table S4).

Targeted NGS sequencing

Amplicons of the Collagen panel achieved a mean coverage of 602x with 95.0% bases covered above 100x, whilst those of the Aortopathy panel achieved a mean coverage of 926x per amplicon with 97.4% targeted bases covered by 100 reads or more.

NGS sequence data were analysed blind to previous genetic testing. The mean number of variants called per sample was 12.7 (range 5- 25) and 28.7 (range 9-51) with the Collagen and Aortopathy NGS panels, respectively. After filtering of variants by allele frequency and variant type, a total of 28 pathogenic variants, four likely pathogenic variants and 22 VUS's were identified (Tables 3 and 4).

Pathogenic variants identified by NGS

In the 21 cases categorised initially as classical EDS or overlapping phenotypes, we identified pathogenic variants in nine cases (41%): seven in the *COL5A1* or *COL5A2* genes and two in *COL3A1* (Table 3). The first of these two (ID 417) had overlapping features of

classical, hypermobility and vascular EDS; the second (ID 636) had convincing clinical features entirely consistent with classical EDS (Table S5). In the 22 patients diagnosed initially as vascular EDS, 11 had pathogenic variants in *COL3A1*, whilst one with overlapping features of vascular and classical EDS had a pathogenic variant in *COL5A1* (functional corroboration was not possible as the patient declined skin biopsy - ID 1088, Table S5). One of the patients with an initial diagnosis of hypermobility type EDS (ID 824) carried a pathogenic *COL5A1* variant (Tables 3 and S5). Of the patients with an initial diagnosis of other HDCT, three had pathogenic variants in *COL1A1* (all three diagnosed clinically with EDS/OI overlap) and a further three had pathogenic variants in *FBN1* (Table 3; Tables S5, S6). Table S7 shows the phenotype details of cases with no identified variants.

Likely Pathogenic Variants and Variants of Uncertain Significance (VUS) identified by NGS

Of the 26 VUS's identified, 22 were dispersed amongst either hypermobile or other HDCT patients (Table 4). These included variants in *COL1A1*, *TGFBR1*, *TGFBR2* and *SMAD3*, which we categorised as likely pathogenic (Tables 4 and S6). One of these patients (ID 893) carried a helical domain Arg>Cys variant in *COL1A1*, a number of which have been shown to be pathogenic in previous reports. [23]

Although two particular variants had previously been reported as pathogenic, we classified these as VUS's in our patients (Table 4 & S5): a *COL1A2* variant[17] (ID 629) due to non-segregation in first degree relatives and *COL3A1* C-propeptide variant[18] (ID 655) because of lack of clinical or biochemical corroboration in the index case or her first-degree relative who also carried the variant. Two hypermobility EDS patients were each found to have two separate VUS's: ID 38 in *COL3A1* and *COL5A2*; ID 39 in *COL1A2* and *COL3A1* (Table 4; and Table S4). One patient initially categorised clinically as classical EDS (ID 636) carried an intronic VUS in *COL5A2*, but also carried a pathogenic *COL3A1* variant (Table S4 & S5).

In silico predictions of missense variants detected by NGS

The majority of missense pathogenic variants detected by NGS had in silico predictive scores of, or close to 1.0 whereas the scores for VUS's were more variable and lower (mean score = 0.70, $p < 0.0001$ for SIFT; 0.67, $p = 0.0005$ for Polyphen2; 0.89, $p = 0.006$ for MutationTaster; 0.60, $p < 0.0001$ for MutationAssessor); a similar pattern was observed for predictions of evolutionary conservation (Table S8). The two variants that were previously reported as pathogenic but that we classified as VUS's (IDs 629 and 655) had high in silico prediction scores (Table S8), but lacked pathological or segregation data to support pathogenicity. In addition a helical Arg>Cys variant in *COL1A2* (ID 1151) and three other VUS's in *COL1A1*, *COL3A1* and *COL5A1* (IDs 39, 824, 828) also had high in silico predictions (Table S8). In the Aortopathy panel, three variants, in *SMAD3* (ID 382), *TGFBR2* (ID 814), and *TGFBR1* (ID 706) also had high in silico predictive scores: these three variants were in functionally important domains and the clinical phenotypes of these patients strongly suggested pathogenicity of the variants (Tables S6 & S8).

Clinical, genetic and pathological correlates of collagen gene variants

Most pathogenic DNA variants in collagen genes were associated with a corresponding collagen protein abnormality on SDS-PAGE but protein abnormalities were much less common in VUS's (81.8% vs. 11.1%; $p = 0.006$). A similar difference in light and electron microscopy abnormalities was observed when comparing pathogenic variants with VUS (76.9% vs. 21.1%; $p = 0.02$). There was no significant difference ($p > 0.05$) in the frequency of presenting vascular complications between pathogenic *COL3A1* variants (38%) and those with variants of other genes or when compared with mutation-negative cases (31%) (Table S9). There was also no significant difference in Beighton score based on gene or variant-type ($p > 0.05$).

Comparison with Sanger sequencing

All of the 22 short pathogenic variants in the collagen genes and the pathogenic variants in *FBN1* and *SMAD3* that were identified by previous Sanger sequencing were also identified by the NGS panels (Figure 1A). Furthermore, the NGS panels newly identified seven

pathogenic or likely pathogenic variants and 18 VUS's that had not been detected by phenotype-guided Sanger sequencing (Tables 3 & 4; Figure 1A). The Collagen NGS panel identified four unexpected pathogenic or likely pathogenic variants in genes that had not been selected for Sanger sequencing: first, a *COL3A1* variant (ID 636), in a patient previously diagnosed as classical EDS on the basis of clinical phenotype and the presence of an intronic, possible splice-disrupting *COL5A2* variant (c.1402-10T>G); second, a loss of function *COL5A1* variant in a patient with overlapping features of vascular and classical EDS phenotype (ID 1088) for whom only *COL3A1* sequencing had been undertaken; third, an Arg>Cys variant in the helical domain of *COL1A1* in a patient with a predominant hypermobility trait with fractures (ID 893) and finally a helical Glycine disrupting *COL5A1* variant in a patient with a predominant hypermobility trait (Beighton score 9/9) but minimal skin hyperextensibility (ID 824) (for details see Tables 3 and S5). In addition, six missense variants were identified with maximal or near maximal in silico prediction scores for pathogenicity (Table S8). These variants did not meet ACMG criteria for pathogenicity or likely pathogenicity and were therefore classified as VUS's. The Aortopathy NGS panel identified four new variants not previously detected by clinical or genetic investigation, in *FBN1*, *TGFBR1*, and *TGFBR2*: two were pathogenic variants of *FBN1* (IDs 766 & 378, both with initial diagnosis of "Other HDCT"), one was a likely pathogenic variant (*TGFBR2*, ID 814, with an initial clinical phenotype of hypermobility type EDS), and the fourth variant we classified as uncertain significance (*TGFBR1*, ID 475 with an initial clinical phenotype of "Other HDCT") (Table S6).

DISCUSSION

To our knowledge, this is the first report of the use of NGS to sequence a panel of relevant collagen and aortopathy genes in a large mixed cohort of patients with EDS or overlapping HDCT.

Our NGS panel was able to detect all previously identified short pathogenic variants in collagen and aortopathy genes and, in addition, newly identified seven pathogenic or likely

pathogenic variants in *COL1A1*, *COL3A1*, *COL5A1* (2 cases), *TGFBR2*, and *FBN1* (2 cases), leading to new diagnoses in these patients. Of 18 newly detected VUS's, a significant proportion had partial evidence of pathogenicity, based on previous reports, clinical phenotype and in silico prediction score, including three in aortopathy genes (*TGFBR1* and *TGFBR2*) and four in *COL3A1* which, if shown to be pathogenic, alter clinical prognosis and management because of the associated high risk of arterial aneurysm, rupture and/or bowel perforation.

Pathogenic collagen variants did not always correlate with the expected phenotype. In two patients we found pathogenic *COL3A1* variants associated with a clinical phenotype of classical or overlapping classical EDS, one of whom (ID 636) also had an intronic *COL5A2* variant, possibly splice site disrupting, which could also contribute to his phenotype.

Classical EDS is usually associated with pathogenic variants in *COL5A1/2*, but has rarely been associated with those in *TNXB*, *COL1A1* or *COL3A1*. [19, 20] Pathogenic *COL3A1* variants are normally considered diagnostic of vascular EDS, with reduced life expectancy from arterial and bowel complications. [4,21]

Since previous vascular EDS series have been mostly selected by clinical criteria (Villefranche) along with collagen type III protein deficiency or pathogenic *COL3A1* variants, the frequency of other connective tissue gene variants in clinical vascular EDS phenotypes is unknown. [4, 21] One of our patients clinically classified as having features predominantly of vascular EDS (ID 1088) showed a Leu1055X variant of *COL5A1*. One pedigree with a pathogenic *COL5A1* variant segregating with a vascular EDS phenotype including arterial ruptures has been recently reported (LOVD ID AN004203). [14,22] A further patient (ID 824) for whom a pathogenic *COL5A1* variant was found, had an initial diagnosis of Hypermobility type EDS on account of extensive hypermobility, soft but not hyper-extensible skin and family history of sudden cardiac death in a second degree relative; functional corroboration was not possible for this patient as they were lost to follow-up. As far as we are aware such a phenotypic pattern has not been observed with a pathogenic *COL5A1* variant, probably

because *COL5A1* sequencing to date has mostly been carried out in phenotypically classical cases.[2,3,19]

Nine VUS's with high in silico prediction scores or other evidence for pathogenicity were observed. These included one Arg>Cys variant within the helical domain of *COL1A2* (ID 1151, p.Arg1338Cys) (Tables S4 & S5). Arg>Cys variants at helical locations in *COL1A1* have been reported previously as predisposing to arterial fragility and other phenotypes (Table S5).[23] Although the *COL1A2* variant may be pathogenic, little evidence exists at the present time to establish its pathogenicity.

We also observed four variants in aortopathy genes *TGFBR1*, *TGFBR2*, *SMAD3* for which there was moderate or supporting evidence of pathogenicity (Table S6). Three of these were considered to be likely pathogenic: two in the functionally active kinase domains of *TGFBR1* (ID 706) and *TGFBR2* (ID 814) known to be associated with the majority of Loeys-Dietz syndrome variants to date,[24] and the third adjacent to the MH2 domain of *SMAD3* (ID 382), which is known to regulate TGF-beta signalling.[25] Coronary artery dissection (seen in our patient) and other vascular complications have previously been caused by *SMAD3* variants.[26] The fourth variant, in *TGFBR1* (ID 475) was in a patient with Other HDCT, bone fragility and a systolic murmur (and normal *COL1A1/2*). This variant was reported previously as a VUS associated with bicuspid aortic valve,[27] and bone fragility is a recent addition to the LDS clinical spectrum,[28] so this variant may underlie some of our patient's features but the evidence is less clear.

We re-classified two variants with high in silico prediction scores as VUS's, though previously reported as pathogenic: The *COL1A2* Arg708Glu variant detected in ID 629 was reported previously in a Marfanoid patient, [17] but segregation analysis revealed hypermobility in all of the patient's seven offspring, hypermobility in her (unrelated) husband, multiple fractures in one of the two offspring who carried the variant and no fractures in the remaining five offspring, leading us to classify this variant as a VUS. The *COL3A1*

p.Lys1313Arg variant detected in ID 655 has been previously reported in two unrelated patients with vascular EDS.[18] However, collagen microscopy and biochemistry were normal in the patient, neither the patient nor her sister, who also carried the variant, had features of vascular EDS and structural studies indicated that the variant was unlikely to impair C-propeptide-mediated helical winding.[29,30]

Consistent with previous reports, we observed significant phenotypic overlap between our EDS diagnostic categories and other HDCT as well as overlap amongst patients with pathogenic variants in individual causative genes.[2,3,6,19,20,22,23] These factors point to the limitations of phenotype-driven genetic testing of individual candidate genes. The NGS approach presented here permits wider genetic testing than is possible with traditional Sanger sequencing, allowing more comprehensive genetic diagnosis. This led to new and revised diagnoses of patients in our cohort and widened the phenotypic spectrum ascribed to individual genes.

Based on our previous experience and taking the results from this study as a whole, some general recommendations can be made. For cases with phenotypes overlapping classical or vascular EDS, the yield of pathogenic variants is high in the normally associated gene (*COL3A1*, *COL5A1*, *COL5A2*) and occasionally one may identify pathogenic variants in another fibrillar collagen gene. Cases of uncomplicated EDS-Hypermobility type with no family history of vascular complication had a low yield of pathogenic variants and a large number of VUS's (most of which will not be fed back): NGS panel testing for such cases is unlikely to be diagnostic. Conversely, potential connective tissue cases with a history of vascular complication, marfanoid features, or with a significant family history should undergo NGS panel testing for collagen and aortopathy genes, as our results indicate a reasonable likelihood of identifying pathogenic variants in one of these genes. Similarly, cases of EDS or other HDCT overlapping with osteogenesis imperfecta should also undergo collagen gene testing to exclude pathogenic *COL1A1* or *COL1A2* variants.

The interpretation of missense variants includes correlation with the complete clinical phenotype. In keeping with ACMG guidelines, we classify variants that are supported by some evidence of pathogenicity (e.g. high in silico scores and presence in functionally active domains) or associated with clinical features such as aortopathy as “likely pathogenic” and recommend they are followed up clinically with vascular imaging, familial segregation studies and available structural or biochemical studies including EM or protein analysis. Initial genetic counseling for such patients should include the fact that the true significance of the variant will not be known until these additional tests are complete. Although in the short term some of these VUS’s may add some uncertainty to the diagnostic process, we believe this is greatly outweighed by the prospect of making specific genetic diagnoses, which would otherwise go undetected and form the basis for preventative screening in relatives. In the longer term, assignment of pathogenicity is likely to be facilitated by data from ongoing large-scale genome sequencing projects in patient and control cohorts.

We used the PCR-based Fluidigm Access Array followed by Illumina MiSeq. Mean coverage per amplicon was greater than 140x for all amplicons, comparable to previously reported assays using this methodology.[9,31] Although this method is unable to detect large deletions or chromosomal rearrangements, these are rare in EDS.[2] In addition, whilst false positive variant calls have been previously reported with this approach,[31] we detected only a single variant (in exon 1 of *SMAD3*) that could not be confirmed by Sanger sequencing. Since NGS methods have higher throughput, achieve greater coverage and may be more cost-efficient than conventional Sanger sequencing,[31] they may be applicable to wider phenotypic groups, for which this study may serve as a guide to future genetic testing. We suggest that the higher throughput, lower cost, and comparable or increased diagnostic yield of NGS could alter the optimal diagnostic pathway, such that genetic testing with NGS panels can occur earlier in the diagnostic pathway, prior to tertiary or quaternary clinical appraisal (Figure 1B).

SUPPLEMENTARY DATA

Supplementary information is available at the *Genetics in Medicine* website.

ACKNOWLEDGEMENTS

The authors thank all patients and families, the EDS National Diagnostic Service, Northwick Park Hospital, London North West Healthcare NHS Trust; also Julie Leary, Carole Cummings, Marion Bartlett, Hilary Bell-Joseph, Claire Neuwirth and Vera Weerasinghe for help with patient recruitment and clinical records; Dr Philip Sawle for Collagen biochemical analysis. TA was supported by intramural funds from the MRC Clinical Sciences Centre, National Institute for Health Research (NIHR) via the Imperial Biomedical Research Centre, Imperial College British Heart Foundation Centre of Research Excellence and University of Edinburgh. RW was supported by an Imperial-Wellcome Trust Clinical Training Fellowship.

DISCLOSURE

TJA has received speaker honoraria and has research collaborations with Illumina and consultancy fees from AstraZeneca. Other authors have no disclosures.

REFERENCES

1. Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ. Ehlers-danlos syndromes: Revised nosology, Villefranche, 1997. *Am J Med Genet* 1998;77:31–7.
2. De Paepe a, Malfait F. The Ehlers-Danlos syndrome, a disorder with many faces. *Clin Genet* 2012;82:1–11.
3. Proske S, Hartschuh W, Enk A, Hausser I. Ehlers-Danlos syndrome--20 years experience with diagnosis and classification at the university skin clinic of Heidelberg. *J Dtsch Dermatol Ges* 2006;4:308–18.
4. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. *N Engl J Med* 2000;342:673–80.
5. Metzker ML. Sequencing technologies - the next generation. *Nat Rev Genet* 2010;11:31–46.
6. Loeys BL, Dietz HC, Braverman AC et al. The revised Ghent nosology for the Marfan syndrome. *J Med Genet* 2010;47:476–85.
7. Nuytinck L, Narcisi P, Nicholls A, Renard J, Pope FM, De Paepe A. Detection and characterisation of an overmodified type III collagen by analysis of non-cutaneous connective tissues in a patient with Ehlers-Danlos syndrome IV. *J Med Genet* 1992;29:375–80.
8. Ong KT, Plauchu H, Peyrol S et al. Ultrastructural scoring of skin biopsies for diagnosis of vascular Ehlers-Danlos syndrome. *Virchows Arch* 2012;460:637–49.
9. Vandrovcova J, Thomas ER a, Atanur SS et al. The use of next-generation sequencing in clinical diagnosis of familial hypercholesterolemia. *Genet Med* 2013;15:948–57.
10. Babraham Bioinformatics available at: <http://www.bioinformatics.babraham.ac.uk/projects/fastqc>
11. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Available at: <http://arxiv.org/abs/1303.3997>
12. McKenna A, Hanna M, Banks E et al. The genome analysis toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 2010;20:1297–303..
13. Wang K, Li M, Hakonarson H. ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* 2010;38. doi:10.1093/nar/gkq603.
14. LOVD - Ehlers-Danlos Syndrome Variant Database. Available at: <https://eds.gene.le.ac.uk/home.php>
15. The Human Gene Mutation Database (HGMD). Available at: <http://www.hgmd.org/>
16. Richards S, Aziz N, Bale S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015;17(5):405–23
17. Phillips CL, Shrago-Howe AW, Pinnell SR, Wenstrup RJ. A substitution at a non-glycine position in the triple-helical domain of pro alpha 2(I) collagen chains present in an individual with a variant of the Marfan syndrome. *J Clin Invest* 1990;86:1723–8.
18. Pickup MJ, Pollanen MS. Traumatic subarachnoid hemorrhage and the COL3A1 gene: emergence of a potential causal link. *Forensic Sci Med Pathol* 2011;7:192–7.

-
19. Malfait F, Paepe ADE. Molecular Genetics in Classic Ehlers – Danlos Syndrome. *Am J Med Genet* 2005;23:17–23.
20. De Paepe A, Nicholls A, Narcisi P et al. Ehlers-Danlos syndrome type I: a clinical and ultrastructural study of a family with reduced amounts of collagen type III. *Br J Dermatol* 1987;117(1):89-97.
21. Pepin MG, Schwarze U, Rice KM, Liu M, Leistritz Dru, Byers PH. Survival is affected by mutation type and molecular mechanism in vascular Ehlers-Danlos syndrome (EDS type IV). *Genet Med* 2014;16:881–8.
22. Monroe GR, Harakalova M, van der Crabben SN et al. Familial Ehlers-Danlos syndrome with lethal arterial events caused by a mutation in COL5A1. *Am J Med Genet A*. 2015 doi: 10.1002/ajmg.a.36997. [Epub ahead of print]
23. Malfait F, Symoens S, De Backer J et al. Three arginine to cysteine substitutions in the pro-alpha (I)-collagen chain cause Ehlers-Danlos syndrome with a propensity to arterial rupture in early adulthood. *Hum Mutat* 2007;28:387–95.
24. Loeys BL, Schwarze U, Holm T et al. Aneurysm syndromes caused by mutations in the TGF-beta receptor. *N Engl J Med* 2006;355:788–98.
25. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. *Nature* 2003;425:577–84.
26. Van Der Linde D, Van De Laar IMBH, Bertoli-Avella AM et al. Aggressive cardiovascular phenotype of aneurysms-osteoarthritis syndrome caused by pathogenic SMAD3 variants. *J Am Coll Cardiol* 2012;60:397–403.
27. Bonachea EM, Zender G, White P et al. Use of a targeted, combinatorial next-generation sequencing approach for the study of bicuspid aortic valve. *BMC Medical Genomics* 2014;7:56. doi:10.1186/1755-8794-7-56
28. Kirmani S, Tebben PJ, Lteif AN et al. Germline TGF-b receptor mutations and skeletal fragility: A report on two patients with Loeys-Dietz syndrome. *Am J Med Genet Part A* 2010;152:1016–9.
29. Bourhis JM, Mariano N, Zhao Y et al. Structural basis of fibrillar collagen trimerization and related genetic disorders. *Nature Structural & Molecular Biology* 2012;19(10):1031–6.
30. Stembridge NS, Vandersteen AM, Ghali N et al. Clinical, structural, biochemical and X-ray crystallographic correlates of pathogenicity for variants in the C-propeptide region of the COL3A1 gene. *Am J Med Genet A* 2015. doi: 10.1002/ajmg.a.37081. [Epub ahead of print]
31. Halbritter J, Diaz K, Chaki M et al. High-throughput mutation analysis in patients with a nephronophthisis-associated ciliopathy applying multiplexed barcoded array-based PCR amplification and next-generation sequencing. *J Med Genet* 2012;49:756–67.

FIGURE LEGENDS

Figure 1. A. Yield of rare variants using traditional Sanger method (left) compared with the NGS panel (right). **B.** Potential alternative clinical pathway to genetic diagnosis in EDS. Boxed numbers show the number of rare pathogenic variants and VUS's identified in each group; percentages are the proportion of new pathogenic or likely pathogenic rare variants in our cohort of 177 EDS referrals. "Other" genetic abnormalities are those that were thought to underlie the EDS phenotype but are not covered by the NGS panel (3 pathogenic variants in *TNXB*, *FBN2*, *FKBP14* & 1 large copy number variant; 1 VUS, a *TNXB* gene duplication). Dashed arrow indicates the potential for NGS panel to become accessible to clinicians in secondary care.





Table 1 Clinical spectrum of cohort

Initial Clinical Diagnosis ^a	No. of cases	Mean Age (range)	Mean Beighton score	No. (%) meeting Villefranche EDS criteria ^c				Arterial complication ^d
				Classical	Vascular	Hypermobility	KPS	
Classical ^a	21	34.8 (19-78)	7.3	21 (100%)	3 (14%)	15 (71%)	0	2 (10%)
Vascular ^a	22	30.7 (6-48)	4.8	5 (23%)	21 (95%)	10 (45%)	0	11 (50%) ^e
Hypermobility	76	32.7 (2-67)	5.8	21 (28%)	14 (18%)	73 (96%)	8 (11%)	14 (20%)
Rare & Complex EDS ^b	16	22 (2-55)	6.2	7 (44%)	4 (25%)	7 (44%)	6 (38%)	0
Other HDCT	11	32.6 (4-52)	6.0	5 (45%)	1 (9%)	8 (73%)	3 (27%)	0
Other HDCT (vascular)	31	43.4 (8-72)	4.5	11 (35%)	18 (58%)	22 (71%)	1 (3%)	31 (100%)

EDS, Ehlers-Danlos syndrome; KPS, kyphoscoliosis type of EDS; HDCT, hereditary disorder of connective tissue (phenotypes further elaborated in Supplementary Table 3).

a. Initial Clinical Diagnosis refers to most applicable classification at first specialist EDS consultation: Classical cases included 9 cases of classical/hypermobility type overlap, Vascular cases included 3 vascular/hypermobility and 2 vascular/classical overlap. **b.** Rare EDS refers to EDS types outside classical, vascular and hypermobility types. **c.** Villefranche classification: numbers (percentages) indicate the number (percent) of patients in each group meeting at least one major criterion for each EDS type. **d.** Arterial complication: history of one or more of aortic or peripheral arterial aneurysm, dissection or rupture, cerebral aneurysm / subarachnoid haemorrhage at first EDS consultation. **e.** $p = 0.002$ (vascular vs. other EDS).

Table 2 Previously identified genetic and pathological abnormalities

Initial Clinical Diagnosis ^a	No. of cases	Gene affected ^b				Collagen abnormality ^c	LM/EM abnormality
		<i>COL1A1</i> <i>COL1A2</i>	<i>COL3A1</i>	<i>COL5A1</i> <i>COL5A2</i>	Other		
Classical	21	0/3	1/7	7/11	1/2	1/9 (11%)	11/15 (73%) ^d
Vascular	22	0/1	11/17	0/1	2/8	7/11 (64%)	9/13 (69%)
Hypermobility	76	0/6	0/24	0/11	0/5	0/21	6/22 (27%)
Rare & Complex EDS	16	0/2	0/6	0/3	1/1	0/1	3/7 (43%)
Other HDCT	11	3/6	0/1	0/0	0/2	3/5 (60%) ^e	5/6 (83%)
Other HDCT (vascular)	31	0/4	0/23	0/5	3/16	3/9 (33%) ^f	9/18 (50%)

LM, light microscopy. EM, electron microscopy. HDCT, hereditary disorder of connective tissue.

a. Initial Clinical Diagnosis refers to most applicable classification at first specialist EDS consultation (as in Table 1). **b.** Pathogenic variants identified by Sanger sequencing (numerator, number of pathogenic variants; denominator, number of separate genetic tests carried out in each category). **c.** Abnormality of the corresponding collagen type on SDS-PAGE. **d.** Four of these cases had collagen rosettes on EM. **e.** These three patients had abnormalities of collagen I had phenotypes overlapping with osteogenesis imperfecta; two had pathogenic variants in *COL1A1/COL1A2*. **f.** Two of these three cases had collagen III deficiency; the third case had collagen I deficiency; none had rare variants in the corresponding genes.

Table 3 Pathogenic variants identified by the Collagen and Aortopathy NGS panels

Initial Clinical Diagnosis ^a	ID	Gene affected	Variant	Functional category	Novel/reported: phenotype	Sanger detected ^b
Classical	636	<i>COL3A1</i>	c.2329G>C: p.Gly777Arg	Missense	Novel	N
Classical	417	<i>COL3A1</i>	c.1922_1923+2delAAGT	Splice site	Reported: vascular EDS ^c	Y
Classical	582	<i>COL5A1</i>	c.2034+1G>T	Splice site	Novel	Y
Classical	31	<i>COL5A1</i>	c.2903delC: p.Pro968LeufsX106	Frameshift	Novel	Y
Classical	429	<i>COL5A1</i>	c.757C>T: p.Gln253X	Stop gain	Novel	Y
Classical	581	<i>COL5A1</i>	c.4552C>T: p.Gln1518X	Stop gain	Reported: Classical EDS ^d	Y
Classical	627	<i>COL5A1</i>	c.831C>A: p.Tyr277X	Stop gain	Novel	Y
Classical	1129	<i>COL5A1</i>	c.1670dupT: p.Leu557fsX?	Frameshift	Novel	Y
Classical	62	<i>COL5A2</i>	c.3445G>T: p.Gly1149Cys	Missense GlyXY	Novel	Y
Vascular	448	<i>COL3A1</i>	c.4319C>T: p.Pro1440Leu	Missense	Reported: Vascular EDS ^e	Y
Vascular	765	<i>COL3A1</i>	c.1662+1G>A	Splice site	Reported: Vascular EDS ^d	Y
Vascular	37	<i>COL3A1</i>	c.2564G>A: p.Gly855Asp	Missense GlyXY	Reported: Vascular EDS ^d	Y
Vascular	42	<i>COL3A1</i>	c.2417C>T: p.Pro806Leu	Missense	Novel	Y
Vascular	46	<i>COL3A1</i>	c.1771G>C: p.Gly591Arg	Missense GlyXY	Novel	Y
Vascular	76	<i>COL3A1</i>	c.2771G>A: p.Gly924Asp	Missense GlyXY	Reported: Vascular EDS ^d	Y
Vascular	405	<i>COL3A1</i>	c.1662+1G>A	Splice site	Reported: Vascular EDS ^d	Y
Vascular	483	<i>COL3A1</i>	c.2553+1G>A	Splice site	Reported: Vascular EDS ^d	Y
Vascular	733	<i>COL3A1</i>	c.2816G>A: p.Gly939Asp	Missense GlyXY	Reported: Vascular EDS ^d	Y
Vascular	420	<i>COL3A1</i>	c.1150-2A>T	Splice site	Novel	Y
Vascular	443	<i>COL3A1</i>	c.3525+1G>A	Splice site	Novel	Y
Vascular	1088	<i>COL5A1</i>	c.3164T>A: p.Leu1055X	Stop gain	Novel	N
Hypermobility	824	<i>COL5A1</i>	c.4564G>T: p.Gly1522Cys	Missense	Novel	N
Other HDCT (OI/EDS)	527	<i>COL1A1</i>	c.1265delG: p.Gly422AlafsX119	Frameshift	Novel	Y
Other HDCT (OI/EDS)	36	<i>COL1A1</i>	c.643G>A: p.Gly215Ser	Missense GlyXY	Reported: OI/OI-EDS ^g	Y
Other HDCT (OI/EDS)	559	<i>COL1A1</i>	c.662G>C: p.Gly221Ala	Missense GlyXY	Novel	Y
Other HDCT (vascular)	66	<i>FBN1</i>	c.3781T>A: p.Tyr1261Asn	Missense	Reported: Marfan ^f	Y
Other HDCT (vascular)	378	<i>FBN1</i>	c.1775G>A: p.Gly592Asp	Missense	Reported: Marfan ^h	N
Other HDCT (vascular)	766	<i>FBN1</i>	c.3373C>T: p.Arg1125X	Stop gain	Reported: Marfan ⁱ	N

EDS, Ehlers-Danlos syndrome; HDCT, hereditary disorder of connective tissue (phenotypes further elaborated in Table S4); OI, osteogenesis imperfecta. Missense GlyXY, substitution of a Gly residue in the helical domain of the corresponding collagen subtype.

a. Initial Clinical Diagnosis refers to most applicable EDS type at first specialist EDS consultation (though some cases overlap multiple EDS types); **b.** variants detected (Y) or not detected (N) by previous clinical diagnostic testing (Sanger method); **c.** c.1923+2_+5delTAAG reported pathogenic in LOVD; **d.** LOVD; **e.** Pro1440Ser reported as pathogenic in LOVD (Morissette et al., 2014) and Pro1440Leu pathogenicity supported by structural prediction (Vandersteen, unpublished); **f.** Y1261C (HGMD CM990591), Y1261D (HGMD CM547000); **g.** Vandersteen et al., 2013 **h.** HGMD CM013919 **i.** HGMD CM055245

Table 4 Variants of Uncertain Clinical Significance and Likely Pathogenic variants identified in the Collagen and Aortopathy NGS panels

Initial Clinical Diagnosis	ID	Gene affected	Variant	Functional category	Novel/reported: phenotype	Sanger detected
Classical	49	<i>COL3A1</i>	c.3511G>A: p.Glu1171Lys	Missense	Novel	N
Classical	636	<i>COL5A2</i>	c.1402-10T>G	Intronic ^a	Novel	Y
Vascular	444	<i>COL1A1</i>	c.3755G>A: p.Arg1252His	Missense	Novel	N
Vascular	384	<i>COL1A1</i>	c.3466A>G: p.Asn1156Asp	Missense	Novel	Y
Hypermobility	893	<i>COL1A1</i>	c.2980C>T: p.Arg994Cys	Missense	Novel ^d	N
Hypermobility	478	<i>COL1A1</i>	c.4315A>G: p.Ile1439Val	Missense	Novel	N
Hypermobility	828	<i>COL1A1</i>	c.3301G>A: p.Glu1101Lys	Missense	Novel	N
Hypermobility	39	<i>COL1A2</i>	c.2861T>C: p.Ile954Thr	Missense	Novel	N
Hypermobility	558	<i>COL1A2</i>	c.1159G>C: p.Ala387Pro	Missense	Novel	N
Hypermobility	1151	<i>COL1A2</i>	c.4012C>T: p.Arg1338Cys	Missense	Novel	N
Hypermobility	38	<i>COL3A1</i>	c.198A>G: p.Ile66Met	Missense	Novel	N
Hypermobility	39	<i>COL3A1</i>	c.2044G>A: p.Glu682Lys	Missense	Novel	N
Hypermobility	655	<i>COL3A1</i>	c.3938A>G: p.Lys1313Arg	Missense	Reported: Vascular EDS ^b	Y
Hypermobility	34	<i>COL5A1</i>	c.4068G>A: p.Ala1356Ala	Predicted splice site disruption	Novel	N
Hypermobility	66	<i>COL5A1</i>	c.805G>A: p.Glu269Lys	Missense	Novel	N
Hypermobility	734	<i>COL5A1</i>	c.3257C>T: p.Ala1086Val	Missense	Novel	N
Hypermobility	799	<i>COL5A1</i>	c.2497C>T: p.Pro833Ser	Missense	Novel	N
Hypermobility	38	<i>COL5A2</i>	c.2228A>C: p.Lys743Thr	Missense	Novel	N
Hypermobility	671	<i>COL5A2</i>	c.470C>T: p.Pro157Leu	Missense	Novel	N
Hypermobility	814	<i>TGFBR2</i>	c.1538T>C: p.Val513Ala	Missense	Novel ^d	N
Other HDCT	475	<i>TGFBR1</i>	c.214A>G: p.Ile72Leu	Missense	Novel	N
Other HDCT	804	<i>COL1A1</i>	c.584C>T: p.Ala195Val	Missense	Novel	N
Other HDCT	629	<i>COL1A2</i>	c.2123G>A: p.Arg708Gln	Missense	Reported: Marfanoid ^c	Y
Other HDCT	708	<i>COL3A1</i>	c.2002C>A: p.Pro668Thr	Missense	Novel	N
Other HDCT (vascular)	382	<i>SMAD3</i>	c.1218G>C: p.Trp406Cys	Missense	Novel ^d	Y
Other HDCT (vascular)	706	<i>TGFBR1</i>	c.827T>C: p.Leu276Pro	Missense	Novel ^d	Y

Column headings and abbreviations as for Table 3. **a.** possible splice site disruption, but this patient also carries a pathogenic *COL3A1* variant and his definitive diagnosis was altered to vascular EDS. **b.** LOVD; ExAC database: likely benign variant (freq. 1:500) **c.** HGMD CM900074; DBSNP rs72658163. **b.** & **c.** both these variants have been previously reported as pathogenic but are classified here as VUS (see text). **d.** variants classified as Likely Pathogenic; see also Tables S5 and S6.

Table S1 Oligonucleotide sequences of Collagen NGS panel

Gene	Assay_Name	Forward Primer	Reverse Primer	Length	% GC	Amplicon	Chr	From	To
COL1A1	COL1A1_1	AAGTCCATGTGAAATTGTCTCCC	CCCCCTTGGACGTGTGGTG	194	52	AAGTCCATGTGAAATTGTCTCCCATTTTTTGGCTTTTGT	chr17	48262737	48262930
COL1A1	COL1A1_10	CACATATGGGCATGGGGAC	GACACCACCTCAAGAGCC	190	62	CACATATGGGCATGGGGACCTGGCATGGCAGGAGT	chr17	48263932	48264121
COL1A1	COL1A1_11	GCGGGCGGGTTCTTG	CCCAGGCACCTCAAGAGAAG	167	60	GCGGGCGGGTTCTTGCGGSTKCCCTCTGGGCTCCG	chr17	48264044	48264210
COL1A1	COL1A1_12	GTCACGGTCACGAACCACATT	TAATCCCCACTCTCTCCCTCTC	183	54	GTCACGGTCACGAACCACATTGGNNNNMNYNYCC	chr17	48264131	48264313
COL1A1	COL1A1_13	CCATGAGCAGAGGGGATGAG	TTTCTCAAACATTTCCTCCACT	166	53	CCATGAGCAGAGGGGATGAGGKGCTAYATAYAAYAG	chr17	48264345	48264510
COL1A1	COL1A1_14	TGTCCTGAACCTTCTCCAG	GGCCTGAACGCTTTTATCT	198	57	TGTCCTGAACCTTCTCCAGAGAGCAAGGGTGCC	chr17	48264733	48264930
COL1A1	COL1A1_15	CTCCTATCCCACAGCACAGCAT	CCTGACAGTTGTCCCTTTCTCT	190	56	CTCCTATCCCACAGCACAGCATGGRGACTGGGGAGG	chr17	48265185	48265374
COL1A1	COL1A1_16	CCTAGAAGAGAGAAAGGGACAAACT	AAGAGCTCATGCTTCTTGTC	197	56	CCTAGAAGAGAGAAAGGGACAAACTGTCAGGCRGAA	chr17	48265344	48265540
COL1A1	COL1A1_17	ACCAGGTACAGGGAAGTGGAG	CCCCCTCTGGCCCTT	198	51	ACCAGGTACAGGGAAGTGGAGCCAGCTAYTTACAGT	chr17	48265857	48266054
COL1A1	COL1A1_18	GCAGGGAAGCAGCAGACA	CCAGTACCTCAGCATGGC	187	57	GCAGGGAAGCAGCAGACAAGGCTGTGGTCATGGAGT	chr17	48266054	48266240
COL1A1	COL1A1_19	GCTGAGGGTACTGGCATGG	CTCTGGCCTGACTCTTCTTCTC	174	58	GCTGAGGGTACTGGCATGGGGCTGGGGACTGCTYA	chr17	48266227	48266400
COL1A1	COL1A1_2	TGGGGGAAAGTTGGTTGG	AGAGTCACACGGAGCC	200	55	TGGGGGAAAGTTGGTTGGRTGGGAGGGAGCYAGG	chr17	48262812	48263011
COL1A1	COL1A1_20	TCCTGTGATGGTTTTCTCAGGG	CCTCACCCCTGTTTGCTC	182	58	TCCTGTGATGGTTTTCTCAGGGMCCCCAAGGTGAC	chr17	48266480	48266661
COL1A1	COL1A1_21	CTCCCCAGCTCTGCACAC	CTGGTCTGCTGGCAAAGAAG	189	58	CTCCCCAGCTCTGCACACCTCCGAGCTGCAGAGATC	chr17	48266686	48266874
COL1A1	COL1A1_22	ATCAGACCAGGGGATCCTTTC	GAGTCTGACAGCCCTCCTATC	184	57	ATCAGACCAGGGGATCCTTTCTGCCAGCAGGGCCT	chr17	48266747	48266930
COL1A1	COL1A1_23	ATCATTGGGTCTCAGTCAGC	GATGAGTTGGCTGTCTCCCTC	197	56	ATCATTGGGTCTCAGTCAGCCCCACCATCCTTCTGGC	chr17	48266947	48267143
COL1A1	COL1A1_24	GAGGGAGAACAGCCAACATCATC	GGACGGGTCCAGGCTT	191	60	GAGGGAGAACAGCCAACATCATCCGACCCAGCTGCCCT	chr17	48267122	48267312
COL1A1	COL1A1_25	GGGCACAGAGGGCCAAG	CTCCCCAGGTAGTGGAATCT	197	60	GGGCACAGAGGGCCAAGCCAYTACAATGGGGYCAC	chr17	48267337	48267533
COL1A1	COL1A1_26	CTCCCTGAGGATGGCTGAC	GCATCTCTCCAATCTGACTCCTT	183	56	CTCCCTGAGGATGGCTGACRCCTTTGTCTATTCCR	chr17	48267591	48267773
COL1A1	COL1A1_27	TGCTGTGTGAAGGGAGGGAA	GCTCTCTGGGGTCATCTACT	186	59	TGCTGTGTGAAGGGAGGGAAAGGCCAAGTATGGGG	chr17	48267845	48268030
COL1A1	COL1A1_28	CTATGTGTAGGGCAGAAGGTGG	CTTGCCCCACTGGAAATCT	190	54	CTATGTGTAGGGCAGAAGGTGGGAGGCGGCCACC	chr17	48268138	48268327
COL1A1	COL1A1_29	AGAGATGGGAGCCATGTAGGG	CCTCACTCCAGTCTTCTGGTTG	188	55	AGAGATGGGAGCCATGTAGGGCTCAGGGGAGGGGG	chr17	48268695	48268882
COL1A1	COL1A1_3	GGGGACCAACGTCCTCAAG	ATAGTGCCCTCTCTCCATCACTC	167	59	GGGGACCAACGTCCTCAAGGGGCCACATMGATGAT	chr17	48262909	48263075
COL1A1	COL1A1_30	GCAGGAGGGGTGAGACCTG	CCTTCACATGCCCTGTCCTT	190	60	GCAGGAGGGGTGAGACCTGGTCCCTGGGCCACTTGC	chr17	48269087	48269276
COL1A1	COL1A1_31	CTCTCGCCTAGAAGGGAAGG	TTTTGCTCACTGTCTGTCTCTCT	184	58	CTCTCGCCTAGAAGGGAAGGACAGGGCATGTGAAG	chr17	48269240	48269423
COL1A1	COL1A1_32	cctctagttgATGGCTGTCTGATT	TAAACCTTCCCTCCCTTCTCCC	190	57	cctctagttgATGGCTGTCTGATTAGCTAGGAGCGGGG	chr17	48269740	48269929
COL1A1	COL1A1_33	GACCAAGAGGTGTTTCTACCC	GAGATCTGGGGAGCAGAAAAGG	198	59	GACCAAGAGGTGTTTCTACCCCTACCTCCCAGCAT	chr17	48269942	48270139
COL1A1	COL1A1_34	GCACAGAGAGAACTACAGTCA	CTCCTAACCTGAGTTCCCTCTT	193	58	GCACAGAGAGAACTACAGTCAACGGGGAGGCCGAC	chr17	48270057	48270249
COL1A1	COL1A1_35	GCCTCTAGCACCCCTCT	CCTCAACCTAAGTCCCTTCTC	164	56	GCCTCTAGCACCCCTCTGCAGGGAGGAGAAAGTGC	chr17	48270273	48270436
COL1A1	COL1A1_36	tgGCTCTTCATGGATCCTCACTT	TTGTCTGTCTGCCTCCCT	188	57	tgGCTCTTCATGGATCCTCACTTAATASTCACAGCRGC	chr17	48271272	48271459
COL1A1	COL1A1_37	AAGGATGGGAGGCAGGAAAG	CTTCTCCCCAAGTCCCACTATA	180	58	AAGGATGGGAGGCAGGAAAGCAGCAGTGRGGACAG	chr17	48271405	48271584
COL1A1	COL1A1_38	GGCCAAGCCAGGCTGAAAG	GAGCCACAACTTGAGACCCATA	180	59	GGCCAAGCCAGGCTGAAAGCCTGGGGCCTCAYCTTG	chr17	48271678	48271857
COL1A1	COL1A1_39	GTCTCAAGTTTGTGGCTCTTTC	GAGTTCACTGGCCTCTCTCC	177	60	GTCTCAAGTTTGTGGCTCTTTCACAGGGCCAAAAGA	chr17	48271840	48272016
COL1A1	COL1A1_4	AGTGATGGAGAGGGCACTATG	CAGACTGGCAACCTCAAGAAGG	196	62	AGTGATGGAGAGGGCACTATGGCTGGCCAAAAG	chr17	48263054	48263249
COL1A1	COL1A1_40	CCAGGCAATGAGGGTGGA	GATGGCCCTCACCACA	200	63	CCAGGCAATGAGGGTGAGYGRGAKGGGCRGGCAI	chr17	48272036	48272235
COL1A1	COL1A1_41	GGCTCTCTCTCTTCTGGATT	CGACTCTCAGTCTATCTCTCT	174	58	GGCTCTCTCTCTTCTGATTTCCTCAGGGGGCTCC	chr17	48272323	48272496

COL1A1	COL1A1_42	CCAGTGCATGGGGTGGG	CCCCTTTCCCTCTGCTCCTA	191	60	CCAGTGCATGGGGTGGGCAGAAAGGGAGAGTTTGGT# chr17	48272552	48272742
COL1A1	COL1A1_43	CCTAGGAGCAGAGGGAAAGGG	GCCACTTTCTAACCTCAGAGTCC	178	54	CCTAGGAGCAGAGGGAAGGGGAGGCAGGCTGCA# chr17	48272721	48272898
COL1A1	COL1A1_44	TGAGGTTAGAAAGTGCAAAGGG	GTTTCCAGGGTGCTTCTGATA	188	55	TGAGGTTAGAAAGTGCAAAGGGGACACTGAGTCG# chr17	48272882	48273069
COL1A1	COL1A1_45	CACTCTGGGTCCCTTTGTTTG	TCTCTTCTCTCGTGACATCT	181	57	CACTCTGGGTCCCTTTGTTTGGGGAACAGGGAGAC# chr17	48273195	48273375
COL1A1	COL1A1_46	CCCATGTGAGCCCAAGAG	CAGTGCTCAGTGGACTTAACGG	164	58	CCCATGTGAGCCCAAGAGCAGAYACTGAGACCCCT chr17	48273440	48273603
COL1A1	COL1A1_47	GGCCAGTCCCTAGAGTTCCT	GCTGTCTCCCATCTCATCTGACT	169	60	GGCCAGTCCCTAGAGTTCCTGGGGAGCCCYTTCCAGA chr17	48273603	48273771
COL1A1	COL1A1_48	AGAAGTCAGATGAGATGGGAGACA	CCAGAGTCCCACCATGAATGAAT	195	53	AGAAGTCAGATGAGATGGGAGACAGCCTTGTTCCCC chr17	48273746	48273940
COL1A1	COL1A1_49	ATTCATTATGAGTGGGACTCTGG	AGGCTCTTCTCAGATCTAGGTG	198	47	ATTCATTATGAGTGGGACTCTGGGGATGTGGAGGAC chr17	48273918	48274115
COL1A1	COL1A1_5	GACAGTGACGCTGTAGGTGAAG	TTCCTGCGCTGATGTCCA	177	59	GACAGTGACGCTGTAGGTGAAGCGGCTGKTGCCCTC chr17	48263151	48263327
COL1A1	COL1A1_50	GGACTTGGGGAGCTTAATGACT	ACTTGGGCTTCATTAGGAGCTG	169	46	GGACTTGGGGAGCTTAATGACTCAAAGGTGASNN# chr17	48274334	48274502
COL1A1	COL1A1_51	GACAAGGAAGGGCCATTAGAACA	GGCATGATGGTCTTTCTCTCCC	181	55	GACAAGGAAGGGCCATTAGAACACATCACTGTGGAC chr17	48274443	48274623
COL1A1	COL1A1_52	CAAATGTGGTGGAGTGGAAATTG	CCAGCCTTCCCCTCTTTTTT	198	48	CAAATGTGGTGGAGTGGAAATTGCAGGACYCAACC/ chr17	48275010	48275207
COL1A1	COL1A1_53	TCTATAGGAGAGTCTGTGTGTTGT	GAAGGTTGACAGGACTGTGCTT	164	45	TCTATAGGAGAGTCTGTGTGTTGTAGAAGGAGTRTG chr17	48275251	48275414
COL1A1	COL1A1_54	TCTTCCCTCCAAAAGACCAAAGC	TCCCAACAGGCATGAATGACTAC	184	53	TCTTCCCTCCAAAAGACCAAAGCCCRAGGAGGCAT# chr17	48275464	48275647
COL1A1	COL1A1_55	TCCTCTGGATACCCATTCTCTC	CCGTCTTCTGCCTTTCAATTAC	182	49	TCCTCTGGATACCCATTCTCTTCTGTATCCATGCTC chr17	48275740	48275921
COL1A1	COL1A1_56	GGACACACAAGGCCTCTCC	CAGGTGGGCATGGCTCTC	185	69	GGACACACAAGGCCTCTCCACTTAYTCTCCGAGRCNI chr17	48276562	48276746
COL1A1	COL1A1_57	CGAGAGCCATGCCACC	AATCTCTGCCCTCGAATTTTGC	187	63	CGAGAGCCATGCCACCTGCAGCCCCCACAGCCAC chr17	48276728	48276914
COL1A1	COL1A1_58	CCAGGTTAGAGAAGGGAGGACTG	GACGGGAGCAGCATTAGCAAAC	162	59	CCAGGTTAGAGAAGGGAGGACTGTGAGGAGTCACG chr17	48276845	48277006
COL1A1	COL1A1_59	AGGCCTCCAGCACGGA	GGTGTGTGCGATGACGTG	200	71	AGGCCTCCAGCACGAGGGGCCAGCGAGCGCCGAcca# chr17	48277012	48277211
COL1A1	COL1A1_6	GGGCCTTCTTGAGGTGCC	TCCCCTCCCCTGCAGTTC	172	61	GGGCCTTCTTGAGGTTGCCAGTCTGCTKGTCCATGTA# chr17	48263225	48263396
COL1A1	COL1A1_60	CGCCCTCGGGGACTTC	CTACTGACAACGCCCTCTTC	198	61	CGCCCTCGGGGACTTCGCGCCNNGGCGAGTTCTTGG chr17	48277144	48277341
COL1A1	COL1A1_61	CGCAAGCGCGATATAGAGT	GCCACAAAGAGTCTACATGTCTAGG	187	56	CGCAAGCGCGATATAGAGTATCCTTGCACTCCCAAA chr17	48278721	48278907
COL1A1	COL1A1_7	CATCAGGCGCAGGAAGGTC	TCTCGATATAACGGTGCAATTGGG	183	62	CATCAGGCGCAGGAAGGTCNNCTGGATGGCCACATC chr17	48263313	48263495
COL1A1	COL1A1_8	TCATGTCCCTTCTGAGCACT	ACATGGAGACTGGTGAGACCT	198	55	TCATGTCCCTTCTGAGCACTGGGCTAGCCCATCTCCTA chr17	48263611	48263808
COL1A1	COL1A1_9	TCCTTGGGGTCTTGCTGATGTA	CCTGACTCCATCTTGCCCTG	176	55	TCCTTGGGGTCTTGCTGATGTAMCAGTTCTTCTGGG chr17	48263724	48263899
COL1A2	COL1A2_1	GTA CTGGCCACGACTGCAT	CTCCCCAAACAAGCTGAAGG	198	57	GTA CTGGCCACGACTGCATGCCCGCGCCCGCAGGT chr7	94024244	94024441
COL1A2	COL1A2_10	GGAAAAGGAGTTGGACTTGGC	TGGCGTGGTAAAAATGTGACATAAA	109	36	GGAAAAGGAGTTGGACTTGGCCCTGGACCAATGRYA# chr7	94030900	94031008
COL1A2	COL1A2_12	TGGAATCAAAACACAACAATGGC	AGAGGCATTACAAGCTTTCAGTA	181	46	TGGAATCAAAACACAACAATGGCACTGCTAAGTTGGT chr7	94033760	94033940
COL1A2	COL1A2_13	ACTGAAAGCTTGTAATGCCTCTT	AAAAACTTATCACAAAGGTGGAAAAATG	175	38	ACTGAAAGCTTGTAATGCCTCTTATGTA AAAAGACAG, chr7	94033919	94034093
COL1A2	COL1A2_14	ACCTTAGTGAAATGATGGGTCTCC	GTCAGGCATATTCAAGCTTTTGGC	198	40	ACCTTAGTGAAATGATGGGTCTCCCATTTTCTTAGGGT chr7	94034116	94034313
COL1A2	COL1A2_15	ACCAAGATTCCCCATTTTGTCT	AGGCCTATGATGTTTGTGCTATCT	168	44	ACCAAGATTCCCCATTTTGTCTGATAGTTTACCAAGA chr7	94034441	94034608
COL1A2	COL1A2_16	TGATGAGAATAAACTTTGGAGGGAA	CCAAAAATAATAGGCATTTTCTCTCTCT	193	37	TGATGAGAATAAACTTTGGAGGGGAAGAAGTCACT# chr7	94034895	94035087
COL1A2	COL1A2_17	TTTTATTTGACCAAACTATCATGGA	ACTTTTTTGGAGGTCATGGGGAA	180	36	TTTTATTTGACCAAACTATCATGGAACAGCATTTTA# chr7	94035504	94035683
COL1A2	COL1A2_18	AGAGTAAAATTGCACTATCAGGAAAAA	AGCAAAAACATTAAAGAAGTTCCATCTCA	194	32	AGAGTAAAATTGCACTATCAGGAAAAATAATTGTTAT, chr7	94037086	94037279
COL1A2	COL1A2_19	ACAGGTTGAAACTGAACAAAGC	TGAAACTGAACAAAAATGGAAGCA	172	41	ACAGGTTGAAACTGAACAAAGCAAAATGATGCCTGT# chr7	94037406	94037577
COL1A2	COL1A2_2	ACTTGTTCTCTATTGTTAATTATTGCTATTGA	AGAGAAGACATCACTGTAGCCAA	167	26	ACTTGTTCTCTATTGTTAATTATTGCTATTGATCnnT# chr7	94026972	94027138
COL1A2	COL1A2_20	TTCTGGTGAGAGAGGACGTG	TGTCAAAACTTACAGCAGGACCC	198	45	TTCTGGTGAGAGAGGACGTGTTGGTGCCCTGGYCC chr7	94037508	94037705
COL1A2	COL1A2_21	ACCTGATCTTCCCTTTATTTTCTCT	AAAGACCTCACAGAACATTTGGT	198	44	ACCTGATCTTCCCTTTATTTTCTTAGGGTGCCCGTC chr7	94037619	94037816
COL1A2	COL1A2_22	TTTCTTACCACCTTCTGCTTTGA	TCTGCAAAACAGTTCCAATCTT	162	43	TTTCTTACCACCTTCTGCTTTGATTTCRSGRTCYAWTC chr7	94038053	94038214

COL1A2	COL1A2_23	ATGCTGTTTCATTATTTGCTGGTT	AGACAGTGGCTACTTACAGGAGG	168	48	ATGCTGTTTCATTATTTGCTGGTTAATTCCTTGGTTTA ^h chr7	94038582	94038749
COL1A2	COL1A2_24	GCTGGTTAATTCCTTGGTTAATTTCTCT	CTTCCCCATACTCCACCTTTGTT	197	46	GCTGGTTAATTCCTTGGTTAATTTCTCTTTTAGGRT ^h chr7	94038599	94038795
COL1A2	COL1A2_25	ATGGGGTCAAAGAAGAACCGAAA	GCTGTAGAGGCAGCACACATTA	184	42	ATGGGGTCAAAGAAGAACCGAAATATTCCAATTAAC ^t chr7	94038809	94038992
COL1A2	COL1A2_26	GCTGCCTCTACAGCCCATC	TTTCAGGATGATGAGAACCACAG	192	53	GCTGCCTCTACAGCCCATCACCTCCCTAATGGACCAC ^h chr7	94038979	94039170
COL1A2	COL1A2_27	AAGAGATTGTCTGCAAGAGAGT	AGCTGGAGAACTGGAATGAGAA	189	42	AAGAGATTGTCTGCAAGAGAGTTTCAACAAATGTTT ⁱ chr7	94039484	94039672
COL1A2	COL1A2_28	ACTCCCTCTCTTTTGTCTTTTCA	GGGGTATCATAATGCGCTCTGG	197	50	ACTCCCTCTCTTTTGTCTTTTCATTAACAGRGCTCY ⁱ chr7	94039699	94039895
COL1A2	COL1A2_29	ACAAACTCTACCTTATCAAAGCCAA	TGCTAAAGCTAATGACACACCA	195	44	ACAAACTCTACCTTATCAAAGCCAAGAGATTTCTTTAA ^h chr7	94040134	94040328
COL1A2	COL1A2_3	ACTACACAAAATGGAAGCTGTT	AGAAGTAGTGACTCTTACCTTTCTTAC	113	26	ACTACACAAAATGGAAGCTGTTTTTAAATATATATAT ^h chr7	94027615	94027727
COL1A2	COL1A2_30	TGTCATTAGCTTTAGCATCCTCCT	TAATGCCAGGTGTGATTGCTC	197	46	TGTCATTAGCTTTAGCATCCTCCTCTATCTGTTTT ^h chr7	94040312	94040508
COL1A2	COL1A2_31	TCTAAGGCTTGAGTATGTAAGTTAAAGTG	AGCCACAAAATAGACTTGATAAGGGT	187	36	TCTAAGGCTTGAGTATGTAAGTTAAAGTGCCAATATA ^v chr7	94041319	94041505
COL1A2	COL1A2_32	AGCTTGAGGTTGTGAGAATATGT	GCTGAGGGTAAGAAAGTTGTGGT	190	49	AGCTTGAGGTTGTGAGAATATGTTGACACTGAGTAAA ^h chr7	94041837	94042026
COL1A2	COL1A2_33	AGCAGGATTCAACATTGCAAAA	GTGGTTCTTAGATGAATGCTATGTG	198	38	AGCAGGATTCAACATTGCAAAAATCACCGTGGTTAATT ^h chr7	94042305	94042502
COL1A2	COL1A2_34	ACATCTTAAACTACCTGGCTTGC	ACTTTTGGACTGAAAATGGAGATG	198	42	ACATCTTAAACTACCTGGCTTGCAAGCTAACCATCAGCC ^h chr7	94042944	94043141
COL1A2	COL1A2_35	GGCCATCTCCATTTTCAGTCCAA	ACAGCTCAATAGGCTGACCAAA	198	44	GGCCATCTCCATTTTCAGTCCAAAAGTTATACAGCTAC ^h chr7	94043115	94043312
COL1A2	COL1A2_36	CCCAAACCTCAATTATTAGCAAATCTCC	AGCAGTGGGGTATTAAACAGGG	200	41	CCCAAACCTCAATTATTAGCAAATCTCCTGAACRTAGCC ^h chr7	94043461	94043660
COL1A2	COL1A2_37	TGCCAGGTTTATTTCACTCTTTCC	AAAAACACATTGCCAGAGTTTATGA	196	35	TGCCAGGTTTATTTCACTCTTTCCAAATTTTTCAAATAT ^h chr7	94044434	94044629
COL1A2	COL1A2_38	CACTGAAAGTGATGAATGGTGCAA	CTGGGCCAAACAGCAATATAGA	187	48	CACTGAAAGTGATGAATGGTGCAACACTTCTCTAAT ⁱ chr7	94045668	94045854
COL1A2	COL1A2_39	TTGATTCTTCATTTCTTTCTTCTCCAC	TTTCTCCCTTGCTCCAGGTAT	166	46	TTGATTCTTCATTTCTTCTTTCTCCACTAAAAATTGATT ⁱ chr7	94046977	94047142
COL1A2	COL1A2_40	ACATGTGTTTGACTCAAGGGTG	ATCCTTGTGCAGCCTCTTTACT	188	48	ACATGTGTTTGACTCAAGGGTGAACTGRTGKTGTTSc ^h chr7	94047018	94047205
COL1A2	COL1A2_41	ACTGAAGGTATCATAGCATCTTCTGTA	CACACGAGCACCATCTCTG	165	35	ACTGAAGGTATCATAGCATCTTCTGTAAAAAAGAAAA ^h chr7	94047703	94047867
COL1A2	COL1A2_43	CAGAGATGGTGCTCGTGTG	ATAGACCCAGGAGAGAAAGGAAT	157	29	CAGAGATGGTGCTCGTGTGRRTAGAATTTTGTTTGA ^h chr7	94047849	94048005
COL1A2	COL1A2_44	ATCCAACCAGAGTGCAGTGAAAG	CTCCAGCAGGACCAAGG	162	43	ATCCAACCAGAGTGCAGTGAAAGTGTTCAGTCACTGT ^h chr7	94048688	94048849
COL1A2	COL1A2_45	TGACAAGGTTCACTTTTGATGATACG	TAGGGAAGGCGGGAAATTTTAGA	176	45	TGACAAGGTTCACTTTTGATGATACGGGGTGTTNNTA ^h chr7	94048745	94048920
COL1A2	COL1A2_46	TGCCCTGGTCTGCT	AGCATTTGTTCCTGCTGCTCTA	189	44	TGCCCTGGTCTGCTGAGGCCACAGGTGACCRGGT ^h chr7	94048830	94049018
COL1A2	COL1A2_47	TCTGTCCACCACGTGTTCTCT	TGTCTAAACATTGTGAGGTGTGA	194	47	TCTGTCCACCACGTGTTCTCTCCCTYCCAGTTCTTTGA ^h chr7	94049458	94049651
COL1A2	COL1A2_48	TGGGTCAATTTTGATACTCACACCT	ACTCCCCAACTAGGATGTTTTCA	196	41	TGGGTCAATTTTGATACTCACACCTCACAATGTTTAGA ^h chr7	94049612	94049807
COL1A2	COL1A2_49	GTCGGAATACCAGAGCTGTAAC	ATCTAATGGGTAGCTGCTGTGTG	192	47	GTCGGAATACCAGAGCTGTAACGTGTTTATTTCCAACA ^h chr7	94049815	94050006
COL1A2	COL1A2_5	TCACTGGAATACTTCTTAGGCAT	TGCCAGTTCCTGTAGTTCTAACAT	169	40	TCACTGGAATACTTCTTAGGCATTTATTATTGTCCT ^h chr7	94028304	94028472
COL1A2	COL1A2_50	GCGGGAATGATCCACTGAAGAA	TGAAAAAGAAAGCGGCGAGAG	178	44	GCGGGAATGATCCACTTGAAGAAAAGAGTAGCATTT ^h chr7	94050238	94050415
COL1A2	COL1A2_51	ACCCAAATCTTGGAGTTGATGT	CCAGGCCCTTTGGCTAGAGTAAAT	162	46	ACCCAAATCTTGGAGTTGATGTTGACTGTGGAATTCT ⁱ chr7	94051155	94051316
COL1A2	COL1A2_52	CCCCAAATGGCCAGGGTATTATT	CCCTTCTTTCCAGCAGGAC	177	46	CCCCAAATGGCCAGGGTATTATTTTATTCATCACCATT ^h chr7	94052140	94052316
COL1A2	COL1A2_53	CAGGCCCTTGGTGATTAACAGAA	AGGGGGACCAACTGCAC	169	52	CAGGCCCTTGGTGATTAACAGAAAGGAAATGACCTTC ^h chr7	94052217	94052385
COL1A2	COL1A2_54	CTGGTCTGTGGGAAAGAAG	TCAGCATAAGGTATTAAGAAAGAGGAGT	179	48	CTGGTCTGTGGGAAAGAAGGGCTTCGTRGTCTCTCR ^h chr7	94052294	94052472
COL1A2	COL1A2_55	AAGCCAACCTGTGTTATCACCTA	ATACTGTCAAGCACTCACACAG	189	49	AAGCCAACCTGTGTTATCACCTAGGGCTTACCATA ^h chr7	94053585	94053773
COL1A2	COL1A2_56	AGGTCCTCAGGGTCTTCTTGG	TCACATTTGAAGTGGCAGCTTTT	162	47	AGGTCCTCAGGGTCTTCTTGGTGCTCTGGTATTCTGC ^h chr7	94053665	94053826
COL1A2	COL1A2_57	TTCCATCGAATAAGGGGAATGTC	TACAAACCAAGTGTGGACTCAC	178	52	TTCCATCGAATAAGGGGAATGTCAATTTTATCTTCTCTG ^h chr7	94054382	94054559
COL1A2	COL1A2_58	TAGCTACAACATAGGGGCTGGTA	AGCATCAATCTGGGTTGCATTTT	188	48	TAGCTACAACATAGGGGCTGGTAGGCAGCAGAGCTT ⁱ chr7	94054851	94055038
COL1A2	COL1A2_59	AAAATGCAACCCAGATTGATGCT	CTGCACTGAGGGACTGGTATTC	186	49	AAAATGCAACCCAGATTGATGCTAAGCTTCAATTTTGC ^h chr7	94055016	94055201
COL1A2	COL1A2_6	ACCACATATAATTCTTAGGTTTCTACAGG	AGCTAAAAGTTAGCAATACGTAAGACAC	194	53	ACCACATATAATTCTTAGGTTTCTACAGGGCCTGTCTA ^h chr7	94029440	94029633

COL1A2	COL1A2_60	CTTCACTTCTGACTTCCCCACAC	TGTTAGTGTTCGAAAGAAATCTTCAG	187	47	CTTCACTTCTGACTTCCCCACACTTGGGGATGGTGGAA	chr7	94055214	94055400
COL1A2	COL1A2_61	CGGTAAGTCTTATCCATCCTTCTGT	TATGTGCGAGATGGCTACAGTTT	172	47	CGGTAAGTCTTATCCATCCTTCTGTTCTTTATAGGGC	chr7	94055700	94055871
COL1A2	COL1A2_62	ATGTCTCTTGACATGTGCTCTG	CACTGCTCGCTTTAGCCTCTATT	165	45	ATGTCTCTTGACATGTGCTCTGAAAGTGTGATTTTCT	chr7	94056267	94056431
COL1A2	COL1A2_63	CATGTACCTGGTGTCTGTCTTCC	ACATTCTTAGGTCCGTGATCTT	186	49	CATGTACCTGGTGTCTGTCTTCTTAGGGCCCTGCTKG	chr7	94056473	94056658
COL1A2	COL1A2_64	AAATCTGCTGCCATGGATGTCTC	TTGGGTCTGAGAGAAGGTGCT	198	46	AAATCTGCTGCCATGGATGTCTCTCACTGAAMAAAA	chr7	94056866	94057063
COL1A2	COL1A2_65	GTAAGCGGTGGTGGTTATGACTT	GCTGGGTTCTTTAGAGCCTTC	173	49	GTAAGCGGTGGTGGTTATGACTTTGGTTAYGATGGAC	chr7	94056978	94057150
COL1A2	COL1A2_66	CCCAAGGACTATGAAGTTGATGC	AAAGCTCAACTGTGAGAAGGGT	189	50	CCCAAGGACTATGAAGTTGATGCTACTCTGAAGTCTC	chr7	94057059	94057247
COL1A2	COL1A2_67	AGTTATTATTAGAATCTGTGTTCTGCTCA	AGTTCTTGGCTGGGATGTTTTCA	188	37	AGTTATTATTAGAATCTGTGTTCTGCTCAATGAGAAGT	chr7	94057537	94057724
COL1A2	COL1A2_69	GGCCCAACCTGAAAACATCC	GTGTTTGGGATTCTCACCCTG	117	51	GGCCCAACCTGAAAACATCCAGCCAAGAACTGGTAT	chr7	94057693	94057809
COL1A2	COL1A2_7	TCAAAAAACATTGCCCTCTTTTAAATAAC	GCCAAGTCCAACCTCTTTTCC	171	26	TCAAAAAACATTGCCCTCTTTTAAATAACAACAGAAAA	chr7	94030750	94030920
COL1A2	COL1A2_71	AACCTGAAAACATCCAGCCAA	GAGATTAATAATGCAGATAATTAACAAACAGTCC	174	43	AACCTGAAAACATCCAGCCAAAGAACTGGTATAGGAC	chr7	94057698	94057871
COL1A2	COL1A2_72	ACTCTTAGTATCTGAGTCTTCTCCA	TTCTTGCAGTGGTAGGTGATGTT	167	42	ACTCTTAGTATCTGAGTCTTCTCCACTTAACCTGGAAT	chr7	94058443	94058609
COL1A2	COL1A2_73	AGGAGTGACTTCCAAGGAAATGG	CCTCAGCAACAAGTTCAACATCA	182	48	AGGAGTGACTTCCAAGGAAATGGCTACCCAACCTGGC	chr7	94058517	94058698
COL1A2	COL1A2_74	CATCACTTACCCTGCAAGAACA	CCACTTCCCAAAGCTATTCCCAT	194	44	CATCACTTACCCTGCAAGAACAGCATTGCATACATG	chr7	94058589	94058782
COL1A2	COL1A2_75	CATGCCAAACAGTGGTTCTTATT	GCACCACCGATGTCCAAAG	198	35	CATGCCAAACAGTGGTTCTTATTAAATCAAAGTTCA	chr7	94059462	94059659
COL1A2	COL1A2_76	TGATGCTTTGTGTATCTATTTTCTTCTC	CTGGGCCAATGTCCACAAGA	170	38	TGATGCTTTGTGTATCTATTTTCTTCTTTAAACAGAA	chr7	94059522	94059691
COL1A2	COL1A2_77	ACCTTTGGACATCGGTGGTG	GCAGAAGAAATGGAAGGATTGAGC	174	34	ACCTTTGGACATCGGTGGTGCTGACCAGGAATCTTT	chr7	94059639	94059812
COL1A2	COL1A2_8	TCAAAAAACATTGCCCTCTTTTAAATAAC	GGGCCAAGTCCAACCTCTT	173	27	TCAAAAAACATTGCCCTCTTTTAAATAACAACAGAAAA	chr7	94030750	94030922
COL3A1	COL3A1_1	TTGATGGTGCTACTTTGAACTGC	TCCATAAAGTTTCTTGAAATCAGTACC	186	41	TTGATGGTGCTACTTTGAACTGCTTTTCTTTCTCTTT	chr2	189839144	189839329
COL3A1	COL3A1_10	GCTTTGAAGCATGGATAAAGTGT	AAAAATGAGGAAGAAAAACCCACCA	162	43	GCTTTGAAGCATGGATAAAGTGATTTTGCATTCATT	chr2	189852738	189852899
COL3A1	COL3A1_11	GAGTAAATTTGCTGATTACATTACAATCC	ACTTACTGAAGGACCACTTGC	171	36	GAGTAAATTTGCTGATTACATTACAATCCTGATTTT	chr2	189853205	189853375
COL3A1	COL3A1_14	GCAAGCTGGTCTCTCAGTAAGT	ACAATTGAAAGAGTCCAAAAGACTCAA	182	28	GCAAGCTGGTCTCTCAGTAAGTTRCAATTAATTTAT	chr2	189853354	189853535
COL3A1	COL3A1_15	TCTATTCATTTTTATTCTTATTTTCAGGG	TTCTGGGATTCTGACATAAAGCAT	171	35	TCTATTCATTTTTATTCTTATTTTCAGGGCCCTCCA	chr2	189854092	189854262
COL3A1	COL3A1_16	CCATTTTGCTTATTGGCTACAATGTATTT	ACATAATAGTTTCAAGTCAAGATATTCCA	185	39	CCATTTTGCTTATTGGCTACAATGTATTTTTCATACAT	chr2	189854750	189854934
COL3A1	COL3A1_17	CAATGGAATTAACCTAAAAACAGAAAGTGT	AGCCCACTGGAATACCTTGTAA	192	33	CAATGGAATTAACCTAAAAACAGAAAGTGTTTTACT	chr2	189854939	189855130
COL3A1	COL3A1_18	TTTAATAATTTTGCTGGTTTTATACATTTCT	GTTGTGATTTACCTTTAATCCAGGAGC	100	38	TTTAATAATTTTGCTGGTTTTATACATTTCTAGGGCT	chr2	189855696	189855795
COL3A1	COL3A1_19	GGTTTTATACATTTCTAGGGCTTCG	CAGAAAACAAGTTAAGGCTCACAA	168	32	GGTTTTATACATTTCTAGGGCTTCGATGGACGAAAT	chr2	189855711	189855878
COL3A1	COL3A1_2	TCAGCAAAACCTAAGGAAACTTCAC	GGGGCAGTCTAATCTTGATCGT	192	43	TCAGCAAAACCTAAGGAAACTTCACRTCATYTAACCTG	chr2	189849440	189849631
COL3A1	COL3A1_20	ATTTTATATGTATCTAGGGTGAAAATGGTC	TTGACATGTGAAGAACAGTTGGG	162	36	ATTTTATATGTATCTAGGGTGAAAATGGTCTCCAGG	chr2	189856196	189856357
COL3A1	COL3A1_22	CCACCCCAACTGTTCTTACACAT	ACAGCCTGAAACTTTACTGAGGC	197	46	CCACCCCAACTGTTCTTACACATGTCAAGATTAGAGT	chr2	189856330	189856526
COL3A1	COL3A1_23	ATTACTCATGACCAGCCATTGAG	TCCACAATCCATAACTTCTCATTACCC	163	40	ATTACTCATGACCAGCCATTGAGAAATTAAGGATAT	chr2	189856850	189857012
COL3A1	COL3A1_24	TGCATAAATATCTTCTTACTTTATATGTGCT	ACATGTTTACCTTAGCACCAGGG	168	39	TGCATAAATATCTTCTTACTTTATATGTGCTCACTTAT	chr2	189857509	189857676
COL3A1	COL3A1_25	CTCCTGGTCTCTCTGGAAC	GATAAAAGCTATCCATTGACTGATTAATAA	162	40	CTCCTGGTCTCTCTGGAACGCCGATTCCCTGGATC	chr2	189857617	189857778
COL3A1	COL3A1_26	TGAAGGGTGAAGTGCTAAGTGA	TACTTACAGGAGGACCTTGAGCA	174	51	TGAAGGGTGAAGTGCTAAGTGAGTAGAAGTGGTAA	chr2	189858019	189858192
COL3A1	COL3A1_27	CCATTAGGGTGAAGTTGGACCTG	AGCACATGCTTTCATGGAGTAAG	196	48	CCATTAGGGTGAAGTTGGACCTGCAGGGTCTCTGGT	chr2	189858080	189858275
COL3A1	COL3A1_28	TCGATACATTTATTTTACACAACAAC	AGCCAGTAATGTGTGGATGAGAT	184	38	TCGATACATTTATTTTACACAACAACCTTCAAATATA	chr2	189858674	189858857
COL3A1	COL3A1_29	GGCTTCTTTTGCAATTTTGATGAC	GCAGTCCAGGAGCACCATTAG	194	46	GGCTTCTTTTGCAATTTTGATGACAATAGATTTGTAT	chr2	189858854	189859047
COL3A1	COL3A1_3	CTGTTGAAGGAGGATGTTCCCAT	GTGGGCAACTGCACAACATTC	189	46	CTGTTGAAGGAGGATGTTCCCATCTTGGTCAGTCTA	chr2	189849486	189849674
COL3A1	COL3A1_30	CCTGGACTGATGGGAGCC	AAATTCACCTGAACAGGAGCAAAA	173	45	CCTGGACTGATGGGAGCCCGGGTCTCCAGGACCA	chr2	189858984	189859156

COL3A1	COL3A1_31	TGATTGTAGTCGAATCCTCCCT	AGTTCAAAGTTTTACCTGTTTACTTTCT	191	40	TGATTGTAGTCGAATCCTCCCTGTGTTTCAACCAAG	chr2	189859212	189859402
COL3A1	COL3A1_32	GAAAGTAAACAGGTAATACTTTGAACTAAA	CCCCATGGAAAACGTACCTT	200	42	GAAAGTAAACAGGTAATACTTTGAACTAAATTCAGT	chr2	189859375	189859574
COL3A1	COL3A1_33	ATTCCAGGTGTTCAGGAGCTAA	AAATTGGCTGTCTCACCTGAAG	180	48	ATTCCAGGTGTTCAGGAGCTAAAGGCGAAGATGGC	chr2	189859462	189859641
COL3A1	COL3A1_34	TGCCACTCAAGAATTATGAAAAAGAA	CAAGAACTGCCATTTGTGGTG	182	42	TGCCACTCAAGAATTATGAAAAAGAAATGAAATCCTT	chr2	189859702	189859883
COL3A1	COL3A1_35	TGTTGCTATCTAGGTAGTGAAGGC	ACAAATGTTTCTGTACCCCTCAT	178	48	TGTTGCTATCTAGGTAGTGAAGGCattttaattttttaaz	chr2	189860357	189860534
COL3A1	COL3A1_36	TGCAGGGCCAGAGGA	TCTGATTGATTAAAGTGCTTTTGATCT	162	44	TGCAGGGCCAGAGGAGCTGCTGGAGAACCTGGCAC	chr2	189860450	189860611
COL3A1	COL3A1_37	TTCATTTTAAATCACCTAACAACCTGACT	ACACACACACACTCAAGGATA	179	42	TTCATTTTAAATCACCTAACAACCTGACTCTTTACTTCA	chr2	189860811	189860989
COL3A1	COL3A1_38	GCATGCTTTAATCTTCTTTATCAAACC	TGAAGAAATTAATGAAGGAACCTCACATC	180	44	GCATGCTTTAATCTTCTTTATCAAACCTTAATG	chr2	189861068	189861247
COL3A1	COL3A1_39	GGGAAGTCAAGGAGAAAGTGGT	TGAAGAGGAGACTGAGTTTGAC	198	46	GGGAAGTCAAGGAGAAAGTGGTCGACCAGGTCTCC	chr2	189861123	189861320
COL3A1	COL3A1_4	CAAGAATTAGACTGCCCAACCC	ACATGGCTATTGTGAACATGACT	189	39	CAAGAATTAGACTGCCCAACCCAGAAATCCATTGT	chr2	189849614	189849802
COL3A1	COL3A1_40	AGTTATTGCCCTTGAGGATTAGT	AGTCAGAAGGTGGAGATGAACG	168	46	AGTTATTGCCCTTGAGGATTAGTAAATACCGACCAC	chr2	189861843	189862010
COL3A1	COL3A1_41	CCAACCTCTGACTTCTCTGT	CCCACCTCCACCTATTTCATC	167	44	CCAACCTCTGACTTCTCTGTGAATCTGTAATTTCT	chr2	189861997	189862163
COL3A1	COL3A1_42	TCACATCACTACTTTTATAATTAAGCAACA	AGTCAGATATGCCGTGACATTTA	198	38	TCACATCACTACTTTTATAATTAAGCAACAGRCCTGTT	chr2	189862321	189862518
COL3A1	COL3A1_43	GCTTTTCTATAAGCCATGTTTGAGGT	CAAAACAGTGTGATTCTTTTGTGTTCTG	166	38	GCTTTTCTATAAGCCATGTTTGAGGTAATTACCTAATA	chr2	189862935	189863100
COL3A1	COL3A1_44	atatttACATAAAATGCACCTGATATGGG	ACTACTAATCAATTGCTCTATAACCTGCT	162	41	atatttACATAAAATGCACCTGATATGGGCCTAATCAT	chr2	189863343	189863504
COL3A1	COL3A1_45	GGCCTGATTCAAAATGATGCAAGT	GTGGAGTTACCTTTCTCCTTCG	195	49	GGCCTGATTCAAAATGATGCAAGTTAAGGTGCTTTGT	chr2	189863925	189864119
COL3A1	COL3A1_46	TCACAGGGTGATGCTGGT	AGCACCTGAAAAAAGTGAGAA	197	49	TCACAGGGTGATGCTGGTRCCCTGGTGAACGTGGA	chr2	189864005	189864201
COL3A1	COL3A1_47	CGAAGGAGGAAAGGTAACCTCAC	TTCCAAGACCTCCTCTTCTCCA	184	46	CGAAGGAGGAAAGGTAACCTCACAGCATTCCATTCA	chr2	189864097	189864280
COL3A1	COL3A1_48	CACTTATTTTCAGGGTGCTGCTG	ACTTTCAGGAGTGTTGCTTTTT	198	46	CACTTATTTTCAGGGTGCTGCTGCTCCTGGGCCA	chr2	189864183	189864380
COL3A1	COL3A1_49	TGAGAGTTACTCCTCTTCTGGC	TAGATAAGGCCTGCTTCTCTCA	167	47	TGAGAGTTACTCCTCTTCTGGCTGATTTTCACTGAAG	chr2	189864492	189864658
COL3A1	COL3A1_5	TGCAAAATCTGTGCTTGTAACTTGT	AGCTCAAATCTAGAAAAAGCAAACCTCT	177	36	TGCAAAATCTGTGCTTGTAACTTGTCTTTTCCAT	chr2	189849877	189850053
COL3A1	COL3A1_50	AGGTATCTATGTCTATATACTTTCTGTTTGAT	AGGTAGTATTAAAGGTTACCTTATCTCCAG	163	37	AGGTATCTATGTCTATATACTTTCTGTTTGATTAATGC	chr2	189866033	189866195
COL3A1	COL3A1_51	ttatttCCTCTAGGGTCTACTGGTC	CACCTTCACCCCTGGAAAAAGAGA	162	46	ttatttCCTCTAGGGTCTACTGGTCTTATGGTCTCTC	chr2	189866110	189866271
COL3A1	COL3A1_52	AGGTAACCCCTAATACTACTCGGA	TAGTACTGTCTGTATGGGGTT	196	43	AGGTAACCCCTAATACTACTCGGAWATAAAAAAGAA	chr2	189866175	189866370
COL3A1	COL3A1_53	TTTCCTGCCTAAAGGAGATGACG	ATAGAGATCCTGGGCTATGGGAC	166	47	TTTCCTGCCTAAAGGAGATGACGCACATTCCTGTG	chr2	189866961	189867126
COL3A1	COL3A1_54	AGCTGAGAGATTGCTGTTGTTGT	agacagaGAAAGAGGAAGGAAC	166	53	AGCTGAGAGATTGCTGTTGTTGTCATGTAGGGACA	chr2	189867649	189867814
COL3A1	COL3A1_55	GGCTTAATGCTTTTCCCAAAATTTGATT	TCTCAAATGCAGCTTTTATACAGGT	196	38	GGCTTAATGCTTTTCCCAAAATTTGATTTTGGTRCTAT	chr2	189868069	189868264
COL3A1	COL3A1_56	AGGGGAAACACAAACCATAAATGAC	ACTTTAACAATTACTTACATTACTACCAGGA	198	37	AGGGGAAACACAAACCATAAATGACTTTCAGGTACAC	chr2	189868334	189868531
COL3A1	COL3A1_57	TATTACCATTTACAGGGTGCTG	ACTAGAGAAATAAGTAGCAATGTGTAAGTTT	170	40	TATTACCATTTACAGGGTGCTGCTGGCTTCCCTGGT	chr2	189868444	189868613
COL3A1	COL3A1_58	ACTTACACATTGCTACTATTTCTCTAGT	CCAGTGTTACCCGCAGGAC	197	38	ACTTACACATTGCTACTATTTCTCTAGTAASCTCTCAA	chr2	189868585	189868781
COL3A1	COL3A1_59	ATTTGTAGGGTAACCCAGGACCC	CATCACCTTTTGGTCCAGACACT	123	62	ATTTGTAGGGTAACCCAGGACCCCGAGTCCAGCGC	chr2	189868700	189868822
COL3A1	COL3A1_6	TGTGAATCACCAGGATTTTCACTATT	CTGAGGACCAGTAGGGCATGATT	166	47	TGTGAATCACCAGGATTTTCACTATTTAATTTATTTT	chr2	189850339	189850504
COL3A1	COL3A1_60	GGTCTGCGGGTAACACT	ATGTGACAGTGTTTTCTCTAATCG	188	47	GGTCTGCGGGTAACACTGGTGCTCTGGCAGCCCTC	chr2	189868762	189868949
COL3A1	COL3A1_61	CAGTGTACATAAAGATGAGCTAAGT	GGCTACCAAAGGAAGGAAGAGTG	198	53	CAGTGTACATAAAGATGAGCTAAGTCTTATTATCTC	chr2	189868939	189869136
COL3A1	COL3A1_63	TTTCCCATAGCAGGCATAGTTTT	TTAGCTCTGGTTTCCCACTTTC	174	27	TTTCCCATAGCAGGCATAGTTTTAATTTTAAATTTCAA	chr2	189869928	189870101
COL3A1	COL3A1_64	GTATACAGGGTGAAAGTGGGAAAC	TGCTACTACATCTCTCCAGGT	126	56	GTATACAGGGTGAAAGTGGGAAACCAGGAGCTAAYG	chr2	189870068	189870193
COL3A1	COL3A1_66	GAGAAGCTGGTCCCCCTG	TGTGGCCATATTTACACTCTTAGACA	173	45	GAGAAGCTGGTCCCCCTGGACCCAGGGTCTTCTCTG	chr2	189870113	189870285
COL3A1	COL3A1_67	GGAAGGTTTCAAGAAATTTTATTTCTTTCTC	CCACGATCACCTGTGAACAAAT	195	37	GGAAGGTTTCAAGAAATTTTATTTCTTTCTCATTTTT	chr2	189870887	189871081
COL3A1	COL3A1_68	AAGTGATCATCATGTTTATTTTGTACCT	CTGCTTTTGGGAACCTCACACTTT	170	51	AAGTGATCATCATGTTTATTTTGTACCTATGAATTTGT	chr2	189871027	189871196

COL3A1	COL3A1_69	TGATCGTGGTGAAAAATGGCTCT	AGATCTGACATTCTACCTTCTACCT	191	50	TGATCGTGGTGAAAAATGGCTCTCCTGGTGCCCTGGC	chr2	189871073	189871263
COL3A1	COL3A1_7	GTATTCCAGGACAACCAAGGTC	ACACTGAATCAGAGAACAGATACAA	197	41	GTATTCCAGGACAACCAAGGTCCTGGTCTCTGG	chr2	189850428	189850624
COL3A1	COL3A1_70	ACTAgTTCcGTGTATGTCTCTCA	TTTTCTGAAACACGcTGGAAAAT	196	41	ACTAgTTCcGTGTATGTCTCTCAATTGAATGTTTTCA	chr2	189871619	189871814
COL3A1	COL3A1_71	ttttattttCCAATATGTATGTGTATATGACT	AACCTGGGGCACCTGGATTA	162	44	ttttattttCCAATATGTATGTGTATATGACTTCAATT	chr2	189872167	189872328
COL3A1	COL3A1_72	AAACAGGTGAACGTGGAGC	GCCTTCAAATCCATTCTCATCTC	198	38	AAACAGGTGAACGTGGAGCTGCTGGCATCAAGGAC	chr2	189872257	189872454
COL3A1	COL3A1_73	TGTACAGTTTCCAGTGCTTTTT	TGCAGACATCTGAAACATGTGGA	165	50	TGTACAGTTTCCAGTGCTTTTTAAGGCCTCACTCT	chr2	189872550	189872714
COL3A1	COL3A1_74	CCACATGTTTCAGATGTCTGCAAT	CCTCTTTCACCTCTGTTACCTCG	169	50	CCACATGTTTCAGATGTCTGCATTTCAGAAAGATAATC	chr2	189872693	189872861
COL3A1	COL3A1_75	TGATGTCATGATACTTCTTAGGGAC	GCGCTGTGTTCTGAAAATGGA	198	46	TGATGTCATGATACTTCTTAGGGACCTGTTGGACCC	chr2	189872739	189872936
COL3A1	COL3A1_76	TTCTTAGAGTGGCGACTGAATGT	AAAACCGCCAGCTTTTTACC	181	56	TTCTTAGAGTGGCGACTGAATGTGCATACCTCAATGA	chr2	189873592	189873772
COL3A1	COL3A1_77	GGCAACCAGGCCCTCC	TGAGTGAAGTCATAATCTCATCGGT	171	52	GGCAACCAGGCCCTCTGGACCTCTGGTGCCCTGG	chr2	189873669	189873839
COL3A1	COL3A1_78	GCTGGGATTGGAGGTGAAAAAG	TTCAGGATGGCAGAATTCAGGT	198	42	GCTGGGATTGGAGGTGAAAAAGCTGGCGGTTTTKCC	chr2	189873740	189873937
COL3A1	COL3A1_79	GCCTCATTAGTCCTGATGTTCT	TGAAAGTAGATGTTTTTCGTTCCCA	174	41	GCCTCATTAGTCCTGATGTTCTCGTAAAAACCCGC	chr2	189873864	189874037
COL3A1	COL3A1_8	ACATCTTTTGGCACACAAAAACCT	GGATAGCCTGCGAGTCCT	195	38	ACATCTTTTGGCACACAAAAACCTATCAGTAGACAGT	chr2	189851661	189851855
COL3A1	COL3A1_80	AGGTAAACAAACAAATCACTTTATTACTGG	CCAGTGTTTCCGTGGAACATTCA	193	36	AGGTAAACAAACAAATCACTTTATTACTGGATTTTAT	chr2	189874833	189875025
COL3A1	COL3A1_81	TTGACCCTAACCAAGGATGCAAA	CCTTTCCTACCTGAAAACACCA	186	43	TTGACCCTAACCAAGGATGCAAAATTGGATGCTATCAA	chr2	189874916	189875101
COL3A1	COL3A1_82	CTGGTGGACAGATTCTAGTGCTG	accaacctGTAACCTTGTCTTGTG	164	38	CTGGTGGACAGATTCTAGTGCTGAGAAAGAACCGT	chr2	189875022	189875185
COL3A1	COL3A1_83	TGCATACACATACTACATGAATCCCTC	GCAGTGATATGTGATGTTCTGGGA	185	43	TGCATACACATACTACATGAATCCCTRCGTGCAGTTA	chr2	189875294	189875478
COL3A1	COL3A1_84	TTTAGCTACGCAATCCTGAACT	TCACCTTCATTGACCCCATCAG	185	46	TTTAGCTACGCAATCCTGAACTTCTGAAGATGTCT	chr2	189875374	189875558
COL3A1	COL3A1_85	TAGCATTGCATACATGGATCAGG	AAAATGCTGACTGCTTATGACC	180	42	TAGCATTGCATACATGGATCAGGCCAGTGGAAATGT	chr2	189875484	189875663
COL3A1	COL3A1_86	GTCAGAGTTGTCTAAGTAATTGTAATGTC	GCCAACGTCCACCAAAATTC	189	41	GTCAGAGTTGTCTAAGTAATTGTAATGTCATGATCAT	chr2	189876294	189876482
COL3A1	COL3A1_87	AGCAAAACAGTCTTTGAATATCGAAC	ACAAGATTAGAACAAGAGGAACACA	199	38	AGCAAAACAGTCTTTGAATATCGAACCGCARGGCTG	chr2	189876372	189876570
COL3A1	COL3A1_9	CCTTGCCACAGAACTATTCTCC	ACTGAATTCCTAGAAGAGCAACCA	180	42	CCTTGCCACAGAACTATTCTCCCACTATGATTTCATAT	chr2	189851774	189851953
COL5A1	COL5A1_10	CTTCCTGGTCTCCATCTACAACG	GGGACAGTTGCCAGAAAGTG	179	61	CTTCCTGGTCTCCATCTACAACGAGCAGGGTATCCAG	chr9	137591819	137591997
COL5A1	COL5A1_11	GCTTGAGCTGGCATCTGTGA	CATTGATGTGCATCATGGGGTGG	171	50	GCTTGAGCTGGCATCTGTGATCCAAGCCCTGTCTTCA	chr9	137592962	137593132
COL5A1	COL5A1_12	GCGTCCACAAGAAAAATGTCACC	GGCACAGGGGTGGTCTG	174	54	GCGTCCACAAGAAAAATGTCACCTTGATCCTCGACTG	chr9	137593037	137593210
COL5A1	COL5A1_13	CCATGCGAGTGCTCTGTGA	TATTATCTGAGTTGGGGTCTG	183	54	CCATGCGAGTGCTCTGTGAGTGCTTTTTTCATGAGCG	chr9	137619060	137619242
COL5A1	COL5A1_14	CTGCTCTTTGTCTCGGACCAC	ATGTGCTCTTTCACCAACCATCC	188	53	CTGCTCTTTGTCTCGGACCACCGGGCAGCTTATGATT	chr9	137619127	137619314
COL5A1	COL5A1_15	GGTTGCGGAAGGAAGGACAG	AGCTTCCACGGCTTCTTG	189	60	GGTTGCGGAAGGAAGGACAGCGCTGGTCGCTCTG	chr9	137620438	137620626
COL5A1	COL5A1_16	CTTTCAGTACACGGAAGGAGACG	CCAGCCCAACCCAGTCC	178	60	CTTTCAGTACACGGAAGGAGACGGCGAGGGTGAGAC	chr9	137620509	137620686
COL5A1	COL5A1_17	CACTGAGATGCTGCAACC	CACGTAGTCATAGTCCCGATG	197	63	CACTGAGATGCTGCAACCCGACATGCGGCAAGTCY	chr9	137621984	137622180
COL5A1	COL5A1_18	GACTCCAGCTGTCTGTCTCTTG	TTCTCCTCCCCCTGCCATA	195	61	GACTCCAGCTGTCTGTCTCTTGCTCCAGGAGCTG	chr9	137622051	137622245
COL5A1	COL5A1_19	GACTATGACTACGTGCCAGTGA	ACCAAACCAATGGGAAGGAAAGA	185	56	GACTATGACTACGTGCCAGTGAGGACTACTACACGC	chr9	137622166	137622350
COL5A1	COL5A1_2	AAGTGGTGCGGTCCCT	GCCCACAGCAGCAGCA	198	79	AAGTGGTGCGGTCCCTGCTGAGTGCCTGCCCCGGC	chr9	137533925	137534122
COL5A1	COL5A1_20	GCCAGGGCCTGATGGA	ATCTCCGACGGGAGCTG	198	63	GCCAGGGCCTGATGGAGAGGCAGTGCCTGGTGCT	chr9	137623269	137623466
COL5A1	COL5A1_21	GAAGGTGCGGATGACTTGGA	AGCCCCCAACCCAC	193	62	GAAGGTGCGGATGACTTGGAGGGGAGTTCACTGAC	chr9	137623360	137623552
COL5A1	COL5A1_22	GGACTTCTTTCTCACTTTTCTCTCT	CTGTTACACCCATACACCC	198	55	GGACTTCTTTCTCACTTTTCTCTGATTCTCTTTCCA	chr9	137623857	137624054
COL5A1	COL5A1_23	GAGCCAGGCTCTTTG	TCTGCAAGTCACAGGATAAAGCC	183	65	GAGCCAGGCTCTTTGTCATGCAGCTGAAGGCGCT	chr9	137630212	137630394
COL5A1	COL5A1_24	GCCAGTTGGAACCTTGGACCTT	ACACCTTGTTGATCTCAGGAAA	173	53	GCCAGTTGGAACCTTGGACCTTGCCCTGCGGCCCATC	chr9	137630522	137630694
COL5A1	COL5A1_25	CCTGGCCTGGTTGCACT	CCTCAGAGGTCTGGTTGGAT	195	64	CCTGGCCTGGTTGCACTCTGACTTGCTCTCTTGCCCC	chr9	137642339	137642533

COL5A1	COL5A1_26	GGGTGCCACGTCACTGC	CTGTCCCTTCAGGCCTCTT	180	63	GGGTGCCACGTCACTGCTCCAGAGTGACCCTTGCTCT	chr9	137642588	137642767
COL5A1	COL5A1_27	CCACATCTCACGGCTCAGG	CCAGCTCTCAGATTGCCAATGA	167	61	CCACATCTCACGGCTCAGGCGCCAGCAAACCGGAGC/	chr9	137644353	137644519
COL5A1	COL5A1_28	GAAGCCCTGTCCCCTCCC	CAGACAGCGAAGGCAAGGAT	188	64	GAAGCCCTGTCCCCTCCCCTGCCCTCCCTGCCACC	chr9	137645591	137645778
COL5A1	COL5A1_29	GACAAGGCTTTGCTCTTTCTCCT	CAAGCTGCTGTCTAAACCACA	165	61	GACAAGGCTTTGCTCTTTCTCTGAGAAAGCGGACT/	chr9	137646049	137646213
COL5A1	COL5A1_30	CGCTCAACTGGTTTAACGGAAA	GGATGACAGTGATGCCAGGG	191	59	CGCTCAACTGGTTTAACGGAAAACCATGGCCCGGGC	chr9	137648520	137648710
COL5A1	COL5A1_31	GGCGGCCATCACTTGGT	CCCATCGTCATGCCTGTGTC	178	62	GGCGGCCATCACTTGGTGGACACCAAGGCRGGGTG/	chr9	137650004	137650181
COL5A1	COL5A1_32	AAAAACAAAGTGGGACCTTGGAC	TTCTGCCCAAATCACTGAGGAG	196	57	AAAAACAAAGTGGGACCTTGGACMAGCCCTGCATGA	chr9	137653694	137653889
COL5A1	COL5A1_33	GTGTCCAGGCTAACAGCTCATT	TAAGCTCTGGCTGATCCCA	198	58	GTGTCCAGGCTAACAGCTCATTCTCTAACCTTGCCTT	chr9	137655486	137655683
COL5A1	COL5A1_34	GTGGAGTCAGGGCCAAGTG	AGACAAGCAGGGCGGTAATG	173	60	GTGGAGTCAGGGCCAAGTGGGCATAGGGGACAGAG/	chr9	137657436	137657608
COL5A1	COL5A1_35	AGCACTGTGAGTTCTTTCGCATT	CTGATGTGGACAGCGATGGAC	197	55	AGCACTGTGAGTTCTTTCGCATTCACTTACATGTTTT/	chr9	137658242	137658438
COL5A1	COL5A1_36	GGAAGGGGATACAGTCCCAGAG	CTCCGGAAGTGAGACGTGTG	179	65	GGAAGGGGATACAGTCCCAGAGCCCCCTTCAGTGCC/	chr9	137658789	137658967
COL5A1	COL5A1_37	CAGGGGAGGGTTCTGAGTCAAT	GATACCAAGGGTCTCCACAG	193	62	CAGGGGAGGGTTCTGAGTCAATCAGCGCCCTCACCTT	chr9	137659092	137659284
COL5A1	COL5A1_38	TGTGGGCAGAAATGTTGAAAAGTA	GATGAGGTGGGCAGGGCTA	176	59	TGTGGGCAGAAATGTTGAAAAGTAACCTTGTGGCC/	chr9	137660158	137660333
COL5A1	COL5A1_39	GAAGGGAAATGGGCTCCATGA	CACCTGGATGCTGAAGGGTAG	194	57	GAAGGGAAATGGGCTCCATGATCATGGATGCTACGC/	chr9	137664529	137664722
COL5A1	COL5A1_4	CTGCTGCTGCTGCTGTG	ATTCCACAGGCCAAGGAAGAAAA	152	74	ctgctgctgctgctgTGGGCGCCGCTCCGAGCCGCGCAG/	chr9	137534103	137534254
COL5A1	COL5A1_40	CTCTGAGATTTCTGATGTTCCC	CAAGGCCACAGTCCCAAC	192	59	CTCTGAGATTTCTGATGTTCCCAAGGCACCTCCACAC	chr9	137666629	137666820
COL5A1	COL5A1_41	TCTAGAAAGGCTGAGACTTGAACC	TGGTTTCTGGAAGAAGCATTGTG	197	57	TCTAGAAAGGCTGAGACTTGAACCATTCACCTCTTTT	chr9	137671891	137672087
COL5A1	COL5A1_42	CTGGTGCTGAGTGTGGTTGTTTG	GCCCAATCCCAACCTGAGATG	177	56	CTGGTGCTGAGTGTGGTTGTTTGAGCGGGGAAGGG	chr9	137674418	137674594
COL5A1	COL5A1_43	TCTCACCTCCTCTTTCTGGCTT	GTCAGATCCCTCCCAAGAAAGTG	181	62	TCTCACCTCCTCTTTCTGGCTTGCAAGGGGAGATCG/	chr9	137676808	137676988
COL5A1	COL5A1_44	CAGAACGCATGTCCTTTCTCTCT	GACACCTAACACGGCCAGAA	165	52	CAGAACGCATGTCCTTTCTCTGCTCCGGGGAAACG/	chr9	137677755	137677919
COL5A1	COL5A1_45	GGCATGCAGGTGGTCCC	CCCAGGGGCCAGGCTAT	164	60	GGCATGCAGGTGGTCCCCAGGCGGCCCATGCAGCA/	chr9	137680914	137681077
COL5A1	COL5A1_46	CAGGGCCGGGCATTTAGAG	AAGTCCCGACACAGACAC	198	61	CAGGGCCGGGCATTTAGAGAGTGAAGTAYCAGCCCC/	chr9	137686878	137687075
COL5A1	COL5A1_47	GTGTCTGTGTGCGGGACTTG	TGTAGCCTTGCAACTTGGGTTT	162	60	GTGTCTGTGTGCGGGACTTGAGCTGACCTTCTCTCT/	chr9	137687056	137687217
COL5A1	COL5A1_48	CAGACGTTTTGATGACGTTGTGG	CTTGAGAGACCCCCGAAG	167	54	CAGACGTTTTGATGACGTTGTGGGCCAGAGTCTTTTC/	chr9	137688132	137688298
COL5A1	COL5A1_49	GGAAGAAATGACACCTGCGTTC	GCCCAGCAAGGAAGCCATTA	187	58	GGAAGAAATGACACCTGCGTTCCAGAGAGCCACCGGC/	chr9	137688586	137688772
COL5A1	COL5A1_50	TTCTCAAAGGTGGTTGCTTCTCA	CGTGCAAGGTGGTCAGAG	173	57	TTCTCAAAGGTGGTTGCTTCTCAGACACGAATGAACC/	chr9	137690192	137690364
COL5A1	COL5A1_51	CAAGCGTCTGCTGAGAACA	GTGACCCATGGAATCTGGGAAG	170	65	CAAGCGTCTGCTGAGAACAGTGCAGGGCMGGGTG/	chr9	137693718	137693887
COL5A1	COL5A1_52	CGTCTGGGCTGACACTGATTTT	CTGACACAGAAGGCTCCAGAAAC	166	63	CGTCTGGGCTGACACTGATTTTCCCCACAGGGTCCC/	chr9	137694703	137694868
COL5A1	COL5A1_53	CTGGTGAGAGGTCTGCGTCA	CTGCACCTGTCCCATTTCATTCC	191	61	CTGGTGAGAGGTCTGCGTCACTGGCTCCAGGAAAGC/	chr9	137696763	137696953
COL5A1	COL5A1_54	GGAATGAAATGGGACAGGTGCAG	CCTTCTGACCTGGAGAGTAGGAT	188	57	GGAATGAAATGGGACAGGTGCAGCCCTGGAGGCCCT	chr9	137696931	137697118
COL5A1	COL5A1_55	CAGTCTGAGAGCCTTTGAAGCAG	CCCAATCCAAGGCAGTACTTACA	176	61	CAGTCTGAGAGCCTTTGAAGCAGAYTTTTTTCTTGCTC	chr9	137697989	137698164
COL5A1	COL5A1_56	GATCTCCAGGGGAGAGAGGTC	GACAAGGCCAGACACGGAAC	178	65	GATCTCCAGGGGAGAGAGGTCCAGCTGGAGCCGCTG	chr9	137698036	137698213
COL5A1	COL5A1_57	TGACCTGAGATCTTCTGTATTCTCT	GCCATGGGTCACTCTGGAATT	163	62	TGACCTGAGATCTTCTGTATTCTCTAGGGCGAGAAA/	chr9	137701002	137701164
COL5A1	COL5A1_58	AAGTTTTAGGGCCACCTGGAAG	CGCCCCGTGCCAATA	198	51	AAGTTTTAGGGCCACCTGGAAGGACACTGTTCTTAA/	chr9	137701978	137702175
COL5A1	COL5A1_59	CAGCCTTATCACGATCCAAGAA	AATAACCGCCATGGGTGAG	198	59	CAGCCTTATCACGATCCAAGAAGCTACCTATGTCTCT	chr9	137703131	137703328
COL5A1	COL5A1_6	GTGTTCCAGGTGCTCCTTC	TTTGGTGACTCTGTAAGCGACAT	188	51	GTGTTCCAGGTGCTCCTTCTCTCYGTGGCTAACTC	chr9	137582698	137582885
COL5A1	COL5A1_60	ATTGCCAGCATCCTCACCCAT	GTGTGGTGAGAACCCACAGTTA	173	64	ATTGCCAGCATCCTCACCCATGGCCGGTTATTTCCCTG	chr9	137703297	137703469
COL5A1	COL5A1_61	TGAAAGCTGTGTGTGTGTTTGAC	CAAATGTTTCCCCAAACATGAGC	188	52	TGAAAGCTGTGTGTGTGTTTGACATACATGACAGA	chr9	137704225	137704412
COL5A1	COL5A1_62	GTACTAGCGGCTCATGTTTGGG	GCACGAGCCTCACCTTCT	192	60	GTACTAGCGGCTCATGTTTGGGGAACATTGCRTT/	chr9	137704380	137704571

COL5A1	COL5A1_63	GATGCCCCACAAGGTCCC	CGTGTATGCACCCCCACAAG	183	54	GATGCCCCACAAGGTCCCCAGGTGGAATAGGAAAC chr9	137704502	137704684
COL5A1	COL5A1_64	GCAGACAGCAGGCAGGATTGG	GGCCATATCCCACCCCTCC	190	64	GCAGACAGCAGGCAGGATTGGCAAATGCTTGAAAC chr9	137705732	137705921
COL5A1	COL5A1_65	GTTGGCTCTGAGGACTTGACACT	GTGTGTCTGGAATACTCACAGGG	166	61	GTTGGCTCTGAGGACTTGACACTGGCCTCTTCTCTCC chr9	137706604	137706769
COL5A1	COL5A1_66	CCAAAGGAGAAAGGGGAGAGAAG	GTCAGAAATGATCCAGTGACAGAG	173	64	CCAAAGGAGAAAGGGGAGAGAAGGGCGAGTCAGGC chr9	137706647	137706819
COL5A1	COL5A1_67	GTGTGGTCTCAGTCAGGTTGC	AACCACCAGAAAGAGGGGAAATG	198	61	GTGTGGTCTCAGTCAGGTTGCTGATGGCCTTGGCTGC chr9	137707364	137707561
COL5A1	COL5A1_68	TGGAGATGCATTGGGAAGTGG	GGTCCCAAGAATACTGACACC	190	56	TGGAGATGCATTGGGAAGTGGTGCATGAACTCAGGG chr9	137707702	137707891
COL5A1	COL5A1_69	AATTGAGTCTAACGGGCCCAA	CAAGCAAAGGTGACGGGGAG	188	54	AATTGAGTCTAACGGGCCCAAATCTCACACTCTGTT chr9	137708817	137709004
COL5A1	COL5A1_7	TCTCTGAAGGTTCTAGATTTTCACA	ACCGCCCCAAACAGAAGG	186	54	TCTCTGAAGGTTCTAGATTTTCACAMCTTGCCTGAT chr9	137582771	137582956
COL5A1	COL5A1_70	CAGGCCACACACACACACA	TCACAGCCTGGCTCCAAAAC	180	63	CAGGCCACACACACACACACCTGAGCGCTGCACCC chr9	137709525	137709704
COL5A1	COL5A1_71	GCTCCGGACCTCATTCTGC	CCCTCACAGCCTACTACCAC	162	70	GCTCCGGACCTCATTCTGCCCTCCGCCGTCTGCAGG chr9	137710466	137710627
COL5A1	COL5A1_72	GGAAGACTGGCCCCATCG	GGATCCTGGGAGACCTGTGTC	188	66	GGAAGACTGGCCCCATCGGCCCCAGGGGGCCCTG chr9	137710530	137710717
COL5A1	COL5A1_73	CCCTGTGGTGAGTAGGCTGT	CTATGCTACCATGAGGAATGTG	174	63	CCCTGTGGTGAGTAGGCTGTGAGGGGCAGAGGGGT chr9	137710603	137710776
COL5A1	COL5A1_74	CACCCAAAGCCCCAAGGATG	CGGATCAAGAGCTGTTGAGTTT	194	57	CACCCAAAGCCCCAAGGATGAGGACTCTGATCCCCCT chr9	137710795	137710988
COL5A1	COL5A1_75	AATGCCCTTCTCTCTTCATTT	CCCAGGGATCTAAAATGCCTCTC	197	60	AATGCCCTTCTCTCTTCATTTTCCACAGGGTCATC chr9	137711931	137712127
COL5A1	COL5A1_76	GCAGCTCCTCCTCGTCTGAA	CCACAATTCTCTAGCTCCACACT	198	60	GCAGCTCCTCCTCGTCTGAAGGTGATAACCTGCATTTI chr9	137713891	137714088
COL5A1	COL5A1_77	GACATGGAGCACGGTGGG	GACGGTTGTCTGGGTAGTTGTT	198	63	GACATGGAGCACGGTGGGGCTGGAGCTGAGACCCG chr9	137714776	137714973
COL5A1	COL5A1_78	TCAAAGTCCCCTCATACCTCTGT	CACACACACACAGTTGCTTTCTC	192	59	TCAAAGTCCCCTCATACCTCTGTGACCAAGGGTTGAT chr9	137715207	137715398
COL5A1	COL5A1_79	ATATCTCTGGGACCCCTCCCATC	TAGTCCACGTAGTTCTCGCCATT	172	64	ATATCTCTGGGACCCCTCCCATCTCCATACCCACYGC chr9	137716387	137716558
COL5A1	COL5A1_8	GGCTGGCTTGTTCGAGAG	GATACCTGCTCGTTGATAGTGG	182	57	GGCTGGCTTGTTCGAGAGGCCATGGCTGGGTGTG chr9	137591671	137591852
COL5A1	COL5A1_80	CTGCCAATCCAGGCATCCAG	CCCAGGGGCCGTTTCATC	164	60	CTGCCAATCCAGGCATCCAGGACGCGCGGAACATC chr9	137716473	137716636
COL5A1	COL5A1_81	CGGACGGCATGGAAGAGAT	CCATGCCCGCTTTGGG	186	66	CGGACGGCATGGAAGAGATCTTCGGCTCTCTCAACT chr9	137716561	137716746
COL5A1	COL5A1_82	CTCCCTCCCGTCTCTGAAAT	GGGCCATGGAGGGACACA	165	56	CTCCCTCCCGTCTCTGAAATCCAGGTGAATACTGGG chr9	137717613	137717777
COL5A1	COL5A1_83	CTGGGGCCTTGCTCTGG	TTAAAGTGACAACCGCAAGACG	189	53	CTGGGGCCTTGCTCTGGAGGCCGARAARTAACCCCT chr9	137721741	137721929
COL5A1	COL5A1_84	CTTTGTGCTGTGTGTGTCCC	CAGGCCACTGACTGGTAGC	175	62	CTTTGTGCTGTGTGTGTCCCCACCCTGCTGAGCCCCA chr9	137726761	137726935
COL5A1	COL5A1_85	CTCTGCCACACAGAACGTC	CGGGATACTCAGACACAGC	175	62	CTCTGCCACACAGAACGTCMCCTACCACTGCTACCAG chr9	137726888	137727062
COL5A1	COL5A1_86	GCTCCAACGACGAGGAGATG	CAGGCATCTTGGGGACAGGTAAA	162	65	GCTCCAACGACGAGGAGATGTCTATGACAACAACCC chr9	137726983	137727144
COL5A1	COL5A1_87	TTTTGGAGCCAGACAGATTGTGG	CGCTTACCAGAGTCATTGAACA	192	53	TTTTGGAGCCAGACAGATTGTGGGGGKGATTGGTA chr9	137733910	137734101
COL5A1	COL5A1_88	CAGACCAAGAAAGGCTACCAGAA	GAGGTACACGAGTTGCTCTC	192	56	CAGACCAAGAAAGGCTACCAGAAGCGGTTCTGGAG chr9	137734000	137734191
COL5A1	COL5A1_9	GGACTTCTCCATCTAACAAC TG	TTGCCATCTGACAGGTTGATGC	198	59	GGACTTCTCCATCTAACAAC TGAAAGCCAAGAAA chr9	137591771	137591968
COL5A2	COL5A2_1	ACTTCAAGAGTCTCAGGATCAACT	GCACGCTTGCCCATCATAGA	192	46	ACTTCAAGAGTCTCAGGATCAACTTCAACAGTCAAA chr2	189898697	189898888
COL5A2	COL5A2_10	CGTTTTGTTTTGTTCATCAGGAGC	ACAATGTGTTAAATGTCTTCCAATCT	198	51	CGTTTTGTTTTGTTCATCAGGAGCCGCCTGATCTTAC chr2	189904131	189904328
COL5A2	COL5A2_11	TTGGACGGAATCTGAGCTATTGA	ACAGTCTTTGTTCTTGACAGGGT	191	49	TTGGACGGAATCTGAGCTATTGAATAAATAGCATTT chr2	189906249	189906439
COL5A2	COL5A2_12	CTCGTACACCTGGAGGTCCAAT	TCTTAGAAATCACTGTTACAGCTCCATA	193	42	CTCGTACACCTGGAGGTCCAATTTGGCCCAAGTGGCCC chr2	189906338	189906530
COL5A2	COL5A2_13	ACCAGGAAAACGATACTCAAGCA	TGGCACAATGCAGGATCCAAATA	198	39	ACCAGGAAAACGATACTCAAGCATTAGCAGTACATCA chr2	189907359	189907556
COL5A2	COL5A2_14	ACATATCCACCTATTTTACAGACAGAT	TGGTGACAAAGGTGATCATGGAG	188	44	ACATATCCACCTATTTTACAGACAGATAAATGTCRTG chr2	189907780	189907967
COL5A2	COL5A2_15	GGGCAGAATAATACTTAAAGGAATAACTTACA	TCATGCCATATCTCTATTTCTAGGGAC	162	50	GGGCAGAATAATACTTAAAGGAATAACTTACAGGAG chr2	189907846	189908007
COL5A2	COL5A2_16	ATAACTTACAGGAGGGCCAGGA	AAATTTTAGTCTCAACAATAATATGTAGCAAG	178	46	ATAACTTACAGGAGGGCCAGGAAGACCTGAAGACC chr2	189907868	189908045
COL5A2	COL5A2_17	AGCTTGAggaATTTCatATTTTTCAGTTAT	TTTCTTTTAGGGTTCTCGGGGTC	172	33	AGCTTGAggaATTTCatATTTTTCAGTTATGAATCTTAA chr2	189909797	189909968
COL5A2	COL5A2_18	AGAGAACTTACAGGTAATCCACGTT	ACGTATTGTTGACATCTGTATCTATG	148	37	AGAGAACTTACAGGTAATCCACGTTTCnnGCTCGAC chr2	189909894	189910041

COL5A2	COL5A2_2	ATTTCACGCCGAATTCCTGGTC	AGGTTGCTGTCTAACATACTGGA	193	41	ATTTCACGCCGAATTCCTGGTCTGWGCCRCMAACA' chr2	189898818	189899010
COL5A2	COL5A2_20	GCATATGGGTGTGCAAACTGTC	ATCATGGTTATTCTGTAGGGTGA	176	56	GCATATGGGTGTGCAAACTGTCAGTGTGAAATTGAC chr2	189910478	189910653
COL5A2	COL5A2_21	TTACCGGATCTCCTCTTTGTCCT	ACATGAACATATGGAATATTGTTGTTTAGA	182	47	TTACCGGATCTCCTCTTTGTCCTGCATCTCTGGAGCA chr2	189910522	189910703
COL5A2	COL5A2_22	AATTAAGAGATTTTCAGATTGCATGACTT	TGCTGTCAATTTTGTACAATTGGA	196	35	AATTAAGAGATTTTCAGATTGCATGACTTTAGATTTT. chr2	189912874	189913069
COL5A2	COL5A2_23	GACACCAGATAACAAGAGAAGAGT	TCAATTTCTTCACAAGTGTGGACAT	196	45	GACACCAGATAACAAGAGAAGAGTATTTTCACTGTA chr2	189914028	189914223
COL5A2	COL5A2_24	AGAGACTCAAAAATTAATGTCCCTACA	GCAACGTGGAGAGAGAGGC	173	39	AGAGACTCAAAAATTAATGTCCCTACAATACTGTTAA' chr2	189915165	189915337
COL5A2	COL5A2_25	GACCGATGCAGCTACTCACC	GGTACAGTTTACCTGGATAGTT	179	57	GACCGATGCAGCTACTACCGCTGGGCTGGTAGGCT chr2	189915276	189915454
COL5A2	COL5A2_26	TTGTGACACTGATCATTATGGGTT	GGGGACCTGGCTCTCAT	178	54	TTGTGACACTGATCATTATGGGTTTCTATTTGTAATA' chr2	189915967	189916144
COL5A2	COL5A2_27	TACAGTTGCCCATCTTCTCCT	CCCTCCTGGGTCTTCTTTTG	198	62	TACAGTTGCCCATCTTCTCCTGGGTCCCCTTTGCTCT' chr2	189916043	189916240
COL5A2	COL5A2_28	TGTGTAATTTTTCATTATCAGTGACTGTCT	AAGGCTTCAGTCTTCTGTGAAA	198	38	TGTGTAATTTTTCATTATCAGTGACTGTCTCACTAA' chr2	189916850	189917047
COL5A2	COL5A2_29	ACATGACCAGGAAGCACTAGGTA	ACATTAGCCTCTTTTGCTTCAC	176	43	ACATGACCAGGAAGCACTAGGTAACATAAGTAGCTG chr2	189917406	189917581
COL5A2	COL5A2_3	AAGGTAAGTTGCCCCAGTTCT	CCTCAAAAAGCTGTGGTTCTCA	198	34	AAGGTAAGTTGCCCCAGTTCTAGTGCYRTAATAGT' chr2	189899544	189899741
COL5A2	COL5A2_32	CTCCAAACATGGGGCACTTGA	GCTTGTTGTATAATTTTATAGGGTCTGA	184	47	CTCCAAACATGGGGCACTTGACTCAAGTTATGYCTTTT chr2	189917585	189917768
COL5A2	COL5A2_34	AGATAAGTGTTTATTTGTAAATTAGGGATATTTGA	TCCTTGCTCTCTAGGTTCT	115	42	AGATAAGTGTTTATTTGTAAATTAGGGATATTTGAAA' chr2	189918106	189918220
COL5A2	COL5A2_35	AAATTATACCTGGGGTCCGGCAA	AGGATAATGTGTGAAAGCTACAGTAATC	106	46	AAATTATACCTGGGGTCCGGCAAAACCAACAGCTCCA chr2	189918141	189918246
COL5A2	COL5A2_36	ACATAACCTAAACCAATAAGCATTGT	TGGACAGTAACCATCTAAAATCTGC	195	37	ACATAACCTAAACCAATAAGCATTGTTTTATATAAA' chr2	189918512	189918706
COL5A2	COL5A2_37	TGTTATAAAATGAAAAGATTTATGAAAGAGCC	ACCTCAATATGCCTATGTTCTGTT	172	41	TGTTATAAAATGAAAAGATTTATGAAAGAGCCTGCTA' chr2	189918800	189918971
COL5A2	COL5A2_38	CCAACCTGACTACCAAGGAAA	GTGGCATAGGAGAAAAAGGTGCT	170	43	CCAACCTGACTACCAAGGAAACATGACTGACTTTTA' chr2	189921582	189921751
COL5A2	COL5A2_39	CCTAGCCCAGCTAGAAAAGGAAT	TGACAATTAGCCTTCACTCTCAT	180	41	CCTAGCCCAGCTAGAAAAGGAATACTTCACTTACTCT chr2	189921664	189921843
COL5A2	COL5A2_4	AGCAAGTGCTTGAAGAACGATA	CTCAGATGACTTTTTTGCCTT	198	39	AGCAAGTGCTTGAAGAACGATATACCGGAATCTAAT chr2	189899644	189899841
COL5A2	COL5A2_40	TCAGCAGAAAGCTGAATAAATGAAC	TGGTATGGTCACTTAATGTTGGT	197	45	TCAGCAGAAAGCTGAATAAATGAAC'Gnnaaaaaaa chr2	189921989	189922185
COL5A2	COL5A2_41	TCTCACCATCATGCGTTTATT	GTGCTAGGGAGAACGAGGAAATC	180	46	TCTCACCATCATGCGTTTATTRAGCAGTAATTTTAA' chr2	189923081	189923260
COL5A2	COL5A2_42	ATGACACTTACTTTTGGGCCATC	TTCCGCACTAGAAGCCATTTCTC	198	44	ATGACACTTACTTTTGGGCCATCAGGACCATGCTCTCC chr2	189923144	189923341
COL5A2	COL5A2_43	TTAAACTGAAGCCAGTGGGAAA	AAACTAGGTGATGAACGGAAAGT	186	36	TTAAACTGAAGCCAGTGGGAAACAAnnTTAATCATG chr2	189923521	189923706
COL5A2	COL5A2_44	AAAGCACAACAGAGCCTCACA	CACAGATTACAATTTTATTTTCTACTTTTG	177	39	aaagcacacagagcctcacacataaaaagtATAATTGAGCC chr2	189925371	189925547
COL5A2	COL5A2_45	TGTAGAATTTCAAATCTTCTGACCATATC	GATCTGGTTATATTCACAATATTTTCTCCT	193	35	TGTAGAATTTCAAATCTTCTGACCATATCYTTTTTTT chr2	189926191	189926383
COL5A2	COL5A2_46	TCCCATACATTCTTATCACTTTCCC	ATCTGTGTGTGATACTAGGGAGC	193	40	TCCCATACATTCTTATCACTTTCCCTGAAACTTACSCA chr2	189927470	189927662
COL5A2	COL5A2_47	CAGGACCAGAAGGACCAACTTC	GGAAACCTGGAGAAGCAGGAAA	178	40	CAGGACCAGAAGGACCAACTTCACCATCTTTCCAGG. chr2	189927602	189927779
COL5A2	COL5A2_48	GAGTCCCTAGTATCACACACAG	GGAATTATACAAAAGTTTCAATTTATCTTTAGGG	184	37	GAGTCCCTAGTATCACACACAGATATTTGTGAGGTG. chr2	189927638	189927821
COL5A2	COL5A2_49	ATTTCTGCTTCTCCAGGTTTCC	CTCCAGGCCCAAAGGTAG	165	41	ATTTCTGCTTCTCCAGGTTTCCAGGGTCACCCTAAA chr2	189927757	189927921
COL5A2	COL5A2_5	GAGGTTCTTAGCTTGATCGTCCA	GGCATTATGAAACCTTCAGTCTT	198	39	GAGGTTCTTAGCTTGATCGTCCATGTATCTACACTGT chr2	189899738	189899935
COL5A2	COL5A2_50	TGTCAAAAACATACCTCTCCAA	ACTTACATGGCTCTGTCAATTC	196	53	TGTCAAAAACATACCTCTCCAAATGAGGATCATGAT' chr2	189927829	189928024
COL5A2	COL5A2_51	TCATTTAAGTTGCATGTCTGTTGAAAAA	ACTGCATATCAGCAACAACTGAC	162	36	TCATTTAAGTTGCATGTCTGTTGAAAAATATTAGTGT chr2	189928642	189928803
COL5A2	COL5A2_52	CACCTCTCCCTTTGATGTAGCA	TTTCTTCATGCATCTGCTTTGCC	174	53	CACCTCTCCCTTTGATGTAGCAAACTTGCTATATT' chr2	189929240	189929413
COL5A2	COL5A2_53	CATGCAGGCCATAGCTAGATCA	ACAACAATTAAGAATCACATTTTGGTCAT	180	48	CATGCAGGCCATAGCTAGATCACCGTGCTGAAAAATG chr2	189929639	189929818
COL5A2	COL5A2_54	TCCCTCACAACGTGAAGAATGTGTT	GGTTGGATGGGTCTTCTGGTAA	194	49	TCCCTCACAACGTGAAGAATGTGTTGTATTATTTAAAT chr2	189931074	189931267
COL5A2	COL5A2_55	TTTGAGCTGTACACTCCAGACA	TGGACTAGCTAAATGTCTTGTTTC	168	38	TTTGAGCTGTACACTCCAGACAATACTATGTTCTACT chr2	189931392	189931559
COL5A2	COL5A2_56	ACTCTTGGCCCTCGTAGTTAGAT	ACTTACCACATCACTCTTGCTGTT	189	51	ACTCTTGGCCCTCGTAGTTAGATTACACTAAAGGATG' chr2	189932681	189932869
COL5A2	COL5A2_57	GCCAATGTCTAAAGAATCATGCC	TCCTTTTGAAGATGGCTGGACA	198	39	GCCAATGTCTAAAGAATCATGCCATTGAGCTTCAC' chr2	189932893	189933090

COL5A2	COL5A2_58	CAGCTTCTGGGCTGGTTCTTA	TGTACAATGCCACTCTCGTATTT	197	51	CAGCTTCTGGGCTGGTTCTTAAATATGCTAGAAACTI chr2	189933472	189933668
COL5A2	COL5A2_59	TCATTCTTCACTTTGGGACTCATGT	TGAATACATGTCTGATTCTTTCTGGT	163	36	TCAATTCTTCACTTTGGGACTCATGTAATCATGTAGCGT chr2	189936697	189936859
COL5A2	COL5A2_6	AGCAAAGTCCTAAATAAATCAAAAATATGTAATAA	CCCATCCAGTGACCACGTAATAA	176	33	AGCAAAGTCCTAAATAAATCAAAAATATGTAATAART/ chr2	189901260	189901435
COL5A2	COL5A2_60	tgtacaaatGGAAGAATGCATGAATAA	AGGCAAATAGAGAAAAATAGTCTAAAAATGTAA	175	32	tgtacaaatGGAAGAATGCATGAATAAAATTAAGAAATTA chr2	189940058	189940232
COL5A2	COL5A2_61	TTCAGTAAACCAAACTGAAAAATGAATTG	TCAAATTAGGTGCTTCAAGAGACATT	171	42	TTCAGTAAACCAAACTGAAAAATGAATTGAAATACAC/ chr2	189943170	189943340
COL5A2	COL5A2_62	TCTTGTGTGAATCTAAAGGCAAGGA	ACACAGAACAAAGTGATGTATCGG	182	40	TCTTGTGTGAATCTAAAGGCAAGGAAATATAACCTT/ chr2	189943719	189943900
COL5A2	COL5A2_63	ACATTTGAAGCAAACTAAGATGCC	TGGTTCTTATGCCTTTGAGGATTGA	181	36	ACATTTGAAGCAAACTAAGATGCCRAAGTGAGGTTA chr2	189944644	189944824
COL5A2	COL5A2_64	TGCAACCATAGACAGTTAAGGACA	TGGATTCTGGGGCTCCT	168	43	TGCAACCATAGACAGTTAAGGACAATTGACAARTTGA chr2	189945594	189945761
COL5A2	COL5A2_65	GAACCTACTCGGTGACCTTCAG	TCTTAATATGTTGCTGAAAACTGTG	180	41	GAACCTACTCGGTGACCTTCAGACCTGGAAGACCAG chr2	189945708	189945887
COL5A2	COL5A2_66	TGCTCCATTTACTTAGTGCCTGA	TTTTGCCTTCCCAATCTCCTACA	198	36	TGCTCCATTTACTTAGTGCCTGATACATGTGCATACA/ chr2	189948604	189948801
COL5A2	COL5A2_67	CCTGAATGGAATAAGAGAAAGG	TTGACATTTCAATTGTCTCAATAATGTTTT	180	38	CCTGAATGGAATAAGAGAAAGTAGCTTACATCTTC chr2	189949855	189950034
COL5A2	COL5A2_68	GGACCTGGGAAGATAAACTCAATA	GGGTTTAATATTCTATTTTCTTGTTG	200	40	GGACCTGGGAAGATAAACTCAATATTTGACATCA/ chr2	189950355	189950554
COL5A2	COL5A2_69	TAAAACCAAGCAAAAGCAGTCA	TGCAACGTTTCTCTCATTTGTT	175	39	TAAAACCAAGCAAAAGCAGTCATGTCACAGAGACCT chr2	189951351	189951525
COL5A2	COL5A2_7	GGAGATTTACTGGCCACC	GACTTATAGTCATGATTGAGATTGCTTT	198	36	GGAGATTTACTGGCCACCAGGTTTACGTGGTACAC/ chr2	189901391	189901588
COL5A2	COL5A2_71	tgtacgACTGTGTTTAAGAAAGATGC	TTCAGCTCAAATGGCTGGGT	190	35	tgtacgACTGTGTTTAAGAAAGATGCATGTTATTCTTTGA/ chr2	189953304	189953493
COL5A2	COL5A2_72	CAGTAAATTTATGCTTACCACAGAGCC	CATTTATCCATATGAAAAGGAcGTTGATGAT	171	39	CAGTAAATTTATGCTTACCACAGAGCCAGGCATTAG/ chr2	189953402	189953572
COL5A2	COL5A2_74	ACGTGACATCAACAATGCACAC	TTTAAGTGGCTGTTTTCCAGGG	162	56	ACGTGACATCAACAATGCACACAACCTACCCTGCTC/ chr2	189957006	189957167
COL5A2	COL5A2_75	CTGCTCAAGCCATCGGGTC	CCTTGCCATTAAAGAAAGTCTGTGC	197	51	CTGCTCAAGCCATCGGGTCTGGGTGGGACGGATGT/ chr2	189957037	189957233
COL5A2	COL5A2_76	TGGAGGTGAAAGAGGAATAGTGC	TTTTCTGTTTTAGGGACCTCCAG	174	51	TGGAGGTGAAAGAGGAATAGTGTCCAGCTTCTTG/ chr2	189961896	189962069
COL5A2	COL5A2_77	CAACTTACAGTCTTCTTTTGGC	AGTGTGGTATTCTGTTTCCAATTTT	167	37	CAACTTACAGTCTTCTTTTGGCCCTCGCTCTCCTCTI/ chr2	189961995	189962161
COL5A2	COL5A2_78	AGAGACCAAGTATCATTGTTTAATTCTTT	GCAGAACTTTACCTTTACAATTTCTTGTT	191	34	AGAGACCAAGTATCATTGTTTAATTCTTTTATCTTCTC/ chr2	189963337	189963527
COL5A2	COL5A2_79	GCTAAGTTTATTTAAGGTACAAGGAAACA	ACATGGCATATTCTAGGGTGACAT	170	35	GCTAAGTTTATTTAAGGTACAAGGAAACAATGATTAT/ chr2	189964784	189964953
COL5A2	COL5A2_8	tggaaatgCAGTTGAGAATAACAATC	ACCCAGGGGTTCTAGCT	200	50	tggaaatgCAGTTGAGAATAACAATCAGAAAMAACGG/ chr2	189903930	189904129
COL5A2	COL5A2_80	TGTGTGGATAGTATTGGATATAAGTCTGC	ACTGTAATTCTGACTCCAGAAGAAATC	185	29	TGTGTGGATAGTATTGGATATAAGTCTGCTTATGAA/ chr2	189968927	189969111
COL5A2	COL5A2_81	TGAGTTGCTGAATGCTGAAAGTG	AAGATAGAATGCCAGGATGTGCT	194	45	TGAGTTGCTGAATGCTGAAAGTGAAAAACACTGCAAC/ chr2	189974863	189975056
COL5A2	COL5A2_82	TTGTGAACAGACAGGACAGCATT	TGGCCAGATGTAATAACAGGG	163	52	TTGTGAACAGACAGGACAGCATTCCCAAGGGGCGT/ chr2	189974979	189975141
COL5A2	COL5A2_83	ATCTTGTCACAGAGAATGGCTCC	TGGCTCACCTTTATTTTCTCAATTCT	194	39	ATCTTGTCACAGAGAATGGCTCCRTTGTCACAGACAC/ chr2	189975052	189975245
COL5A2	COL5A2_84	ACCTATTTCCAAACCGTGCAAT	TTTTCACTCTCAGGAGAACCAC	193	41	ACCTATTTCCAAACCGTGCAATAAACACTACAAGCA/ chr2	190044178	190044370
COL5A2	COL5A2_9	CTGGGTGCTTTTTCGAGCCATC	CTTGGGGATATCATGGGGCACTA	181	51	CTGGGTGCTTTTTCGAGCCATCGGGGCTGCGCATGGT/ chr2	189904046	189904226

Genomic co-ordinates based on GRCh37/hg19 human reference sequence

Table S2 Oligonucleotide sequences of Aortopathy NGS panel

Gene	Assay_Name	Forward Primer	Reverse Primer	Length	% GC	Amplicon	Chr	From	To
ACTA2	ACTA2_1	TGAAGGCATAATTCACAGGACA	GCAAATACTCTGTCTGGATCGGT	191	49	TGAAGGCATAATTCACAGGACATTCACAGTTGTGT	chr10	90694914	90695104
ACTA2	ACTA2_2	GGCCCCGGCTTCATCGTAT	AACATCCAGGCTCTGCTCTACC	198	50	GGCCCCGGCTTCATCGTATTCCTGTTTGCTGATYCACA	chr10	90695008	90695205
ACTA2	ACTA2_3	TCTGTGGTTATAGGGCTGACACT	GACATCAGGAAGGACCTCTATGC	185	54	TCTGTGGTTATAGGGCTGACACTGCTGGCGCATTGT	chr10	90697756	90697940
ACTA2	ACTA2_4	CATGGTGCTGGGTGCTAGG	ACCATGGCCTGTGTCTCTTTT	198	52	CATGGTGCTGGGTGCTAGGGCCGYGATCTCMTTCTG	chr10	90697827	90698024
ACTA2	ACTA2_5	GCTGGCTTGATATGGAAGAAGACA	ACTGCCGCATCCTCATCCT	181	53	GCTGGCTTGATATGGAAGAAGACAATGACTCCCCTT	chr10	90699201	90699381
ACTA2	ACTA2_6	TTTGTTCCTACCGATGAAGGAT	CGGGACATCAAGGAGAACTGTG	187	51	TTTGTTCCTACCGATGAAGGATGGCTGGAACAGGG	chr10	90699252	90699438
ACTA2	ACTA2_7	CCATCAGGCAACTCGTAACCTCTT	CACCTGTGCAGACCTAATGTTT	174	49	CCATCAGGCAACTCGTAACCTCTCAAGGGAGGATC	chr10	90699332	90699505
ACTA2	ACTA2_8	AGTGAGGATGGTCTGGAAAGTTA	CCATCTATGAGGGCTATGCCTTG	192	55	AGTGAGGATGGTCTGGAAAGTTACTGAGCAACACAC	chr10	90700914	90701105
ACTA2	ACTA2_9	TCAGGATCTTCATGAGGTAGTCAG	ACTTGTCCAGCAAGTAACCACAT	197	54	TCAGGATCTTCATGAGGTAGTCAGTGAGATCTCGGC	chr10	90701016	90701212
ACTA2	ACTA2_10	CTCCAACCAGCTTGCTGTCC	TGCTCTCCTGACCATTCTTTGTC	187	52	CTCCAACCAGCTTGCTGTCCGCCAGCCACCTACCA	chr10	90701507	90701693
ACTA2	ACTA2_11	CTAACAGAAGTTCCCCAGACCC	CTCTGTCCCCAACTCACTAGAT	187	55	CTAACAGAAGTTCCCCAGACCCASAGTGTGTGTG	chr10	90703499	90703685
ACTA2	ACTA2_12	ACTTGAGTCATTTTCTCCCGTT	AGTAGCTTCTGGTCCCTTTTGG	197	53	ACTTGAGTCATTTTCTCCCGTTGGCCTTGGGGTTCA	chr10	90703552	90703748
ACTA2	ACTA2_13	AGTTGAGCAATGTGAGCCAGTTA	TGACGAAGCACAGAGCAAAAGAG	198	49	AGTTGAGCAATGTGAGCCAGTTATTTCCCAGAGTA	chr10	90706905	90707102
ACTA2	ACTA2_14	CATACCTTTTCCATGTCTGCCA	ACAAGTTTGGGAGATGCTGACT	180	47	CATACCTTTTCCATGTCTGCCAGTTGGTGATGATGC	chr10	90707010	90707189
ACTA2	ACTA2_15	TGGGGATAAACATGAACACAGAGG	ATGTGTGAAGAAGAGGACAGCAC	198	51	TGGGGATAAACATGAACACAGAGGAACCTAATCTGT	chr10	90708490	90708687
ACTA2	ACTA2_16	CCACAATGGATGGGAAAACAGC	GTGCCACAAATGCCCAATTACAG	188	54	CCACAATGGATGGGAAAACAGCCCTGGGAGCATCGT	chr10	90708576	90708763
FBN1	FBN1_1	TGTTTTTCTTTTAATTATTGGTCTCTGGA	CCAGTGGCTGGAACCTAATTCAT	190	34	TGTTTTTCTTTTAATTATTGGTCTCTGGATGGTGAAT	chr15	48703150	48703339
FBN1	FBN1_2	TCATCTTCAGATTATCACCCAGTTC	ACCAAAAGGAAGGGATCAGCTAC	174	39	TCATCTTCAGATTATCACCCAGTTCACCACTKAGGTA	chr15	48703210	48703383
FBN1	FBN1_3	GCCACTGGCTTCTTCTTTGTGAA	AGACAGCCATCTTGCTTTCAAT	193	42	GCCACTGGCTTCTTCTTTGTGAAGTGAGGTAGCTGA	chr15	48703332	48703524
FBN1	FBN1_4	GAACCTTGTTACTGACGTGGGAA	TTAGTGTGAAATTGAGTCATTTTTTCTTT	191	38	GAACCTTGTTACTGACGTGGGAAATATTGAAAGCAA	chr15	48703477	48703667
FBN1	FBN1_5	CTTGAGGAAACACAGGAATCT	GGATGACAATCACTCTCCCCAG	187	50	CTTGAGGAAACACAGGAATCTGGAAGGGCTTTCC	chr15	48704691	48704877
FBN1	FBN1_6	GCATCAGTTTCGTTTGCTTCT	CAGGCACTGTGTTCTGGAATG	165	52	GCATCAGTTTCGTTTGCTTCTCCGTTTCTGCCCCY	chr15	48704779	48704943
FBN1	FBN1_7	CTGGGGAGAGTGAATTGTCATCC	ATCTCACAACCTGCAAGGAACAGG	186	50	CTGGGGAGAGTGAATTGTCATCCATTTCACCACTGAC	chr15	48704855	48705040
FBN1	FBN1_8	TGCTAGGACAGGTAATTTTGAGTT	AGACATCAATGAATGTGGCTCTG	200	49	TGCTAGGACAGGTAATTTTGAGTTCAGTATACTTAAT	chr15	48707644	48707843
FBN1	FBN1_9	AATCTCCAACCATGACCAGGAAG	GCCGGCTTCCAGTATGAACAG	184	55	AATCTCCAACCATGACCAGGAAGAGCACTGCTTACCC	chr15	48707698	48707881
FBN1	FBN1_10	TCATTGATGTCTTGGCATCCTCC	CCTCAATAGAAATCTCTGGCTGCT	189	52	TCATTGATGTCTTGGCATCCTCCACTGAACTGTTCAT	chr15	48707832	48708020
FBN1	FBN1_11	TTGCTTCATAGGACCTGATAGCC	TTCTTTTTCAGACGTGGACGAGT	186	53	TTGCTTCATAGGACCTGATAGCCATGTCATCTTGAGAG	chr15	48712829	48713014
FBN1	FBN1_12	CTGTAGCCCCAATGATGTTCTG	GTAGGATGTGTAGGGGCCAGATT	162	51	CTGTAGCCCCAATGATGTTCTGGCAGCCATGCTGGC	chr15	48712937	48713098
FBN1	FBN1_13	GGCTGATGATGAAGGTGCCAATA	GACATCAATCTGTGCGGGTCTAA	193	54	GGCTGATGATGAAGGTGCCAATAGCCACACAGGCCA	chr15	48713671	48713863
FBN1	FBN1_14	CCGGTCTGATCAAGTGAGAATCC	AGAGCTTTGGGGAATTTTAACCC	164	49	CCGGTCTGATCAAGTGAGAATCCCCGCTGGCATTAC	chr15	48713769	48713932
FBN1	FBN1_15	TCCCAACAGCAGAGGAAATAGAA	GATGAGTGTGCAACCAAGCAAC	193	44	TCCCAACAGCAGAGGAAATAGAAAATAATCCCTTAA	chr15	48714068	48714260
FBN1	FBN1_16	CAGGACGTATGGTGTGGGTAAA	CCTGATCCTGTTTTGTGGCTTG	166	46	CAGGACGTATGGTGTGGGTAAATCYGGGAGGACA	chr15	48714154	48714319
FBN1	FBN1_17	GTGGAGTCTTACAGGCAAGGA	GCTCCAAACCTGCAATTTTATC	179	48	GTGGAGTCTTACAGGCAAGGAATGCAGCCATGTG	chr15	48717490	48717668
FBN1	FBN1_18	TGAGGGGCAATGGTCAATTCTAC	ATGCACAGTCACGCTGATTTCT	184	46	TGAGGGGCAATGGTCAATTCTACTTTACCTTTGCAGC	chr15	48717538	48717721
FBN1	FBN1_19	TCCTATGAAACTGCACAGACTTTTT	GCCGAAATGGGGAATGTGTCAA	198	37	TCCTATGAAACTGCACAGACTTTTTAGATTTTAGCTT	chr15	48717831	48718028
FBN1	FBN1_20	CCACTTGAGGATAAGCCATCAGAAA	ACAGATATCGATGAATGCAAGGTT	166	41	CCACTTGAGGATAAGCCATCAGAAATAGACACTTACC	chr15	48717900	48718065

FBN1	FBN1_21	CATTGACACATTCCCCATTTCCGG	TCTTAGGCCCAAAATATAGTAACACA	174	30	CATTGACACATTCCCCATTTCCGGCAAACATCGTGAAT,	chr15	48718005	48718178
FBN1	FBN1_22	TCACACAAAAACAATAAATAGATTCCC	CACCAAAATCGGAATGCTGCTG	191	48	TCACACAAAAACAATAAATAGATTCCCTGCAAGTA	chr15	48719704	48719894
FBN1	FBN1_23	GAGTTTCTGAAAGCCACAGTCC	CCCCTTTGCCATATAATGTCCT	198	54	GAGTTTCTGAAAGCCACAGTCCCCTGGAAAGGGCA	chr15	48719801	48719998
FBN1	FBN1_24	AGAAGTCTGGGTTTCCAGCATCC	CCAGGGATCTGTGAGAATGGG	173	57	AGAAGTCTGGGTTTCCAGCATCCCAGTGTGGAGGCT	chr15	48720473	48720645
FBN1	FBN1_25	TGCCAACTGTACTACCAAGG	TGGTCAGATGACTCTTCTGTTT	190	49	TGCCAACTGTACTACCAAGGCACTCCTCTGGTTGG	chr15	48720527	48720716
FBN1	FBN1_26	GTTCTTCTGTCCACTGTCACTT	GTGTGAAGAGGGAAAACATGACT	184	47	GTTCTTCTGTCCACTGTCACTTCTGATGCACTCAAAG	chr15	48722806	48722989
FBN1	FBN1_27	GTGCAATGAGGTTCTTGCAATC	CAGCCAGTAGTGAAATAACAGATGA	197	33	GTGCAATGAGGTTCTTGCAATTCATTTGTTTTCAGT	chr15	48722927	48723123
FBN1	FBN1_28	CTCCCCTCACAGATAAAGCTTCC	AATGAATGTGCCAGAATCCTCT	173	48	CTCCCCTCACAGATAAAGCTTCTGGCTTAGATGACC	chr15	48725008	48725180
FBN1	FBN1_29	TGACTCACCTTGCACATCCTAC	TTGGTAGGTTCCCTTTTGTGCT	193	46	TGACTCACCTTGCACATCCTACGGTCTTCTGAGCA	chr15	48725055	48725247
FBN1	FBN1_30	AATCAACCAATTGTTCCAGGAT	GGCAATCCTGTGGAATGGAAC	163	44	AATCAACCAATTGTTCCAGGATCAGTACACGTAATC	chr15	48726728	48726890
FBN1	FBN1_31	ATTGGACCGGGCTCAAATCC	aacaacaaaTTACAGTTTAAATCCTCTG	197	39	ATTGGACCGGGCTCAAATCCTCTCGCAGGTGCATT	chr15	48726805	48727001
FBN1	FBN1_32	ACTTATTTCACTGCCATCTGGT	ACATGGACAGTGATCAATACAGA	191	36	ACTTATTTCACTGCCATCTGGTACCTATAATCATGGC	chr15	48729050	48729240
FBN1	FBN1_33	CACCTACACATTCATTCCTGCT	TCACGTTTAAAAATACCTGTTATTCACT	171	37	CACCTACACATTCATTCCTGCTAGAATATAACCAAA	chr15	48729155	48729325
FBN1	FBN1_34	AAGTGAAGAAGCAGATTGAGAA	TGTGGAGAAGCTTGAATGAATTG	190	44	AAGTGAAGAAGCAGATTGAGAACTGAGAAAT	chr15	48729456	48729645
FBN1	FBN1_35	ACTGTCTTTAAGGCCTACAGTCTT	ACCCAAATCCAGAAATCACTCCA	185	54	ACTGTCTTTAAGGCCTACAGTCTTACTTACATCATGG	chr15	48729878	48730062
FBN1	FBN1_36	CATACCACAGGTTCCGTGGG	AGTAGGAAAGCACTGAAGGGTG	197	49	CATACCACAGGTTCCGTGGGGCAGAGCTCGCAGGG	chr15	48729960	48730156
FBN1	FBN1_37	AGACCACCACAAATAAACATGCAG	CCCTGGGCACATGCAGTA	147	47	AGACCACCACAAATAAACATGCAGATTGAAAGCCG	chr15	48733861	48734007
FBN1	FBN1_38	CTTCCACTGGAGGACAAGGAAAA	TGTGTGTCCACATTGTGTGTTG	196	43	CTTCCACTGGAGGACAAGGAAAAACCTTCTGGACAC	chr15	48733929	48734124
FBN1	FBN1_39	ACGTCAATACAAAAATCTCATTCTGC	AGAACCACAGAAATGTGCCACG	183	44	ACGTCAATACAAAAATCTCATTCTGCTWAGTCCAGT	chr15	48736656	48736838
FBN1	FBN1_40	GCTTTCCTACCTTCACACTTCTC	TGTTTGATGGAAGTCATGCCAGT	189	43	GCTTTCCTACCTTCACACTTCTCATTTTGAAGACTGT	chr15	48736728	48736916
FBN1	FBN1_41	TGCATGATTCTTGAGTGGTCTC	TGTGCAAGTGGAAATGGGAATCT	182	46	TGCATGATTCTTGAGTGGTCTCTGGAAGCATCTTT	chr15	48737509	48737690
FBN1	FBN1_42	CATCTGGAGCCACTCATAGC	TGCTGGGATTATGACATCTTTGGA	172	41	CATCTGGAGCCACTCATAGCCTTCATTGCACTGGCA	chr15	48737588	48737759
FBN1	FBN1_43	AGCTGGAACACTAGAGATGATGC	TGAAAGAGATGCCTGTGGGAATG	189	42	AGCTGGAACACTAGAGATGATGCTRATTACAAGAA	chr15	48738818	48739006
FBN1	FBN1_44	CACAATTTTGCACACGCACCTAT	TGTTTCTTTATGGCCTTCTTCCT	165	42	CACAATTTTGCACACGCACCTATACAGTCATTGTTGT	chr15	48738884	48739048
FBN1	FBN1_45	CCATATTTAGAATCAAATGAAGCTTTCAACA	CCAATATATGCAGTCATGGGCAGT	168	35	CCATATTTAGAATCAAATGAAGCTTTCAACAGCATAT	chr15	48740899	48741066
FBN1	FBN1_46	CAAGCACATGGTTTGGTCATCATT	TCITCTAAGTTCTCACTTAAGATGCT	163	38	CAAGCACATGGTTTGGTCATCATTGTTTTAAACCA	chr15	48740966	48741128
FBN1	FBN1_47	TCATGAAGACAAACTCTTGGGT	AGATATTGACGAGTGTGAGAACGG	178	56	TCATGAAGACAAACTCTTGGGTAGGCATGTCCAGCC	chr15	48744706	48744883
FBN1	FBN1_48	TACCATTGCACTGTCTGTGGAG	TCATGTGAGAGGCTTTGTTGACT	198	52	TACCATTGCACTGTCTGTGGAGGTGAAGCGGTAGS	chr15	48744756	48744953
FBN1	FBN1_49	TCGCCAAGTGTGTATCAAGTAGC	GATCCCAGGGGTCTGTGAAAATG	179	42	TCGCCAAGTGTGTATCAAGTAGCTCATCAGTTAGCTC	chr15	48748762	48748940
FBN1	FBN1_50	GCCACTTACCTTCACAAACCAAC	GATCATGTGCTGTCTGTCACTC	181	45	GCCACTTACCTTCACAAACCAAACTTGTCAATTATAC	chr15	48748825	48749005
FBN1	FBN1_51	TGCTAACACAAAGGCAAAAAACC	TTGTTCTTTGCTGACCCTATCC	179	44	TGCTAACACAAAGGCAAAAAACCAGAAAGTTCTGAC	chr15	48752389	48752567
FBN1	FBN1_52	TCGCTAAGACTGATTTCCCAAC	CCAGACCTGTGATGGAGAATTGTTA	195	43	TCGCTAAGACTGATTTCCCAACAATTATGGGTAAT	chr15	48755200	48755394
FBN1	FBN1_53	TTACAGGGCTTGTTCAC	TTGTGATTTCCACATGGCATCA	196	43	TTACAGGGCTTGTTCACGCCCGCCAATGTTGTAG	chr15	48755301	48755496
FBN1	FBN1_54	TGAACTTGTGAGCTCTCTCCTC	ATCTGTGGTCCAGGGACATGTTA	169	43	TGAACTTGTGAGCTCTCTCCTCTTTGtagatgagaacca	chr15	48756024	48756192
FBN1	FBN1_55	ACCCATGCAATTATTTCCCAT	TCAGGCCATTCCAAATGTGAAG	186	41	acccatgcaattatccccattcactgcatgtagTCTGGAGGA	chr15	48756094	48756279
FBN1	FBN1_56	TCTGTTTTGCAGGTCACTTCT	AGATATTGATGAGTGCCAGGAGC	191	47	TCTGTTTTGCAGGTCACTTCTTGATATCTGCAAGAC	chr15	48757702	48757892
FBN1	FBN1_57	AGGACCATTACCATCACACACT	ATTTCTTGGGTTTATTACAATGCT	194	43	AGGACCATTACCATCACACACTCRTGTRTCTTCATTC	chr15	48757753	48757946
FBN1	FBN1_58	GCTCTGGCACTCATCAATATCT	TTGTTTCAATAGCCGAGTACAAAAT	198	38	GCTCTGGCACTCATCAATATCTATCAAAAATCAAAAC	chr15	48757870	48758067
FBN1	FBN1_59	CGGTGATAGGATTTGGTCGGAAA	GGCAGAGTAACAACTAAAGATTCCTG	186	34	CGGTGATAGGATTTGGTCGGAAACCTTCCCTCCAGC	chr15	48757999	48758184

FBN1	FBN1_60	GGAGAACTGGCTGGAGTTGAAA	CGAGGAGACAATGGAGATACAGC	178	47	GGAGAACTGGCTGGAGTTGAAAATAATAAATAGC	chr15	48760084	48760261
FBN1	FBN1_61	GGACACATCTCACAAGGAGTACC	TCTGCCTGATGCTTTTGTGTTTG	188	46	GGACACATCTCACAAGGAGTACCCAGGCTTTACCCA	chr15	48760149	48760336
FBN1	FBN1_62	TTGCAAACTTTGAGAATGGAATGT	ATCCAACCACGTGCATCAGT	193	42	TTGCAAACTTTGAGAATGGAATGTYGGTGTGTTTT	chr15	48760521	48760713
FBN1	FBN1_63	TTACCAACACAGCCAACCTCG	TTATGGTGATGTCTGCCTACACT	190	48	TTACCAACACAGCCAACCTCGAGTTGGGTTCAAGTCAA	chr15	48760605	48760794
FBN1	FBN1_64	TGCTTTTCTGTCTTCTGTGACG	TCTTTGGAAGTGTCCACAACCT	198	57	TGCTTTTCTGTCTTCTGTGACGGCCCTGTGTAGTCC	chr15	48762723	48762920
FBN1	FBN1_65	GACACCAGGGAGCTGATTTTGAT	CCCCAAGATATTGATGAGTGCT	171	54	GACACCAGGGAGCTGATTTTGATGCCAGTGAGAGTC	chr15	48762791	48762961
FBN1	FBN1_66	TGGCAAGTTCCAAAGACACAGAT	AAGTGCCAGATTGGTGTAGAT	178	36	TGGCAAGTTCCAAAGACACAGATGTTCCGAAGGGA	chr15	48762905	48763082
FBN1	FBN1_67	TAACCTAATCTCATCAAGCCCAG	AGAACCTGAATCTCTGTGGCAAT	162	55	TAACCTAATCTCATCAAGCCCAGCAAGGCTCCCATG	chr15	48764694	48764855
FBN1	FBN1_68	CCATCAGTTACCTTCACAGGCTT	CCGAGGAAGAGTAACGTGTGTT	174	53	CCATCAGTTACCTTCACAGGCTTCCCGTCAGCACTG	chr15	48764737	48764910
FBN1	FBN1_69	TTGCTAGCCTGAGAAATGTGGAA	TCCAATGGAACCATATGTGCAG	184	48	TTGCTAGCCTGAGAAATGTGGAATGCCTGGCTTCTCT	chr15	48766377	48766560
FBN1	FBN1_70	TTTCCAGCGTGAACATACCTGT	GTTTTAAATACCACCTTTCTGTTAATAATG	192	42	TTTCCAGCGTGAACATACCTGTACAAGTGAAGCCATC	chr15	48766434	48766625
FBN1	FBN1_71	TCATATGTGTAATCTATGCAGTCCTT	TGTGAAATTGGAGCACACAACG	169	44	TCATATGTGTAATCTATGCAGTCCTTGATAAGCAAC	chr15	48766668	48766836
FBN1	FBN1_72	GCACTTAATGCCATCTCCAATCC	AGACATTTGTGCTGAGCCTTTTT	166	43	GCACTTAATGCCATCTCCAATCCACCCGGGACTGCAG	chr15	48766729	48766894
FBN1	FBN1_73	GGAAGCTAAATTAATGAAAAATGTTATGCAA	CTGCCACTGTGATATGGGCTAC	198	29	GGAAGCTAAATTAATGAAAAATGTTATGCAAAATGT	chr15	48773707	48773904
FBN1	FBN1_74	ACAGCCAGTTTTCTTTTTTGC	TCCAAATATCTGCCTAAGTGGGAC	100	45	ACAGCCAGTTTTCTTTTTTGC	chr15	48773856	48773955
FBN1	FBN1_75	TTTTTGCCGGAGTAGCCCATATC	ATGTCTCGAGGGGAAAGTACTCA	175	38	TTTTTGCCGGAGTAGCCCATATCACAGTGGCAGATA	chr15	48773872	48774046
FBN1	FBN1_76	AATCTTTCTATCACTGACCCAACT	TCCCAATATCTGTATGGTGGTC	198	38	AATCTTTCTATCACTGACCCAACTAATTTATGTAAT	chr15	48775921	48776118
FBN1	FBN1_77	ATGTCTTCAGATGCCATGAATCC	ACTGCGGTGAGTAAATGTTTTCT	192	42	ATGTCTTCAGATGCCATGAATCCATCATAACACAAGC	chr15	48776029	48776220
FBN1	FBN1_78	TGACAAAACAGGGTTTGACTCA	CTTCTGCACAACTCTGAAGGC	193	48	tgacaacaagggttggactcaagcctgctgactccaagcctgg	chr15	48777461	48777653
FBN1	FBN1_79	ACTGAGAGATTCAACATGAGGCTA	aaccatcatcaGAAGTGATATTATTTTCATT	198	41	ACTGAGAGATTCAACATGAGGCTAGAACMTACWCA	chr15	48777535	48777732
FBN1	FBN1_80	ACTCAGAGTACATAGAGTGTGTTAGG	GTGAACCTCATAGGGAAGTATCAGT	198	28	ACTCAGAGTACATAGAGTGTGTTAGGKAGAGatgaal	chr15	48779150	48779347
FBN1	FBN1_81	GCCTATCGGGAGTTGAATGGTAG	ACATCATTGCCAAGTTGGAAGC	175	48	GCCTATCGGGAGTTGAATGGTAGCCAGGGTTGCAG	chr15	48779284	48779458
FBN1	FBN1_82	ACACCCAAACATAAGCTTCCAAC	AGAGATCCTCTCCTATGCCGAG	196	48	ACACCCAAACATAAGCTTCCAACTTTGCAATGATGT	chr15	48779422	48779617
FBN1	FBN1_83	ACCACAAGTAAATGGTGAAAAGT	CCCCCACCTTTAACATGGTCATT	197	49	ACCACAAGTAAATGGTGAAAAGTCTTCTCCTYACC	chr15	48779473	48779669
FBN1	FBN1_84	TCAAAGCTTCATGGAATCCTTCTCT	TGTTTTTGTGCAGACATTGACGA	198	44	TCAAAGCTTCATGGAATCCTTCTCTTCTGTGTTGATC	chr15	48780254	48780451
FBN1	FBN1_85	ATCCCAAACCTACCCATGCAGTT	GCAAGAATTAAGGCTGTCTGAGA	198	47	ATCCCAAACCTACCCATGCAGTTCTTCATCATKAG	chr15	48780297	48780494
FBN1	FBN1_86	GGACAGCCTTAATTCTTGCGACA	CACGGCAAGTGCGAGAAACAC	177	45	GGACAGCCTTAATTCTTGCGACAATATGTTAAAGATA	chr15	48780476	48780652
FBN1	FBN1_87	GGCTCATTAACTGACCTGTGC	ACTTATTTTGCCCCACATTTTCTT	175	45	GGCTCATTAACTGACCTGTGCGAGTTCNNNNNTTCAG	chr15	48780550	48780724
FBN1	FBN1_88	AAGTAGAGTGCTGAGATCATGAAA	GGTACTGAGGAATGCGAGGA	200	43	AAGTAGAGTGCTGAGATCATGAAAATGCATCCTATT	chr15	48781966	48782165
FBN1	FBN1_89	GGTCCTCTCGGACACAGCTC	CTGACAGATATCCGCTGGAAC	188	61	GGTCCTCTCGGACACAGCTCCTCGTACTCAGGAGTAT	chr15	48782095	48782282
FBN1	FBN1_90	CTCCTCGCATTCTCTCAGTACC	GTTGGCAGTTTGGGGCAGT	196	60	CTCCTCGCATTCTCTCAGTACCCAGGCTGCCCGACG	chr15	48782145	48782340
FBN1	FBN1_91	CTGTACCTGAAGCTAAGTGCTCA	GGAGTGTGTAATAATGGCCTGTG	198	37	CTGTACCTGAAGCTAAGTGCTCARCTATATCTTGTTA	chr15	48784560	48784757
FBN1	FBN1_92	GACAGATCCTTCTCTGTGGCATC	TGACTCTATGAGTAGAATAAGGTAGAATGA	197	36	GACAGATCCTTCTCTGTGGCATCAAAGTCATTCCACT	chr15	48784661	48784857
FBN1	FBN1_93	CTCTGCTGCATATTTCTCCCTGT	TGTTTTCTGTTTTGTTTTCTGCTTT	198	34	CTCTGCTGCATATTTCTCCCTGTGAAGTTATATGACA	chr15	48786288	48786485
FBN1	FBN1_94	ACTAGGCTTCCCCTTTTATGCAA	GTGAGATCAACATCAATGGAGCC	162	52	ACTAGGCTTCCCCTTTTATGCAAAGACCAATTGGAGT	chr15	48787251	48787412
FBN1	FBN1_95	GCTTCCCCACGCAGCA	TGTCTATAATTCCAAGGTGTATGTTTGA	187	44	GCTTCCCCACGCAGCACCCGAGGGAGGAGCAGCACTG	chr15	48787342	48787528
FBN1	FBN1_96	TTGCAGGAAAAGCTGACATTAAAG	TTGATGAATGCGAATCAAGTCTCT	190	35	TTGCAGGAAAAGCTGACATTAAAGTATAACAACATTG	chr15	48787593	48787782
FBN1	FBN1_97	GGCTGTTCTTGACAGACTCCATT	ATTAGCCAGCTTTACTGTGTG	176	40	GGCTGTTCTTGACAGACTCCATTAAAGTGAAGGACTTGA	chr15	48787732	48787907
FBN1	FBN1_98	TGGCATTCCAAAAGATAGCAAAG	TGAATGTGTACTGAACAGTCTCC	173	37	TGGCATTCCAAAAGATAGCAAAGTACACAGTATAAG	chr15	48788243	48788415

FBN1	FBN1_99	ACCTTCACATGTTTTAGATCAGGTTT	AGGCCAAAGTTTGGGCCCTTTT	177	37	ACCTTCACATGTTTTAGATCAGGTTTGTAGATAAAAT(chr15	48788295	48788471
FBN1	FBN1_100	ATTTGCCAGTCTCTAAGCTAC	TGCCAAATGGAATCTGTGAAAC	198	41	ATTTGCCAGTCTCTAAGCTACTCAAAGGCAGTTTT(chr15	48789359	48789556
FBN1	FBN1_101	CTTCTACCAACGCAGTTTTTCC	TCTTAATTGATTTTGACTTTTTTGTGGT	167	37	CTTCTACCAACGCAGTTTTTCCCAGTTGAATCCACTT chr15	48789455	48789621
FBN1	FBN1_102	CAACTGGAACCCACAAGAAAGC	CAAGGGCAGGATCTACCTGTTC	195	46	CAACTGGAACCCACAAGAAAGCCTGATGCTGCCTC(chr15	48791105	48791299
FBN1	FBN1_103	AAAGACCTCAATGGTGGCAGAAG	GCTATGGTGGATACAAGAGAGGC	192	49	AAAGACCTCAATGGTGGCAGAAGGCTGGCAGTACG(chr15	48795924	48796115
FBN1	FBN1_104	AAGGTTCCCCAAATGCATACTCA	GTGACAGTGTGATGACAGATGCT	162	46	AAGGTTCCCCAAATGCATACTCAGTGTGGCRCAAC(chr15	48796011	48796172
FBN1	FBN1_105	CCATTGGGCTTTATTGAGTGACAG	TGAAACCCCTGGGATCTGCAT	177	50	CCATTGGGCTTTATTGAGTGACAGAGGCTGAACCTC(chr15	48797155	48797331
FBN1	FBN1_106	TGTTTTCTTACCAACACACACAG	ACTTCATTTTTAATAAGTGCTTTCTCT	169	49	TGTTTTCTTACCAACACACACAGGCCATCCAGACCC(chr15	48797211	48797379
FBN1	FBN1_107	ACAACATAAGGAGGAGAAAAGGC	GGATGAATGCAGCATAAGGAACA	179	40	ACAACATAAGGAGGAGAAAAGGCAYGTGAAGAACA(chr15	48800719	48800897
FBN1	FBN1_108	CGAACCTTTGCAATAACGTCCAT	TCATCCAGATTGGTTTCTTCGT	198	38	CGAACCTTTGCAATAACGTCCATCTGATGCCAGCTGG chr15	48800774	48800971
FBN1	FBN1_109	CCCCTGATATTGAACTGCAATGG	GTGTTTACAGAATGGCCGATCT	174	43	CCCCTGATATTGAACTGCAATGGAAGGAGAGGACT chr15	48802183	48802356
FBN1	FBN1_110	TTCACAGTTCTTCCCATCTCGTG	ACTCCCCTAAATAAGCTATTTCTCT	171	40	TTCACAGTTCTTCCCATCTCGTGTAACATGAAAGCCC(chr15	48802242	48802412
FBN1	FBN1_111	GTCTCTCCGGCATGGGTATTT	TGGTGAGTGTATTAACACACGGG	189	51	GTCTCTCCGGCATGGGTATTTAACTCCAYGGAAC chr15	48805643	48805831
FBN1	FBN1_112	CATTCTGTCCGCGTGAGTGT	CCCAGAAAGCTTAGAATTATGAGGTA	183	43	CATTCTGTCCGCGTGAGTGTGCTCTGATATCCAGCTC(chr15	48805751	48805933
FBN1	FBN1_113	aGAGTCAAGGAACAGAATTACAACA	CGTTACTGATTACTGCCAGTTGGT	184	51	aGAGTCAAGGAACAGAATTACAACAGACCTTGGTG(chr15	48807525	48807708
FBN1	FBN1_114	GCTGGAACCTTTGTGTCAC	TGTCAGATTAAGTACTGATGAAAGATACCA	186	43	GCTGGAACCTTTGTGCACTCACACCGYAACTCCC(chr15	48807608	48807793
FBN1	FBN1_115	TGAACAATGCAAGAAAAATAACTAGATGA	AGACCAGAATATCTCCCCAC	180	49	TGAACAATGCAAGAAAAATAACTAGATGATTTTTGA(chr15	48808336	48808515
FBN1	FBN1_116	GGTCGAGGGACCGGAATTTG	AGCTCAGCTGTTGTGTTTGT	181	51	GGTCGAGGGACCGGAATTTGAGGTCCAGGAGGAAA chr15	48808418	48808598
FBN1	FBN1_117	ACCCAAGTTTCCATTACATCTGC	TGCCACAGTCCATAACCAAAATG	197	54	ACCCAAGTTTCCATTACATCTGCATCATGCACATTGCC chr15	48812761	48812957
FBN1	FBN1_118	TCTGATGGGACACATCTCAGGG	TCAGCGATGTGTGTGTGTATG	192	53	TCTGATGGGACACATCTCAGGGGCGACAGTGACCCC chr15	48812863	48813054
FBN1	FBN1_119	ACCTCAGTTGATAAATTATATGTGCTCCT	AATGTACAAACACAGTCAGCAGT	188	38	ACCTCAGTTGATAAATTATATGTGCTCTTAACAAGC(chr15	48818220	48818407
FBN1	FBN1_120	GGTACCATCTGGAGAGGTGTAAA	ACATCTGAGTCTTCTACTGACGA	193	40	GGTACCATCTGGAGAGGTGTAAAAACAGGGGGAC(chr15	48818337	48818529
FBN1	FBN1_121	TTTTGCCTGCCCCACTAC	TCTGACAGATGGGATGAATGCC	185	47	TTTTGCCTGCCCCACTACACCCCCAACTGCAAAAGC(chr15	48826226	48826410
FBN1	FBN1_122	CAATTCCTCCCTGACAGAGCC	TGTGATGGACAAATAACTCACCGA	176	35	CAATTCCTCCCTGACAGAGCCCGGGATGGCCTGG(chr15	48826354	48826529
FBN1	FBN1_123	AGCTGACACTACTTTTCAATTCTCT	CCCTGTGAGATGTGCTCTG	178	49	AGCTGACACTACTTTTCAATTCTTCAACTTCATTGG(chr15	48829709	48829886
FBN1	FBN1_124	CAGGGGTGAGGCTGGG	TGCTTTCTGGATTTTCATCAGATTTT	197	50	CAGGGGTGAGGCTGGGCGAGACACATCTCAGGG(chr15	48829852	48830048
FBN1	FBN1_125	AGTAACAGCTTTAGGTACCAGCA	GCGTCTCAGCTCTCTCTTATTT	180	43	AGTAACAGCTTTAGGTACCAGCATGTCTTTAYGTAAA chr15	48888424	48888603
FBN1	FBN1_126	TAAACATGCTGTGTCCAGGTAA	AATATTGCTGTATGAATGGAGGT	198	39	TAAACATGCTGTGTCCCAGGTAATCGARGAAAATCC(chr15	48892223	48892420
FBN1	FBN1_127	CTTACGTTGTCCACAGTGAGTCC	CTCCTGTGAGCTGTTGCAATCTA	168	41	CTTACGTTGTCCACAGTGAGTCCCTATGTATCTTTCT chr15	48892331	48892498
FBN1	FBN1_128	ATTGCAGGAAAGAGGAAAGCCAA	TTCTGTGGGGATGGATTTTGTT	180	39	ATTGCAGGAAAGAGGAAAGCCAAATCAAATTTAGC chr15	48902831	48903010
FBN1	FBN1_129	CCACAGGAAGGAGCTATCTGAC	ctcattTGAGATTGGTCCCCTA	164	47	CCACAGGAAGGAGCTATCTGACCAGATGGRCAAGTG chr15	48902936	48903099
FBN1	FBN1_130	AGGACATGCAGAATGACAAGTTT	TGGCCATCTCTTCTCTTCTCT	180	37	AGGACATGCAGAATGACAAGTTTTCTATTTACTTAYG chr15	48905171	48905350
FBN1	FBN1_131	CCGTTGTTCTGGATCTTGAAACT	ATTTACCGTGCTTTTAGCGTCTCT	191	55	CCGTTGTTCTGGATCTTGAAACTTGGGAGACCCACAC chr15	48936741	48936931
FBN1	FBN1_132	CCTCCACCGCCTCTTCTCTT	TGGCGGCTCGGCATCA	161	61	CCTCCACCGCCTCTTCTTCTTGGCCGACTGGCTCTGG(chr15	48936821	48936981
FBN1	FBN1_133	GGACGCTAAAAGCACGGTAAATC	GACGGGCGGCGGGGATA	175	75	GGACGCTAAAAGCACGGTAAATCCCAGGGCGATCTC chr15	48936910	48937084
MYH11	MYH11_1	CGCATTGGGCAGAAAAGAAATGG	ATACTTAACCGGCTCTTCTTG	168	52	CGCATTGGGCAGAAAAGAAATGGATACTGAGACAA(chr16	15802595	15802762
MYH11	MYH11_2	CATTTGCAGGCCGAAAGGAG	GAGTCCCAGCGCATCAACG	198	66	CATTTGCAGGCCGAAAGGAGCCGAGCCCCCAGTGC chr16	15808681	15808878
MYH11	MYH11_3	CCCATGGCCTCGTTGCTC	AGCCGGCCTCCCCTAAC	181	64	CCCATGGCCTCGTTGCTCTCGTGGCCTCATCCAGCT(chr16	15808799	15808979
MYH11	MYH11_4	TGGGTGGCAGGGGCTA	CAGGTGACACACCAGCTACAAG	195	56	TGGGTGGCAGGGGCTACCTGTCTTGTACTGCTCG(chr16	15809004	15809198

MYH11	MYH11_5	CACTATGACTCCTGCTGTCCATC	GAGCGGCAGAACAAAGGAGC	198	61	CACTATGACTCCTGCTGTCCATCACCCCCCTGCAAAC	chr16	15810933	15811130
MYH11	MYH11_6	TTGACGGCCCCCTCCATC	TCTTGGGCTTCCTGAGTCC	179	64	TTGACGGCCCCCTCCATCTCGTGGAGCTTGTCCGGA	chr16	15811075	15811253
MYH11	MYH11_7	TGCTGCAGGAGAGACAGTAGG	AACGCACTCCAGGACGAGAAG	176	66	TGCTGCAGGAGAGACAGTAGGCAGCGTACTGTGG	chr16	15812119	15812294
MYH11	MYH11_8	GCCCTCACCTGCTGTGT	GTAGAGGCCCCACCAT	166	69	GCCCTCACCTGCTGTGTGGCTTTCGGACCCGGTCG	chr16	15812164	15812329
MYH11	MYH11_9	GTCCCCCATCCTCTGCTT	AGACAACAGCCTTCCTCCCT	168	61	GTCCCCCATCCTCTGCTTCAGAGCCCTTCTCTCCAT	chr16	15813027	15813194
MYH11	MYH11_10	AGGAGGACGAAATGAAATCTGGG	CCGTGCCTCCAGAGATGAGAT	192	54	AGGAGGACGAAATGAAATCTGGGAATGCACAGACT	chr16	15813341	15813532
MYH11	MYH11_11	CGAGGCTTTACCTCTGTAGCTG	GGGAGTAAGGACATCTGAGCTTG	185	51	CGAGGCTTTACCTCTGTAGCTGCATGAGGTCTGCTT	chr16	15813431	15813615
MYH11	MYH11_12	GGCCTGAGGGGAACTGTG	GAAGACGAGCGAAAGCAACG	197	60	GGCCTGAGGGGAACTGTGCCCTCCCTCCACCCATGCC	chr16	15813949	15814145
MYH11	MYH11_13	CAGTTTGCCTAGCTGCTTGATG	GGCAGCACACATCTTATTCCTC	188	57	CAGTTTGCCTAGCTGCTTGATGGCTTCTCTCCCTCCCT	chr16	15814011	15814198
MYH11	MYH11_14	GATAGGAATGAAAAAGGCCACCC	TGGAGGACGAGCTGCAAG	198	61	GATAGGAATGAAAAAGGCCACCCGACCTCCCTCTGC	chr16	15814638	15814835
MYH11	MYH11_15	TTTCGAACTGGCCCTTGAGC	TGAAGTTGAGCCTCATAGAATGG	198	61	TTTCGAACTGGCCCTTGAGCGCTGCATGTTGACTTC	chr16	15814755	15814952
MYH11	MYH11_16	GGTGAATAGCACAGAGGGTGG	AAACCAAGGCCCTGTCCC	198	55	GGTGAATAGCACAGAGGGTGGGCGAGCGAAACATG	chr16	15815215	15815412
MYH11	MYH11_17	AGGTCTTCCATTTCCGGCTTGAG	GTTGTAGTTGTAGCCGAGGAGA	189	52	AGGTCTTCCATTTCCGGCTTGAGCAYTTTGTGGTCC	chr16	15815310	15815498
MYH11	MYH11_18	CTTTGGCTTCCAAGGCCTCTTC	TTACAATTCACTGACGCTGACCC	196	53	CTTTGGCTTCCAAGGCCTCTTCAAGGGCCGAGCCAC	chr16	15815359	15815554
MYH11	MYH11_19	CTGCAGAGCTGATCCCCAAC	TGGAAAAGACCAAGAACAGGCTT	177	55	CTGCAGAGCTGATCCCCAACCCAGCGTCCATGGCCA	chr16	15817954	15818130
MYH11	MYH11_20	GCCCTCTACCTGATCAAATTTCC	GGAAGAAGAGGTTCCAGAAGGAG	197	52	GCCCTCTACCTGATCAAATTTCTCTGCTTCTTTTCCA	chr16	15818009	15818205
MYH11	MYH11_21	AAGCCTGTTCTTGGTCTTTTCCA	CTACCCTGGACGCTGTCTT	183	54	AAGCCTGTTCTTGGTCTTTTCCAGTTTATCATANGCG	chr16	15818108	15818290
MYH11	MYH11_22	GCGCAGAGAAGTTGAGAGGAC	TCAAGAAGAAACCCGCGAGAA	198	59	GCGCAGAGAAGTTGAGAGGACCCATGAAGGAAGCA	chr16	15818451	15818648
MYH11	MYH11_23	ACCTGGATGTTGAGAGTGGAGAT	GGGACCTCTTGTACCTCCCTT	181	57	ACCTGGATGTTGAGAGTGGAGATGTGGCGCTCCAG	chr16	15818502	15818682
MYH11	MYH11_24	CAGGTCCCCTGGATGATGTG	ATCCCCTTCTAGAGGCTTTGACT	184	56	CAGGTCCCCTGGATGATGTGGCAGGACACTCACCTG	chr16	15818712	15818895
MYH11	MYH11_25	gaggctctCCCCACAGAA	CCAAGCAGGAGGTGGAACA	190	62	gaggctctCCCCACAGAACTGGGACCACCCAGACTC	chr16	15820637	15820826
MYH11	MYH11_26	CCATCGCTGCACTTGGA CTG	CCCTCCCTCTGCTTCTCTC	186	61	CCATCGCTGCACTTGGA CTGCACTCCTGCACTGCG	chr16	15820751	15820936
MYH11	MYH11_27	ACCTGTAGTAATTTGAGGCTGCT	GAAGAAGGCCCTGGATGAAGAGA	188	52	ACCTGTAGTAATTTGAGGCTGCTGATGTCACCTTAY	chr16	15826348	15826535
MYH11	MYH11_28	AGCATCACCAAAAAGCATTACCC	AACTGCCATTCAGTGTTCTCTC	197	57	AGCATCACCAAAAAGCATTACCTCTTGAACCTGCTCA	chr16	15826400	15826596
MYH11	MYH11_29	ACGATTTGCTTTGGGTTTGTC	GCCAGGAACAAGGCTGAAAAG	198	58	ACGATTTGCTTTGGGTTTGTCCTCTTCTGCCCCCAT	chr16	15829135	15829332
MYH11	MYH11_30	GTGTGTCTTCCAGCTCTGTCTT	CCTGGAAGGCTTGACGATGAAAT	190	57	GTGTGTCTTCCAGCTCTGTCTTTAGGGCCTCCAGCTC	chr16	15829254	15829443
MYH11	MYH11_31	CTTCTGCTTTTCAGCCTTGTTCC	GCCACATTGTAAGAGAGGAAACC	195	55	CTTCTGCTTTTCAGCCTTGTTCTGCGGCCGCTCTG	chr16	15829306	15829500
MYH11	MYH11_32	GCCCAGGGGATACATGGACA	GAAGCTGAAACGGAAGCTGGAG	183	63	GCCCAGGGGATACATGGACACACAGAAATGCCCTC	chr16	15831255	15831437
MYH11	MYH11_33	GCAGCTCCTCTCCTTCTTG	CTTCTGAAGAGCACCTTGGTTT	185	56	GCAGCTCCTCTCCTTCTTGCCAGCTGCATCTTGAG	chr16	15831322	15831506
MYH11	MYH11_34	aataaaaaTAAATCTCTTGGTAGCTGGTT	CCCCAAAAAGGAACGAAAACCTC	166	38	aataaaaaTAAATCTCTTGGTAGCTGGTTTACCTTCCAG	chr16	15832390	15832555
MYH11	MYH11_35	AGCTTGGTAAGATTCTTGGCCTT	GGGTTTTTCTTTCAACTGTTTACATGG	189	37	AGCTTGGTAAGATTCTTGGCCTTTCTCTCTTCTG	chr16	15832460	15832648
MYH11	MYH11_36	AGACACTGGCCACCACA	TCATGGATGATCAGAACATAAAATATCAA	200	49	agacactggccaccacacctggctaactctttagttagatg	chr16	15833740	15833939
MYH11	MYH11_37	cccgccCCTACTCACTT	CCTTGAAGAACAGCTGGAGGAG	152	51	cccgccCCTACTCACTTTTGATAGTTTATTGTTCTGAT	chr16	15833892	15834043
MYH11	MYH11_38	CCAGGATCTCATCTCCAGTTTC	GGCCTAGCCCTGTATTATTAG	197	50	CCAGGATCTCATCTCCAGTTTCTTGATCTTGGCCTCA	chr16	15833940	15834136
MYH11	MYH11_39	CCTGTGGTGAGGGTCAAGTG	CTGGCGGCCAAGAAGCAG	182	60	cctgtggtgagggtcaagtgatttctaccaccacgggct	chr16	15835261	15835442
MYH11	MYH11_40	CTGCTGGCCCCGTCTTCTC	CCTCTCCCAACCACT	193	63	CTGCTGGCCCCGTCTTCTCTCTCTCCAGCGGGCC	chr16	15835359	15835551
MYH11	MYH11_41	CGGGGCCAAGTCTGTTC	GTGTGCAGGTGAAGCCACT	192	58	CGGGGCCAAGTCTGTTCCTCCAGCAACCCAGCCATC	chr16	15835565	15835756
MYH11	MYH11_42	TTCTGTCCAGCTCCTTAAGCTC	TCCCTTTGCCACAAAAACAAATGA	168	54	TTCTGTCCAGCTCCTTAAGCTCATTCTGCCTTCTG	chr16	15835627	15835794
MYH11	MYH11_43	TGTGAAGGCTCCAGAGTGAA	CCTTCTCTCCCCCTCC	200	60	TGTGAAGGCTCCAGAGTGAAGAASCAGGGCTGGGG	chr16	15838917	15839116

MYH11	MYH11_44	tcagggaaTCAGAACAGAAAGGC	AGCAAAATCTTCTCCGAAGTGG	191	50 tcagggaaTCAGAACAGAAAGGCCCTGTTTGATTCT chr16	15841352	15841542
MYH11	MYH11_45	TCTTTACTTTCTGGCCAAGTAGC	GGAGCTCTTCTTTCTTCTCTTT	196	51 TCTTTACTTTCTGGCCAAGTAGCCACGACATCGCC chr16	15841420	15841615
MYH11	MYH11_46	GCCAGTGATGACATGGGTAAGAA	GGGTGACTTCTGCTCTGTGTT	190	58 GCCAGTGATGACATGGGTAAGAACGGTCCACCAAG chr16	15841637	15841826
MYH11	MYH11_47	CTCGTAGCTTGAAACACAGAGCA	TGCAATGGGGTGCTGGAAG	190	60 CTCGTAGCTTGAAACACAGAGCAGAAGTCAACCCGG chr16	15841794	15841983
MYH11	MYH11_48	CAGACCTTGGGACTTACCGTTG	ATCCACTGCCCTCTTGACCTTT	166	60 CAGACCTTGGGACTTACCGTTGGCGGAACCTCTGGA chr16	15841887	15842052
MYH11	MYH11_49	CTGTGACCGCTTGGGACAG	CCAAGACCAAGAAGGGCATGTTC	193	63 CTGTGACCGCTTGGGACAGCCCTGGYTTCTGGRAGC chr16	15843933	15844125
MYH11	MYH11_50	GCGTAGCGTGGTCATCAG	CCTATTTAGGGGTGGGTGGG	198	63 GCGTAGCGTGGTCATCAGCTTGCCAGCTGCTCCTG chr16	15844046	15844243
MYH11	MYH11_51	CATGTAAGGCCTCCCCTCCT	AGAATATGGACCCGCTGAATGAC	189	56 CATGTAAGGCCTCCCCTCTGGGGCAGGTGTGAGA chr16	15847146	15847334
MYH11	MYH11_52	CTTACCGTCTTCCACAGGTC	TCCTGGCCTTGTTTCTAAGTTT	185	54 CTTACCGTCTTCCACAGGTGCGCCACAACTTGTCG chr16	15847246	15847430
MYH11	MYH11_53	GCGCTGAGCAGCCACT	GAATGCTGTTCCCCAAAGC	198	60 GCGCTGAGCAGCCACTGGGGTCCCCTGAGACAGAC chr16	15850138	15850335
MYH11	MYH11_54	AACTCAGTCTTGTCTTGAGCTG	GATTCAAGCCCTACTGTCTCCC	176	57 AACTCAGTCTTGTCTTGAGCTGCTTGGGCTTCTGGA chr16	15850223	15850398
MYH11	MYH11_55	CTCCACAGAGGCCACACAC	TTCAACACACCATGTTCATCCT	181	61 CTCCACAGAGGCCACACACGTGTACAAGGTGTGACR chr16	15851620	15851800
MYH11	MYH11_56	GTCCAGCCCAAAGTCGATGAAG	TGACTTCATACCAAGATGCTCAC	190	56 GTCCAGCCCAAAGTCGATGAAGTTCACCTCGATGCCC chr16	15851717	15851906
MYH11	MYH11_57	AAAAGCCCATCTCAGACAACCAA	CAACATATGAGCGCTTTTCCG	178	53 AAAAGCCCATCTCAGACAACCAAGACCATGGCTCTTA chr16	15853377	15853554
MYH11	MYH11_58	TATATCCAGGATCCCAGGAAGG	AGCCTGGCTTATGTGAAATGGA	197	55 TATATCCAGGATCCCAGGAAGMAGCCCCCTTGCCG chr16	15853454	15853650
MYH11	MYH11_59	TGAGTGAACAGGTGGATAGATGG	GCCACCTCATGGGAATTAATGTG	182	46 tgagtgaaacaggtggatagatggatgaatggatggatgggtgggtg chr16	15854319	15854500
MYH11	MYH11_60	TGTCTGAGCTTTCTGTACCACAT	TCCATGCGATGTGCTTCTTG	183	45 TGTCTGAGCTTTCTGTACCACATCTGCCCCAACCTTGA chr16	15854406	15854588
MYH11	MYH11_61	CCAGTGGTTAAATGTCACCTCCC	CTCTGCCCTTCTCTCCCCAC	195	51 CCAGTGGTTAAATGTCACCTCCCCACCCCCCAACCC chr16	15857579	15857773
MYH11	MYH11_62	TCTGTCTGACCAGAGAAGAGTT	CTTCCTCTCAATGGCTTTGTGC	194	53 TCTGTCTGACCAGAGAAGAGTTCTTAACAGTTTCCA chr16	15865342	15865535
MYH11	MYH11_63	AAGGTGTGAGGCTTACATAGCTG	TATTGACCTGACCTGTCTTCCT	193	52 AAGGTGTGAGGCTTACATAGCTGCTCCTCTCGCTGA chr16	15865410	15865602
MYH11	MYH11_64	TCTGATGAAAGGGAAGGCTCAAG	TATCCCCAGAATCCCTAACTCCC	188	46 TCTGATGAAAGGGAAGGCTCAAGCCATCCAATCACA chr16	15869879	15870066
MYH11	MYH11_65	AAGATAGAGGTGGCTCTTGACT	CAGCAAAGCCTGAACTGTGTTTT	193	55 AAGATAGAGGTGGCTCTTGACTCTCCAGCCTCTG chr16	15872542	15872734
MYH11	MYH11_66	CAGGCAGGAGATGACACCAAAG	CCTAGGTTGCTTTCTCCAATAACT	193	45 CAGGCAGGAGATGACACCAAAGCTTTCTGGA AAA chr16	15876185	15876377
MYH11	MYH11_67	AAACTCTAGGGCCTACCCCATTT	TGTGATGGAAATAACGCTGACAT	198	47 AAACTCTAGGGCCTACCCCATTTCTACCASCAGCTAYF chr16	15878430	15878627
MYH11	MYH11_68	CTGGAGACCGTTGGCTAAA	CCATGGAACGTGTGCATAGATGA	195	54 CTGGAGACCGTTGGCTAAATCATGGCCTCTGATTG chr16	15880436	15880630
MYH11	MYH11_69	CTCTGCACTCATGGATCTTTTCT	CCAAGTCCAGACCCCTTAGCTC	198	36 ctctgcaactcatggatcttttcttcatagttggatctcgactacagav chr16	15892415	15892612
MYH11	MYH11_70	TTCTGGCAAGAACTGCAGACA	ACATGTACAAGGGCAAGAAGAGG	162	59 TTCTGGCAAGAACTGCAGACAAGCAGGACAGGAG chr16	15917034	15917195
MYH11	MYH11_71	CTGCGATGGCGTAGATGTGAG	CCTGGAGGAGGTCTGGAAGTAA	172	55 CTGCGATGGCGTAGATGTGAGNGGCATCTCGTGCC chr16	15917139	15917310
MYH11	MYH11_72	cagccCTCCAACACATTTCTAA	AAGATGAACCCACCCAAGTTCTC	192	53 cagccCTCCAACACATTTCTAATGCCTACTTTCTTAT chr16	15931687	15931878
MYH11	MYH11_73	CCGCTCCCTCAGTTGTGTA	GCAGCCAGCATTAAAGGAGGAG	186	57 CCGCTCCCTCAGTTGTGTAGCACGGAGGCTTCGTT chr16	15931786	15931971
MYH11	MYH11_74	TCTGGATGTACCTTTCCCAACC	ACAAAAACTTCATCAACAGCCGAG	183	57 TCTGGATGTACCTTTCCCAACCGTGACCTTCTTGCCA chr16	15931878	15932060
MYH11	MYH11_75	TCATCCCCCTTCTCCTCTTAAT	TTATTCCACAGGGGACCAACAAG	198	57 TCATCCCCCTTCTCCTCTTAATGCTGGCTGCCTCRAA chr16	15931940	15932137
MYLK	MYLK_1	TGACTTAGAAACTGCTTTTCTCTGG	ATTAGTGATGTTTGGGGGATGA	173	49 TGACTTAGAAACTGCTTTTCTCTGGCTTTGTTTCACTC chr3	123332920	123333092
MYLK	MYLK_1_1	CACCTAGAAAAGACACACAGCTCC	TGCAGTTACAGAGCAACTTCAGG	197	53 CACCTAGAAAAGACACACAGCTCCCCCTCTCTGCAGCCT chr3	123550300	123550496
MYLK	MYLK_1_2	TCTGTTGTTTGTGTGGCAACTG	CGTGTCTGTCTCTGATTGCGCTT	162	57 TCTGTTGTTTGTGTGGCAACTGGGCCAGTGGGACAC chr3	123550405	123550566
MYLK	MYLK_2	CCTTCCTCATCGTTTCCACAAT	AGATGACCAGTCAATCAGGGAGT	183	51 CCTTCCTCATCGTTTCCACAATGWGCTCTGCTGTGC chr3	123332983	123333165
MYLK	MYLK_2_1	TGAAAGGAAGTGCTTTTCTGTA	TTTCTTGATTGTGTATTAGGAAGGATT	186	29 TGAAAGGAAGTGCTTTTCTGAGAAACTATAAAGT chr3	123595300	123595485
MYLK	MYLK_2_2	TGCTATTACCTTTATTTTCTCTTCAGC	tgTCAACCTGATTGATGTTTCACT	132	30 TGCTATTACCTTTATTTTCTCTTCAGCTGGCCCAA chr3	123595397	123595528
MYLK	MYLK_3	CAGGTGTACTTGGCATCGTCATC	CTGCAACTGTGTTCTCTCCCTG	176	51 CAGGTGTACTTGGCATCGTCATCCCGCAACATCAC chr3	123333052	123333227

MYLK	MYLK_4	CTACCATCCAGCCACACCTATT	AAGATGTGTCCCAAGCTTTCCTT	186	44	CTACCATCCAGCCACACCTATT	CATGGTGAAGAGAA	chr3	123337432	123337617
MYLK	MYLK_5	AGCACAGCTACAACCTACCTTCA	TGACCTGGTCTTCTCTGTGCT	178	43	AGCACAGCTACAACCTACCTTCA	ATCTTGCAAGTCAAA	chr3	123337468	123337645
MYLK	MYLK_6	ACCAACCAAAACCTCAAAATGCC	CCTCTATGGCAATGATCTCAGGG	172	51	ACCAACCAAAACCTCAAAATGCC	CTTGTCCCCAGT	chr3	123338975	123339146
MYLK	MYLK_7	ACTCCTCTTACCTTCAGATTCTAGT	CAGCTGGAACAGGGACAAC	194	52	ACTCCTCTTACCTTCAGATTCTAGT	TTTTCTGCATTG	chr3	123339042	123339235
MYLK	MYLK_8	TGAAAGTGGCTTGAACAACACAA	CAGCATCATGGCTAATGAAAGA	162	46	TGAAAGTGGCTTGAACAACACAA	ATAGAGGGGCA	chr3	123345599	123345760
MYLK	MYLK_9	GACCTCTCATTACCTGCCATTT	TCCTCTGCTCAAAAATCTCTG	178	50	GACCTCTCATTACCTGCCATTTCT	CTTGCCATGTAT	chr3	123345651	123345828
MYLK	MYLK_10	AAAGGAATCCCCCTTGTCTTC	GACAACGATAACGAAACCTTGGC	198	49	AAAGGAATCCCCCTTGTCTTCCA	ACACAGGGCAGG	chr3	123348248	123348445
MYLK	MYLK_11	CTGATGAAATCCTTGGCATCGTC	CTAGCCACACCTGCTGTCC	165	54	CTGATGAAATCCTTGGCATCGTC	GAGATCTCATCGA	chr3	123348345	123348509
MYLK	MYLK_12	GACCTCTGTGGAACCTC	GTCTCTGAAGGTCTCTTGGC	194	58	GACCTCTGTGGAACCTCAGCCCC	ACCCACTGGT	chr3	123356838	123357031
MYLK	MYLK_13	ATGTAGCAGATGACCCGATG	TCCGTGATGTGCTGGCAATTTAT	165	52	ATGTAGCAGATGACCCGATGTCC	ACATGTCTGTG	chr3	123356921	123357085
MYLK	MYLK_14	CACTCAGTGTGAGAGGAAACGG	GGAGTACATCCACAAGCAGGG	189	56	CACTCAGTGTGAGAGGAAACGG	CAAGTCAATACAC	chr3	123359064	123359252
MYLK	MYLK_15	CCAAAGTCGATGAGCTTGATCCT	TCATTGACGAGGACTTTGAGCTG	172	54	CCAAAGTCGATGAGCTTGATCCT	GCTGGCCGCTTGT	chr3	123359151	123359322
MYLK	MYLK_16	GATGCCCTGCTTGTGGATGTA	CATGAGCCTGTGGCCTGAC	167	57	GATGCCCTGCTTGTGGATGTA	CTCACTCCCTCCGAG	chr3	123359228	123359394
MYLK	MYLK_17	CAGTAGGGGAGACAGTTTGG	AGGCATATTCAGCAAAGAGAAAGA	197	54	CAGTAGGGGAGACAGTTTGGGG	GCTCCCTGTGTG	chr3	123366007	123366203
MYLK	MYLK_18	ACACTGGACCACTTAGGGT	GGCTAAATGTGGCTTTTCTCTCC	198	46	ACACTGGACCACTTAGGGTGGT	GAGGCAGTTTCA	chr3	123366118	123366315
MYLK	MYLK_19	TGAGGCACTGAATCTAACTGTG	ACCAACCTGACCTGTGC	196	51	TGAGGCACTGAATCTAACTGTG	AGACCCGACCACT	chr3	123367741	123367936
MYLK	MYLK_20	TAATCAACCTCGGGCTCCTTCTC	CTGTGCTCTCTGTCTTCTT	191	59	TAATCAACCTCGGGCTCCTTCT	CATCTGTGGGCACA	chr3	123367887	123368077
MYLK	MYLK_21	AAGGTCAGTCACGCACATTTGTT	AGCACCTCTTCAACGTCAG	187	49	AAGGTCAGTCACGCACATTTGTT	CAAGCYACTGATG	chr3	123375919	123376105
MYLK	MYLK_22	GGCTTGGCTCACTGGTT	GTCCTGGTATGGCTCCTCAT	200	54	GGCTTGGCTCACTGGTTCCAYAC	AGTTGATTGCACG	chr3	123376012	123376211
MYLK	MYLK_23	TAGTTCCTTCCACGCTTGTGG	TCTGGAAGGTGTGGTGATGTTG	198	54	TAGTTCCTTCCACGCTTGTGGCT	GAGTCCAGATCT	chr3	123376118	123376315
MYLK	MYLK_24	CCTGAGGCCACGTATCTTG	ATGGCAGCAAGCTCACCATC	195	65	CCTGAGGCCACGTATCTTGCTGG	GGGCTCCTGCC	chr3	123382871	123383065
MYLK	MYLK_25	GCTGCCACGCTTGTCTCC	GAGCCCCCTCTTCTCTAGC	189	62	GCTGCCACGCTTGTCTCCACCA	GCAGTGTGTAGCAG	chr3	123382983	123383171
MYLK	MYLK_26	GGTCCAAAGGCTGTACGGATTATT	CCTCAGATCATCCAGTTCCCTGA	182	57	GGTCCAAAGGCTGTACGGATTAT	TCCAGCACCCCCA	chr3	123385004	123385185
MYLK	MYLK_27	GCTTTCGGAACCTCATCCAGGTA	TGATCAGAATGCCTGAGACCCTT	183	55	GCTTTCGGAACCTCATCCAGGT	ACAGGTGATGGGCT	chr3	123385068	123385250
MYLK	MYLK_28	CAAAACCCCATGGTAGATGACT	GCCAGTGGACAAGACTGCAT	198	47	CAAAACCCCATGGTAGATGACTT	CTTTGACCCCAGA	chr3	123385928	123386125
MYLK	MYLK_29	GCAAGAGTGAGTGACCAGAAAAGT	CAGCCAGTGAGAACACCAAGG	186	61	GCAAGAGTGAGTGACCAGAAAAG	TGGGGCTCTGAG	chr3	123400966	123401151
MYLK	MYLK_30	AGTACTCACTCTCAGTTCTTAGC	GAGTTTGGCTGAGGTGGGATTTT	188	51	AGTACTCACTCTCAGTTCTTAGC	ACGGGAGGAAGAG	chr3	123401062	123401249
MYLK	MYLK_31	CTGACAGGCAAGGTATGGTAAGG	GCCTGAGGACAGAGGCTTATACA	170	59	CTGACAGGCAAGGTATGGTAAG	GAAGGSAGGGGCT	chr3	123411495	123411664
MYLK	MYLK_32	GAGAAATGGGACCCCTGTGTATG	TGGTTCACTCCACAATCTTCTCT	198	58	GAGAAATGGGACCCCTGTGTAT	GGGTGGCGCGAT	chr3	123411530	123411727
MYLK	MYLK_33	GAGACCAACGCTCCATGAGCTA	CAAGAAGCTGCTGCTCCAGT	188	57	GAGACCAACGCTCCATGAGCTA	GAGTGGCCCTGGT	chr3	123418792	123418979
MYLK	MYLK_34	TTACGCGTCCAGATGATGGTG	ATGATGTGAACTGCAAGAGAGGC	184	55	TTACGCGTCCAGATGATGGTGG	CTGGGGGTGAGAA	chr3	123418914	123419097
MYLK	MYLK_35	CTTCTGCCCTCTGCCACAT	CCAAGCCTGATGAGAACCTGAAA	185	48	CTTCTGCCCTCTGCCACATGAA	ACATCTTGACAGCT	chr3	123418973	123419157
MYLK	MYLK_36	TCACATCATTTCTAACGTCCTTCTTGA	GTTCCAAGCCCCTGAGCAAT	198	54	TCACATCATTTCTAACGTCCTT	CTTGAGNNSTNNNN	chr3	123419089	123419286
MYLK	MYLK_37	CATTGGCTTCAGGGTCTCAGC	CCTGCCACCCCGATTTTC	189	58	CATTGGCTTCAGGGTCTCAGAG	GCTTGGCGTTGCC	chr3	123419201	123419389
MYLK	MYLK_38	CTTGGCATTACAGGGTCTCGG	GAAGAGAGGAAGGTGCACAGC	198	58	CTTGGCATTACAGGGTCTCGG	CACTGCTGCCATTC	chr3	123419297	123419494
MYLK	MYLK_39	CGGTGGCACCTTCTCAGG	CAAAGACCTATCGGAAGACG	200	56	CGGTGGCACCTTCTCAGGCAC	GGGGCTTGGRAGT	chr3	123419396	123419595
MYLK	MYLK_40	CTGTGCACCTTCTCTCTCTC	GGTGGAGCAGCTGGACTTC	168	55	CTGTGCACCTTCTCTCTCTC	AGACAGTCTTTGG	chr3	123419475	123419642
MYLK	MYLK_41	CCGATAGGGTCTTTGTA	CTCACTTCTTSCCAGGAG	174	63	CCGATAGGGTCTTTGTA	CTCACTTCTTSCCAGGAG	chr3	123419581	123419754
MYLK	MYLK_42	GCGCCTCTTCAGCACCC	ACTTCTCTTTTCCCTACACTGGT	195	63	GCGCCTCTTCAGCACCCCTCG	ACGTCCTCGCCGTCT	chr3	123419687	123419881

MYLK	MYLK_43	CCAGGAGGAAGGTGGGGAT	GAGGGCCTCTTGATCTTTATTGA	171	58	CCAGGAGGAAGGTGGGGATGSGGGCATGGCCTGGA	chr3	123420226	123420396	
MYLK	MYLK_44	GTTAGGGGAGCTAGGAATTTGGA	ACTGGCTCAGAGATGGCAAAG	196	55	GTTAGGGGAGCTAGGAATTTGGAGGGAAGGGTTAA	chr3	123426538	123426733	
MYLK	MYLK_45	TGAACACGTCTCTATTCTGAAGC	CACCCAGCCCTGGTTCATC	179	58	TGAACACGTCTCTATTCTGAAGCACCTCGAAGTGGCC	chr3	123426659	123426837	
MYLK	MYLK_46	CTTTGCCATCTCTGAGCCAGT	CTGCCTGCTGAGGGACATC	189	59	CTTTGCCATCTCTGAGCCAGTGCACGGTAGGAAAGG	chr3	123426713	123426901	
MYLK	MYLK_47	TTCTTGCTCTCAAATCACTTTT	AGAGGAACTCAGCACAGCCTT	198	60	TTCTTGCTCTCAAATCACTTTTGAGGGGGCTGCAGC	chr3	123427468	123427665	
MYLK	MYLK_48	CCAGGCCTCGCAGGTGTA	GAGGACCTCCCTAACCAATCCC	196	57	CCAGGCCTCGCAGGTGTACGTGCCGTGTCTCCGGC	chr3	123427591	123427786	
MYLK	MYLK_49	CCCATTGCAACCAAGACCATTTT	AGTAGCAGGAAGAGTGAGTACCT	189	52	CCCATTGCAACCAAGACCATTTTCATGTTAATCCNNI	chr3	123428544	123428732	
MYLK	MYLK_50	GTCATAGTGACCTGGCTTCCATC	GAATGCATGAATGTTACCCAC	168	51	GTCATAGTGACCTGGCTTCCATCATGACTTTGAGAT	chr3	123428617	123428784	
MYLK	MYLK_51	CCATTTTCTACAAATGTGCCCTTCC	GAGGACCATGGCACCTACAC	163	57	CCATTTTCTACAAATGTGCCCTTCTCCAAAGCARAA	chr3	123440891	123441053	
MYLK	MYLK_52	AGGCGCTGCAGGACAC	GAGCCTTCTGTGCTTCTC	163	65	AGGCGCTGCAGGACACCTGCCCAAGGCATTCTCAG	chr3	123440990	123441152	
MYLK	MYLK_53	TGGCTCAGAGGGATAAGTGAGAA	TGAAGGACTGCGCTGTTATTGAG	177	60	TGGCTCAGAGGGATAAGTGAGAATTCAGGCAGCGC	chr3	123444707	123444883	
MYLK	MYLK_54	CACCATTGACGACGCAAGTGA	GATCTGAGCTGACCTGTCTTTT	170	59	CACCATTGACGACGCAAGTGATCCGGGGCACTGGGG	chr3	123444788	123444957	
MYLK	MYLK_55	CCATGAATGGTTGTCCACAGAG	AGGTTTATGAAGATGCTGGCTCC	186	55	CCATGAATGGTTGTCCACAGAGAATCGGGGTGAC	chr3	123451689	123451874	
MYLK	MYLK_56	CAGCTGTATGTCCCACTGTCC	GCATAGGGAGCTCACGTTCTTTA	187	56	CAGCTGTATGTCCCACTGTCCCTGGTCCGGGCTTTCA	chr3	123451799	123451985	
MYLK	MYLK_57	GGCCACCAAGGGGCTAC	GAGCCAAGATGTTGTGAGCAAG	194	50	GGCCACCAAGGGGCTACATTTTGGCAATYGGTGACC	chr3	123452480	123452673	
MYLK	MYLK_58	TTTTCTTGACCTCTGGCTTTG	GAAGAGAGGAAGAGGCCAGCTC	179	58	TTTTCTTGACCTCTGGCTTTGGGGCTTGCTCTCAA	chr3	123452560	123452738	
MYLK	MYLK_59	TTAGCAGCCTTGCTCACAACATC	GTCCTTCAGAAGACTTCCAGCTC	191	60	TTAGCAGCCTTGCTCACAACATCTTGGCTCCCCAGGC	chr3	123452644	123452834	
MYLK	MYLK_60	CTGGCCTCTTCTCTCTTCTCC	GTCCAAGCTGGAGTCATGCAA	167	59	CTGGCCTCTTCTCTCTTCTCCAGAAGGTGATAGGnn	chr3	123452720	123452886	
MYLK	MYLK_61	GGGTGATGGAGCTGGAAGTC	AGGAGTCGAAGCTGGACA	198	61	GGGTGATGGAGCTGGAAGTCTTCTGAAGGACCRGR	chr3	123452804	123453001	
MYLK	MYLK_62	GGGAGCCACCTCTCTGG	CATTCTATTCTCCCTCTCTCAC	198	54	GGGAGCCACCTCTCTGGGGCTGGAGCAGTTCTTGC	chr3	123452927	123453124	
MYLK	MYLK_63	CCAATTCTTGCCCCATAAGATGA	CTAACAGTCTTCCACCCTTCCC	163	44	CCAATTCTTGCCCCATAAGATGATTAGAAATTCAT	chr3	123454135	123454297	
MYLK	MYLK_64	CAGTGAACAAGCAGCTCCTCTA	CGGCATGCAGGTTCTGGAAA	194	57	CAGTGAACAAGCAGCTCCTCTAGGAGGGTGCGGCAC	chr3	123456147	123456340	
MYLK	MYLK_65	CTGACATCGAGGCCTTCCC	TATGACCAAGTTACCCCATTGCC	179	54	CTGACATCGAGGCCTTCCCCGACCCGTTACCACCAG	chr3	123456243	123456421	
MYLK	MYLK_66	CGGGTATGTCTATTAGCAGCATGAG	GGGGAGTGCCACCAAAG	194	55	cgggtatgtctattagcagcatgagaacagactaataca	GGMTG	chr3	123457670	123457863
MYLK	MYLK_67	GCCGGCCAGTGATCTTG	GATGTTGAATTGCTGCCTTGTC	195	53	GCCGGCCAGTGATCTTGACAGAGAATCGTCCCATTCT	chr3	123457770	123457964	
MYLK	MYLK_68	CTCAAGTCAGCAGGAAAGCAATC	CACCCCTGCTGTTGAATCTTTT	188	46	CTCAAGTCAGCAGGAAAGCAATCCAACCTTACTCTG	chr3	123458742	123458929	
MYLK	MYLK_69	GCCTTGGGGTAACTGAGAGC	CCGCTTCTGCTGGATTG	200	57	GCCTTGGGGTAACTGAGAGCTCAGCTCCCTCCTGGA	chr3	123471121	123471320	
MYLK	MYLK_70	ACAGGTATACTTTCCCTGTCTT	caggctcttaCCTTTCTTCTTT	185	57	ACAGGTATACTTTCCCTGTCTCTCATGACAGCA	chr3	123471233	123471417	
MYLK	MYLK_71	GGCCCCTGCCCATCCTT	CGTCACACATTTCCAAAACCTCC	191	58	GGCCCCTGCCCATCCTTCCCCACAGCCTCCCCATCCA	chr3	123512473	123512663	
MYLK	MYLK_72	CTTACCCGCCCTTCGAACTTG	TTGTCTCTTCTCTCTTTTTC	198	54	CTTACCCGCCCTTCGAACTTGCGGTGGCTCCTTCTT	chr3	123512519	123512716	
SMAD3	SMAD3_1	GGCCGAGCTCCCTCT	CGCCTTCTCGCACCATTTCTC	189	72	GGCCGAGCTCCCTCTGCGCCCCGCGTCCCGTCGA	chr15	67358406	67358594	
SMAD3	SMAD3_2	ATGTCGTCCATCCTGCCTTTC	GATGCACTTGGTGTGACGTTT	195	59	ATGTCGTCCATCCTGCCTTTCACCTCCCGATCGTGA	chr15	67358493	67358687	
SMAD3	SMAD3_3	GCCTGGTCAAGAACTCAAGAAG	CTCTCTCTCCCTCTTCCATCTC	198	68	GCCTGGTCAAGAACTCAAGAAGACGGGGCAGCTGC	chr15	67358602	67358799	
SMAD3	SMAD3_4	GGAAGGGCTGTATTGTCTTATCA	GGGGAGACGAGTTCAAGAAAGAG	197	56	GGAAGGGCTGTATTGTCTTATCATCAGAATCCCTCC	chr15	67430295	67430491	
SMAD3	SMAD3_5	CAGAAAGCAAGCACAATCCACAT	TATTGAAGGCGAACTCACACAGC	194	60	CAGAAAGCAAGCACAATCCACATTTCCCTCTTTTCT	chr15	67457176	67457369	
SMAD3	SMAD3_6	GGGCTCCCTCATGTCTACT	CTGGCACTGCTGTCCC	197	60	GGGCTCCCTCATGTCTACTGCGCGCTGTGGCGAT	chr15	67457270	67457466	
SMAD3	SMAD3_7	GGGACTTTGGTGCTGGTCTG	GGGAAGTTAGTGTTTTCGGGGAT	162	60	GGGACTTTGGTGCTGGTCTGGCATCGACACTGAGCC	chr15	67457529	67457690	
SMAD3	SMAD3_8	CCACGCCACACAGAGATCC	CAGAGATTGGGGCCACAGG	195	64	CCACGCCACACAGAGATCCGGCCGAGTTCCCCCACA	chr15	67457611	67457805	
SMAD3	SMAD3_9	TCAGAGCCAAGCTGTGAAGG	GATGAACCCACAGCTGCTAATC	187	52	TCAGAGCCAAGCTGTGAAGGCCTTTTAACAGACCAC	chr15	67459063	67459249	

SMAD3	SMAD3_10	AGTGTTTAGTAACCTGGCTCTCCA	GCCCCCTCCCACACT	198	53	AGTGTTTAGTAACCTGGCTCTCCAGGCCAAGAATCTT	chr15	67462822	67463019
SMAD3	SMAD3_11	GAGGGAGCATGGGGCTTG	AATTGGAGGGGTGGTGAAG	195	61	GAGGGAGCATGGGGCTTGGGACACCCAATGACCCA	chr15	67473522	67473716
SMAD3	SMAD3_12	CGCGTCGGGGAGACATT	GGGGAATGGAGCCACCC	167	60	CGCGTCGGGGAGACATTCCACGCTCGCAGCCATC	chr15	67473647	67473813
SMAD3	SMAD3_13	TGCTGTTCTGCCTCCTTTC	CTGTTTACAGTTGGGAGACTGG	188	56	TGCTGTTCTGCCTCCTTTCGAGCCTCAGGTGGCCCC	chr15	67476972	67477159
SMAD3	SMAD3_14	TACTACATCGGAGGGGAGGTCTT	CATGCACTCGGAGAGGGAC	173	59	TACTACATCGGAGGGGAGGTCTTCGAGAGTGCCTC	chr15	67477082	67477254
SMAD3	SMAD3_15	GGACTTGCTTTATCCAGGAGGG	GCACATTCGGGTCAACTGGTAG	179	56	GGACTTGCTTTATCCAGGAGGGGAGCAACGGACCTG	chr15	67479625	67479803
SMAD3	SMAD3_16	AGTTCGCTGCCCTCCTG	CCAGAGTCACCTGGAGTTGG	167	59	AGTTCGCTGCCCTCCTGGCCAGTCGGTCAACCAGG	chr15	67479733	67479899
SMAD3	SMAD3_17	ACTGTCACCAAAGCAGAAAAAGC	CCATCTGGGTGAGGACCTTG	182	51	ACTGTCACCAAAGCAGAAAAAGCTTCTGACTTGTGT	chr15	67482658	67482839
SMAD3	SMAD3_18	ATTTTTTAAGTCCCCACCCAC	CTGCCCTCCCTACCATACTT	196	54	ATTTTTTAAGTCCCCACCCACCCCTTCCCTATTTCT	chr15	67482707	67482902
TGFBR1	TGFBR1_1	CGTCCTCCGAGCAGTTACAAA	cAGCACGAGGAGGAGCAG	186	77	CGTCCTCCGAGCAGTTACAAAgggccggagcgaggccgcq	chr9	101867353	101867538
TGFBR1	TGFBR1_2	CGGCGGGACCATTGGAG	cATGTTTGAGAAAGAGCAGGAGC	193	76	CGGCGGGACCATTGGAGGCGGGGTGCTGCTCCGC	chr9	101867478	101867670
TGFBR1	TGFBR1_3	TGGATAATTTCAAAGTTAACCTTGAG	TGCTGTGTGTATAACTTTGTCTGTG	170	38	TGGATAATTTCAAAGTTAACCTTGAGATTTTTTCTA	chr9	101891078	101891247
TGFBR1	TGFBR1_4	GTTACAGTGTCTTCTGCCACCTCT	TGCACATACAAACGGCTATCTC	163	42	GTTACAGTGTCTTCTGCCACCTCTGTACAAAAGACAAT	chr9	101891138	101891300
TGFBR1	TGFBR1_5	ACACAACAGCATGTGTATAGCTGA	GTATGAAGAGTTTTTCTGTAGTATCTAGG	198	36	ACACAACAGCATGTGTATAGCTGAAATTGACTTAATT	chr9	101891237	101891434
TGFBR1	TGFBR1_6	GTTGCCACCTACAGTGTTTTTGT	ATTTGGCACTCGATGGTGAATGA	198	47	GTTGCCACCTACAGTGTTTTTGTGTTGTTGATGTTA	chr9	101894730	101894927
TGFBR1	TGFBR1_7	TGCATCTCACTCATGTTGATGGT	GATGTCTTAGGAAAAAGGAGAAACAA	198	41	TGCATCTCACTCATGTTGATGGTCTATAYCTGCCACA	chr9	101894859	101895056
TGFBR1	TGFBR1_8	ATCAGTTTTCTGGGTCACTCATT	CCACTTTCCTCTCCAACTTCTCC	192	36	ATCAGTTTTCTGGGTCACTCATTAGTGCCTATCATGA	chr9	101900047	101900238
TGFBR1	TGFBR1_9	TTCAGAGAACAAATTGCGAGAACT	TCCCAGGATGTTTTCATGACGTA	194	42	TTCAGAGAACAAATTGCGAGAACTATTGTGTACAAG	chr9	101900156	101900349
TGFBR1	TGFBR1_10	CATTGGCAAAGGTCGATTTGGAG	ACAGACCTTTATTGTCTGTCTGCT	182	43	CATTGGCAAAGGTCGATTTGGAGAAGTTGGAGAGC	chr9	101900196	101900377
TGFBR1	TGFBR1_11	ATGTTACGTCATGAAAACATCCTG	TGTATTGCACTTAATGGGTCTAATCTAC	187	34	ATGTTACGTCATGAAAACATCCTGGGATTATAGCAC	chr9	101900323	101900509
TGFBR1	TGFBR1_12	CCATTGAACAAATAAATCATAAATGGTCTGC	AGCAAGTTTTATCATCTCTCCACA	176	37	CCATTGAACAAATAAATCATAAATGGTCTGCAGCCCA	chr9	101904755	101904930
TGFBR1	TGFBR1_13	AGACAATGGTACTTGGACTCAGC	TGGGTACCAACAATCTCCATGTG	168	44	AGACAATGGTACTTGGACTCAGCTCTGGTTGGTGTCT	chr9	101904816	101904983
TGFBR1	TGFBR1_14	AGGAATGATAAACTGCTCTGTCCA	AAAGCTTAAATAATAGAACTGCTTATAGAAATTACC	108	41	AGGAATGATAAAACTTGCTCTGTCCAYGGCGAGCGG	chr9	101904912	101905019
TGFBR1	TGFBR1_15	TGGGAGAAGAGACTTTTGAACCTAA	AATCATGTCTTACTGCCAGTCCT	191	36	TGGGAGAAGAGACTTTTGAACCTAAAGATGTGAGTT	chr9	101906928	101907118
TGFBR1	TGFBR1_16	TGATTCCTTAGGAAAGCCAGCCAT	GTTCCCACTCTGTGGTTTGGGA	162	40	TGATTCCTTAGGAAAGCCAGCCATTGCTCATAGAGAT	chr9	101907003	101907164
TGFBR1	TGFBR1_17	ACATGATTACGCCACAGATACCATT	CCATGAGATCTTCTACCTGTTGG	198	34	ACATGATTACGCCACAGATACCAATTGATATTGCTCCA	chr9	101907111	101907308
TGFBR1	TGFBR1_18	TGTATAAAGAAATGTCTGAAAGGAGGT	TCCCAGAATACTAAGCCCAATTGC	186	36	TGTATAAAGAAATGTCTGAAAGGAGGTTTATCCAAA	chr9	101908680	101908865
TGFBR1	TGFBR1_19	CCCCTGAAGTTCTCGATGATTCC	ACAATTCTTGAACAACTTCTGCTC	176	41	CCCCTGAAGTTCTCGATGATTCCATAAATGAAACA	chr9	101908775	101908950
TGFBR1	TGFBR1_20	TGCCTTGGCATTAGCTGAATAAA	GCCATCTGTTGGGATATTGGC	178	34	TGCCTTGGCATTAGCTGAATAAATTCATCAAAATTTA	chr9	101909878	101910055
TGFBR1	TGFBR1_21	TCATGAAGATTACCAACTGCCTT	TAGAAAATTGCCTAATATCAAAAAGAAATACTCA	162	36	TCATGAAGATTACCAACTGCCTTATTATGATCTTGTAC	chr9	101909940	101910101
TGFBR1	TGFBR1_22	ACAGAAGTTAAGGCCAAATATCCCA	ACATTGGTTTGACTGCTATGAAAAA	175	31	ACAGAAGTTAAGGCCAAATATCCCAACAGATGGCA	chr9	101910021	101910195
TGFBR1	TGFBR1_23	TCTTATCCAGACCAATGGAAAATGG	ATGCCTTCTGTTGACTGAGTTG	178	37	TCTTATCCAGACCAATGGAAAATGGTGCAATG	chr9	101911400	101911577
TGFBR1	TGFBR1_24	GTATGCCAATGGAGCAGCTAGG	ATATCCTTCTGTTCCCTCTCAGT	192	42	GTATGCCAATGGAGCAGCTAGGCTTACAGCATTGCG	chr9	101911500	101911691
TGFBR1	TGFBR1_25	TATCGCAACTCAGTCAACAGGAA	ATTACACTGCTGCAAAGGAAGC	166	41	TATCGCAACTCAGTCAACAGGAAGGCATCAAAATGT	chr9	101911550	101911715
TGFBR2	TGFBR2_1	TATGACGAGCAGCGGGGTC	GTCAAGCGCAGCGGAGAG	193	71	TATGACGAGCAGCGGGGTCGCCATGGGTCGGGGG	chr3	30648353	30648545
TGFBR2	TGFBR2_2	AAAAACAGCTCTCTGAGATGGATA	ATTAAGCAGTGAGGGAGCATGAC	185	36	aaaaacagctctctgagatggatataattatcctgttttacagatgtg	chr3	30664648	30664832
TGFBR2	TGFBR2_3	AACATCTTCAGGAATTCATTGGC	CTCATGCAAGGATTTCTGTTGTCT	186	40	AACATCTTCAGGAATTCATTGGCAGGCTGCCTGGCA	chr3	30686165	30686350
TGFBR2	TGFBR2_4	GTGCAGTCAAGTTTCCACAACCTG	ACATTATGTAAAAAGGGGAAAAAGAAAGA	189	42	GTGCAGTCAAGTTTCCACAACCTGTGTAATTTTGTGA	chr3	30686272	30686460
TGFBR2	TGFBR2_5	CCCTCGCTTCCAATGAATCTCTT	GCACTCATCAGAGCTACAGGAAC	197	44	CCCTCGCTTCCAATGAATCTTCTCACTCTAGGAGAAA	chr3	30691731	30691927

TGFBR2	TGFBR2_6	ACTAGAGACAGTTTGCCATGACC	GGTCCACACCTTAAGAGAAGA	198	44	ACTAGAGACAGTTTGCCATGACCCCAAGCTCCCCTAC	chr3	30691786	30691983
TGFBR2	TGFBR2_7	CCCACTTCCTGACAGTACTTACC	TGATGACAGATATGGCAACTCCC	163	47	CCCACTTCCTGACAGTACTTACCTACCACATCCAATC	chr3	30713063	30713225
TGFBR2	TGFBR2_8	AGTCATATTTCAAGTGACAGGCATCA	CTGATGTCAGAGCGGTCATCTTC	198	52	AGTCATATTTCAAGTGACAGGCATCAGCCTCCTGCCA	chr3	30713161	30713358
TGFBR2	TGFBR2_9	CAACCTGGGAAACCGGCAA	TATAGACCTCAGCAAAGCGACCT	183	56	CAACCTGGGAAACCGGCAAGACGCGGAAGCTCATG	chr3	30713271	30713453
TGFBR2	TGFBR2_10	CCAACAACATCAACCACAACACA	GTCCTTCTCTGTCTTCCAAGAGG	182	51	CCAACAACATCAACCACAACACAGAGCTGCTGCCCAT	chr3	30713370	30713551
TGFBR2	TGFBR2_11	TTCAGAGCAGTTTGAGACAGTGG	CGGTGATCAGCAGTATTGTTTC	176	48	TTCAGAGCAGTTTGAGACAGTGGCAGTCAAGATCTT	chr3	30713476	30713651
TGFBR2	TGFBR2_12	AGCATGAGAACATACTCCAGTTCC	GATCACTGTGGAGGTGAGCAATC	195	58	AGCATGAGAACATACTCCAGTTCCYACGGCTGAGG	chr3	30713574	30713768
TGFBR2	TGFBR2_13	GACGCGGCATGTCATCA	CAGGGAAAGCCCAAAGTCACA	196	59	GACGCGGCATGTCATCAGCTGGGAGGACCTGCGCA	chr3	30713686	30713881
TGFBR2	TGFBR2_14	TGTGGGAGGCCCAAGAT	GAGGCCAGGCTCAAGGTAAA	200	54	TGTGGGAGGCCCAAGATRCCCATCGTGACAGGGAC	chr3	30713777	30713976
TGFBR2	TGFBR2_15	CAGGGGCCACCATCAGCTATATT	ACCAGAGCCATGGAGTAGACATC	187	45	CAGGGGCCACCATCAGCTATATTGTGAAAATAAAAA	chr3	30715514	30715700
TGFBR2	TGFBR2_16	TGTCTGTTTTGCTATAGGTGGGA	ACCACTACACAATGATGCTGGTC	192	48	TGTCTGTTTTGCTATAGGTGGGAAGTGCAGATACA	chr3	30715579	30715770
TGFBR2	TGFBR2_17	GCATCTCACCATGCTCATTTCT	CGATCTCTCAACACGTTGTCCTT	164	49	GCATCTCACCATGCTCATTTCTTTGGCTGCACATGCC	chr3	30729800	30729963
TGFBR2	TGFBR2_18	GTGTTTGCTGGCTTTCTTCACAG	GCAACTTGGTTGAATCTTACTGACC	198	48	GTGTTTGCTGGCTTTCTTCACAGAAAGTAAAGATTAT	chr3	30729853	30730050
TGFBR2	TGFBR2_19	CAAGGTCAGCAGGCCACC	GCCTGTCCAGATGCTCCAG	191	60	CAAGGTCAGCAGGCCACCTTGCTTCCGCGGAGCCC	chr3	30732836	30733026
TGFBR2	TGFBR2_20	CTGGGACCACGACCCAGAG	GGGCAGCCTCTTTGGACA	186	61	CTGGGACCACGACCCAGAGGCCCGTCTCACAGCCCA	chr3	30732947	30733132

Genomic co-ordinates based on GRCh37/hg19 human reference sequence

Table S3 Transcript IDs used

Gene	Refgene	ENSGene
COL1A1	NM_000088	ENSG00000108821
COL1A2	NM_000089	ENSG00000164692
COL3A1	NM_000090	ENSG00000168542
COL5A1	NM_000093	ENSG00000130635
COL5A2	NM_000393	ENSG00000204262
ACTA2	NM_001141945	ENSG00000107796
FBN1	NM_000138	ENSG00000166147
MYH11	NM_002474	ENSG00000133392
MYLK	NM_053031	ENSG00000065534
SMAD3	NM_005902	ENSG00000166949
TGFBR1	NM_001130916	ENSG00000106799
TGFBR2	NM_001024847	ENSG00000163513

Table S4 Detailed phenotypic and genetic background of cases with pathogenic variants and variants of unknown significance (VUS)

Patient ID	Variants identified by NGS		Genetic testing by previous Sanger sequencing [a]				Age (yrs)	Sex	Initial clinical diagnosis	Phenotype details	No. relatives affected [b]	Affected mut.positive /mut.negative [b]	Beighton score (0-9)	Villefranche criteria - No.major criteria(No. minor criteria)					Ghent [c]	Signs OI [d]	Biochem [e]	LM [f]	EM [g]
	Gene	Variant type	COL1A1 /COL1A2	COL3A1	COL5A1 /COL5A2	Other Genes								Classical	Vascular	Hypermob	Kyphoscol	Other EDS					
31	COL5A1	Pathogenic		1			27	M	Classical		1		7	3(3)	1(0)							+	++
49	COL3A1	VUS					19	M	Classical		1		9	3(3)	2(0)								
62	COL5A2	Pathogenic		1			33	F	Classical		1	1	8	3(3)				4				-	++
429	COL5A1	Pathogenic		1			39	M	Classical	Thin skin over chest & spine, hypermobile, iliac artery aneurysm and rupture	1		4	2(4)	3(2)			1			Normal	+	++
581	COL5A1	Pathogenic		1			42	M	Classical		1	1	7	2(3)	0(1)							+	++
582	COL5A1	Pathogenic		1			56	M	Classical				9	1(1)	0(1)	2(0)					Col V	+	++
627	COL5A1	Pathogenic		1			78	M	Classical	Loose fragile skin, atypical for Classical EDS	0			3(1)							Normal		++
1129	COL5A1	Pathogenic		1			33	F	Classical	Joint hypermobility, fragile skin, Varicose veins	4	1		2(4)	0(1)								+
636*	COL3A1	Pathogenic		1		TNXB: 0	21	M	Classical	Hyperextensible skin, generalised hypermobility including marked distal hypermobility, facies suggestive of Classical EDS, no signs of Vascular EDS		0	8	2(1)	0(1)	2(0)		3			Normal	+	+
	COL5A2	VUS																					
67						TNXB: 1	33	M	Classical / Hypermobility overlap	Hyperextensible skin, hypermobility and anal prolapse	3	1		2(4)	2(1)			1				-	+
417	COL3A1	Pathogenic		1			31	M	Classical / Hypermobility / Vascular overlap	Widened atrophic scars, bruisability and friability of skin, marked generalised hypermobility, normal facies, history of recurrent colonic perforations	1		6	2(0)	1(2)	1(0)		1			Col III	+	+
671	COL5A2	VUS				PLOD1: 0	45	F	Classical / Hypermobility overlap		3	1	7	2(4)	1(0)	2(1)	1(1)	2				-	
37	COL3A1	Pathogenic		1			15	M	Vascular	Popliteal artery rupture	6		6	0(1)	3(0)	2(1)					Col III	+	+
46	COL3A1	Pathogenic		1			42	F	Vascular	Vascular EDS facies and aortic rupture	0		0		3(1)						Col III		+
76	COL3A1	Pathogenic		1			26	F	Vascular	Spontaneous colon perforation	0		9		3(2)	2(2)					Col III	+	+
384	COL1A1	VUS	1	0		FBN1: 0 TGFBFR1: 0 TGFBFR2: 0	42	F	Vascular	Acrogeria suggestive of vascular EDS; Ascending aortic aneurysm	2		0	1(1)	3(3)			0			Col III	-	-
405	COL3A1	Pathogenic		1			7	M	Vascular	Acrogeria & easy bruising	3				3(2)								
443	COL3A1	Pathogenic		1			44	F	Vascular		2	1		1(0)	3(3)	1(0)							
448	COL3A1	Pathogenic		1			26	F	Vascular	Typical acrogeric Vascular EDS	1		5		2(3)						Col III	+	-
483	COL3A1	Pathogenic		1			39	M	Vascular	Spontaneous colon perforation and positive family history of vascular EDS	1	1			3(4)			5				+	+
733	COL3A1	Pathogenic		1			33	M	Vascular	Spontaneous intra-abdominal haemorrhage	2	2		0(1)	3(3)								
1125						FBN2: 1	38	M	Vascular		1	1									Normal		
444*	COL1A1	VUS				CNV ¶	29	M	Vascular	varicose veins, small joint hypermobility, mildly thin and hyperextensible skin, learning difficulties	0	0/0	0	0(0)	0(2)	0(1)		2			Col III	-	-
42	COL3A1	Pathogenic		1			38	F	Vascular / Hypermobility overlap		6	1/3 Δ	4	0(2)	1(1)	0(1)		1	1-a		Col III (mild)	(+)	+
765	COL3A1	Pathogenic		1			6	F	Vascular/ Hypermobility overlap	Subependymal intracerebral haemorrhage at birth, Hypermobility, easy bruising	1		9		3(0)	1(1)			1-a				
1088	COL5A1	Pathogenic					40	M	Vascular/ Classical overlap		0		3	2(0)	2(2)			2					
66*	FBN1; COL5A1	Pathogenic; VUS		0		FBN1: 1	55	M	Other HDCT with vascular phenotype	Hypermobility / non-Marfan fibrinilopathy (Ghent =1), short stature, ectopia lentis, Aortic & Mitral valve surgery (aortic dilatation, MV prolapse).	3			1(0)		1(0)		1				-	-
378	FBN1	Pathogenic		0		SMAD3:0 TGFBFR1:0 TGFBFR2:0	42	F	Other HDCT with vascular phenotype	Hypermobility, Carotid artery dissection, early onset osteoarthritis	1			0(1)	1(0)	1(2)		0					
420	COL3A1	Pathogenic		1			27	F	Vascular/ Classical overlap	Vascular EDS facies (prominent eyes, small ear lobes) with hyper-extensible skin and extensive hypermobility. Haemothorax.	1		9	3(2)	3(1)	2(0)							+
34	COL5A1	VUS		0			36	F	Hypermobility / BJHS	Benign connective tissue phenotype with carotid(cervical) artery dissection	! (both sides of family)		3	-mild(1(0)							-	-
475	TGFBFR1	VUS		0	0		33	F	Other HDCT	Hypermobility, soft skin, multiple fractures, mild blue sclerae, systolic murmur	3		7	0(3)		2(1)			2-a. b			-	-
478	COL1A1	VUS		0	0		41	F	Hypermobility / BJHS		3		6		1(3)			0			Col III	-	+

538			0	FLNA : 1	23	F	Hypermobility / BJHS	Hypermobility, periventricular nodular heterotopia (FLNA mutation not segregating with EDS signs)	3	0(FLNA)	7	0(1)	1(0)	1(1)	1		-	-
558	COL1A2	VUS			22	M	Hypermobility / BJHS		0		6			1(0)	0		-	+
655	COL3A1	VUS	1		28	F	Hypermobility / BJHS	Marfanoid hypermobility syndrome	1	1	7	2(2)		2(2)	2	Normal	-	-
734	COL5A1	VUS	0	0	35	F	Hypermobility / BJHS		0		6	3- mild(0(0)	2(0)	1-a		-	+
799	COL5A1	VUS	0	0	46	F	Hypermobility / BJHS		1		5	1(3)	(3)	2(0)				+
801				CNV 36 NSD1:0 DMPK: 0	9	F	Hypermobility / BJHS	Hypermobility with significant learning difficulties & epilepsy	7		8	2(5)		1(0)	2(2)			
814	TGFBR2	Likely Pathogenic \$	0		34	F	Hypermobility / BJHS	Marfanoid hypermobility, thin skin, varicose veins, mild blue sclerae	2		8		1(1)	1(3)	0(2)	2		+
824	COL5A1	Pathogenic				F	Hypermobility / BJHS		1		9	1(2)		2(3)				
828	COL1A1	VUS	0		30	F	Hypermobility / BJHS	Hypermobility, soft skin, easy bruising, tall stature, arterial ectasia, mild varicose veins, early onset of	3			1(4)		1(0)	0	Normal	(+)	(+)
893	COL1A1	Likely Pathogenic \$	0		51	F	Hypermobility / BJHS	Hypermobility with pelvic floor weakness, fractured tibia and fibula	2			2(3)	0(1)	2(3)	0		-	-
1151	COL1A2	VUS	0		65	F	Hypermobility / BJHS		2		4	1(2)	0(1)	2(0)	0		+	-
38*	COL3A1; COL5A2	VUS; VUS	0		57	F	Hypermobility / BJHS	Benign connective tissue phenotype with coronary artery dissection	1		7	3(2)	1(1)	2(1)		Normal	+	+
39*	COL1A2; COL3A1	VUS; VUS	0	0	CNV \$	31	M	Hypermobility / BJHS	Marfan hypermobility with bowel fragility	3(partial)	3(TNXXB-hets)		1(0)	1(1)			+	+
57				PLOD1: 1 +	30	F	Kyphoscoliosis		1	1	9	3(3)		2(2)	3(4)	3	1-a	
732				PLOD1: 1 +	22	F	Kyphoscoliosis		1		4			2(0)	3(3)	3		
802				PLOD1: 1 +	10	F	Kyphoscoliosis		2 (partial)	2(het)		2(1)	1(0)	1(1)	0(4)		1-a	
822				FKBP14: 1 PLOD1: 0	3	M	Kyphoscoliosis		2	2(het)				2(1)		3	-	-
36	COL1A1	Pathogenic	1		7	F	Other HDCT	OI/EDS overlap (pelvic fracture, blue sclerae, hyperextensible skin, hypermobility)	4		6	0(0)	0(1)	2(2)	1	2-a,b		
527	COL1A1	Pathogenic	1		28	F	Other HDCT	Silence type I Osteogenesis Imperfecta/ EDS VIIA or VIIB : repeated fractures, deafness, blue sclerae, kyphosis, early postural hip problems	2	0/0	5	0 (1)	0(0)	1(0)	Arthroch alasia type: 1(0)	3	3-a,b,c	Col I + +
559	COL1A1	Pathogenic	1		48	M	Other HDCT	OI/EDS overlap (blue sclera, fractures, slight presenile conductive hearing loss, aortic valve disease, easy bruising, hypermobility, significant family history of vasculopathy)	5		4	1(3)	0(3)		0	2-a,b		
629	COL1A2	VUS	1		46	F	Other HDCT	OI/EDS overlap (mild blue sclerae, fractures, osteopenia, hypermobility, mild skin hyperextensibility), history of recurrent embolism	7	7/2		0(2)		2(0)	2	2-a, b	Col I + -	
804	COL1A1	VUS		PLOD1: 0 TNXB: 0	5	F	Other HDCT	Congenital hip dysplasia, postural kyphosis, joint hypermobility	2(partial)	0/0		1(3)	0(0)	1(2)	2(2)	2		
79			0	TNXB:1 (VUS), FBN1: 0	47	M	Other HDCT with vascular phenotype	Non specific connective tissue phenotype with vascular phenotype (venous aneurysm), generalised hypermobility, skin hyperextensibility, some features of Marfan syndrome, cutis laxa (of the face) and dysmorphic features	2(mildly)			2(2)	0(1)	2(1)	4	Col III	+	+
706	TGFBR1	Likely Pathogenic \$	0	TGFBR1:1 (VUS)	45	M	Other HDCT with vascular phenotype	Descending thoracic aortic dissection, subclavian artery aneurysm, pectus excavatum, soft skin	2		3	1(1)	1(1)	1(1)	1		-	-
708	COL3A1	VUS			11	F	Other HDCT with vascular phenotype	Marfanoid Hypermobility, joint pain, soft thin skin, aortic dilatation, colitis	5	2	4	0	(1)	1(2)				
766	FBN1	Pathogenic	0		8	M	Other HDCT with vascular phenotype	Generalized joint laxity (Hypermobility), marfanoid habitus, mild aortic dilatation, narrow palate, precocious puberty	0		7	0(0)	0(0)	2(0)	1(1)	Arthroch alasia type: 1(1)	6	1-a
382	SMAD3	Likely Pathogenic \$		SMAD3:1 (VUS)	49	F	Other HDCT with vascular phenotype	Hypermobility (9/9), Coronary artery dissection, ASD, Mildly marfanoid features			9	2(2)	1(0)	2(3)	2			

EDS, Ehlers-Danlos syndrome. VUS, variant of uncertain clinical significance. Beighton, score for extent of joint hypermobility (/9). OI, osteogenesis imperfecta. HDCT, Hereditary disorder of connective tissue. ASD, atrial septal defect. CNV, copy number variant.

a. Genetic testing by previous Sanger (performed by clinical service, independently of NGS): 1 = alteration identified, 0 = no alteration identified, [blank cells] = not tested

b. Segregation: numbers show the no. affected relatives carrying the variant / no. affected not carrying variant ("affected" = any relative sharing at least one EDS phenotype with index).

c. Ghent systemic score /20

d. Signs of OI: shows the no. and type of signs of OI: a. blue sclera, b. hereditary osteoporosis/fractures, c. presenile conductive hearing loss

e. Biochemical abnormalities: shows collagen type harbouring abnormality by SDS-PAGE

f. LM, Light Microscopy: '+'=abnormal; '-' = normal; [blank cells]= not tested

g. EM, Electron Microscopy: '+'=abnormal, '-' = normal, [blank cells]= not tested, '++' = collagen rosettes (only in Classical/COL5A1/2 cases)

*IDs 38, 39, 66, 444 had more than one rare variant co-existing. ♂ Karyotyping revealed 0.1 megabase deletion to chromosome q23.1, likely to be a polymorphic CNV (non pathogenic). § TNXB gene duplication ¶ translocation involving COL3A1 & COL5A2. Not shown: 3 cases of Kyphoscoliotic EDS diagnosed by urinary cross-link assay (PLOD1). Δ Of the 4 affected relatives tested genetically, 1 carried the p.Pro806Leu variant. The 3 who did not carry this variant had joint hypermobility but no other features of EDS. \$ See Table S6 for ACMG classification as Likely Pathogenic.

Table S5 Details of atypical genotype-phenotype correlations identified by the Collagen NGS panel

Patient ID	Gene	Variant	Variant Classification	Observed phenotype	Functional studies	Family history / Segregation	Comments
636	<i>COL3A1</i>	c.2329G>C: p.G777R	Pathogenic	Classical EDS. Clear phenotype - markedly hyperextensible skin, generalised hypermobility (Beighton 8) including marked distal hypermobility, facies suggestive of Classical EDS, no criteria met for Vascular EDS	Collagen Proteins: normal pro α 1(III) pattern ^a LM: thickened elastic fibres. EM: irregular packing of collagen fibrils (no collagen rosettes)	Not known	Not detected in clinical setting.
417	<i>COL3A1</i>	c.1922_1923 +2delAAGT	Pathogenic	Classical/Hypermobility/(vascular) overlap. Widened atrophic scars (marked forehead scarring), no skin thinning, tissue fragility, marked generalised hypermobility (Beighton 6), normal facies, history of colonic perforation.	Collagen proteins: absent pro α 1(III) and collagen III; LM: marked collagen depletion & increased elastin staining; EM: variable collagen fibril size & shape, dilated rER	Mother[d.], arterial rupture; segregation unknown.	-
1088	<i>COL5A1</i>	c.3164T>A: p.L1055X ^b	Pathogenic	Vascular/classical overlap. Thin translucent skin over anterior chest wall, bruising of the shins, with moderate hyperextensibility of the skin, distal hypermobility	[Not done]	Not known	Not detected in clinical setting.
824	<i>COL5A1</i>	c.4564G>T; p.G1522C	Pathogenic	Hypermobility EDS. Extensive joint hypermobility (Beighton 9/9) with recurrent shoulder dislocations, easy bruising; soft non-hyperextensible skin.	[Not done]	Mother –hypermobility Maternal grandfather - sudden cardiac death	Not detected in clinical setting.
893	<i>COL1A1</i>	c.2980C>T: p.R994C ^c	Likely Pathogenic	Hypermobility EDS. Predominant hypermobility trait with hyperextensible skin, marked pelvic floor weakness, history of fractured tibia and fibula.	Collagen proteins: [not done]. LM, EM: non-specific	Incomplete segregation of phenotype: Daughter-hypermobility, variant negative; Mother[d.] - hypermobile with pelvic floor weakness, genotype unknown	Not detected in clinical setting.

629	<i>COL1A2</i>	c.2123G>A: p.R708E d	Uncertain significance	Other HDCT. Juvenile hypermobility, now mild hypermobility, very mildly blue sclera 1/6, osteopenia	Collagen proteins: broadening of Pro α 2(I) band. LM: moderately increased elastin:collagen ratio. EM: relatively normal	Incomplete segregation: 7 offspring affected with mild connective tissue phenotype; 2/7 carry variant (one had hypermobility with history of fractures, one had hypermobility only)	-
-----	---------------	--------------------------------	---------------------------	---	---	---	---

EDS, Ehlers-Danlos syndrome, VUS, variant of uncertain clinical significance. HGMD, human genetic mutation database. (CM- no's are specific to HGMD entries). LOVD, Leiden Open Variation Database. Beighton, score for extent of hypermobility /9. LM, light microscopy. EM, electron microscopy. [d.], deceased Variant classification is as described in the Methods and for those variants not known to be pathogenic, using ACMG criteria (Richards et al. *Genet Med* 2015 [16]), see footnotes c. & d.

a. Pepsinised medium not done due to technical reasons. **b.** pathogenic *COL5A1* variant (p.Gly1537Val) causing vascular EDS phenotype also reported in LOVD (Munroe et al.) **c.** Helical R/C variants known to be pathogenic in *COL1A1* (ACMG criteria supporting this variant: 2 Moderate & 4 Supporting criteria); R/C variant also observed in *COL1A2* in Patient ID 1151 - hypermobility EDS with mild phenotype). **d.** Previously reported in a marfanoid hypermobile patient with slow migration of pro α 2(I) on SDS PAGE (HGMD CM900074; DBSNP rs72658163), this variant classified as "Uncertain significance" owing to contradictory evidence for and against pathogenicity

Table S6 Rare variants identified in Aortopathy-susceptibility genes

Patient ID	Diagnosis	Clinical details	Gene	Variant	Variant Classification	Novel/reported: Phenotype	Pathogenicity details	Previously detected?
66	Other HDCT (vascular)	Hypermobility / non-Marfan fibrinillopathy (Ghent =1), short stature, ectopia lentis, Aortic & Mitral valve surgery Family history: sudden death (father) & mitral valve prolapse (sister, first cousin)	<i>FBN1</i>	c.3781T>A: p.Tyr1261Asn	Pathogenic	Reported: Marfan a	Known interacting domain of FBN1, highly conserved residue. In silico predictions: deleterious	Y
378	Other HDCT (vascular)	Hypermobility, carotid artery dissection, early onset osteoarthritis	<i>FBN1</i>	c.1775G>A: p.Gly592Asp	Pathogenic	Reported: Marfan b	Known pathogenic	N
766	Other HDCT (vascular)	Generalized joint laxity (hypermobility), marfanoid habitus, mild aortic dilatation narrow palate, precocious puberty, parental consanguinity	<i>FBN1</i>	c.C3373T: p.Arg1125X	Pathogenic	Reported: Marfan c	Known pathogenic	N
706	Other HDCT (vascular)	Descending thoracic aortic dissection, subclavian artery aneurysm, pectus excavatum, soft skin	<i>TGFBR1</i>	c.T827C: p.Leu276Pro	Likely Pathogenic d	Novel	Ser-Thr kinase domain: multiple mutations in this region observed in LDS/Marfan spectrum - p.267 is closest. Conserved residue, In silico predictions: all deleterious	Y
382	Other HDCT (vascular)	Hypermobile (9/9), coronary artery dissection, ASD, Mildly marfanoid features (Ghent = 2)	<i>SMAD3</i>	c.1218G>C: p.Trp406Cys	Likely Pathogenic e	Novel	Proximate to MH2 domain (key interacting domain for other SMADs) In silico predictions: all deleterious	Y
814	Hypermobile	Marfanoid hypermobility, thin skin, varicose veins, mild blue sclerae. Family history of thoracic aortic rupture(sister), marfanoid features(sister, father)	<i>TGFBR2</i>	c.T1538C: p.Val513Ala	Likely Pathogenic f	Novel	Ser-Thr kinase domain: multiple mutations in this region observed in LDS/Marfan spectrum - p.C514R is closest. Conserved residue, In silico predictions: mostly deleterious	N
475	Other HDCT	OI/EDS overlap (multiple fractures, mild blue sclerae, soft skin, hypermobility, systolic murmur)	<i>TGFBR1</i>	214A>G: p.Ile72Leu	Uncertain significance g	Reported: BAV	Extracellular (ligand binding) domain – variants in this domain reported in LDS; In silico predictions: equivocal	N

HDCT, hereditary disorder of connective tissue. Ghent, Ghent systemic score for marfan syndrome.HGMD, human genetic mutation database. LDS, Loeys-Dietz syndrome. Ser-Thr, Serine-threonine kinase (main intracellular signalling mechanism of TGFBR). ASD, atrial septal defect. Variant classification is as described in the Methods and for those variants not known to be pathogenic, using ACMG criteria (Richards et al. *Genet Med* 2015 [16]), see footnotes d-g.
“Previously detected”: variants detected (Y) or not detected (N) by previous clinical diagnostic testing (Sanger method). **a.** Y1261C (HGMD CM990591 El-Aleem 1999), Y1261D (HGMD CM547000, Arbustini 2005) **b.** HGMD CM013919 Loeys 2001 **c.** HGMD CM055245, Rommel 2005 **d.** ACMG criteria supporting variant: 2 Moderate + 3 Supporting **e.** 2 Moderate + 2 Supporting **f.** 2 Moderate + 4 Supporting **g.** this variant reported by Bonachea et al. (*BMC Med Genomics* 2014;7:56) as a VUS in a bicuspid aortic valve (BAV) series, incomplete evidence of pathogenicity.

Table S7 Detailed phenotypic and genetic background of cases without identified pathogenic variants or variants of unknown significance (VUS).

Patient ID	Genetic testing by previous Sanger sequencing [a]					Age (yrs)	Sex	Initial clinical diagnosis	Phenotype details	No. relatives affected [b]	Affected mut.positive/mut.negative	Beighton score (0-9)
	COL1A1 / COL1A2	COL3A1	COL5A1 / COL5A2	Other genes								
56			0			32	M	Classical	Clinically & ultrastructurally classical EDS with aortopathy and mitral valve prolapse			
445	0		0				F	Classical	Complex connective tissue disorder resembling classical EDS with cerebral aneurysm and family history of aortic and cerebral aneurysm.			
595		0				31	M	Classical	Clinically classical EDS with family history of young onset cerebrovascular accident in first degree relative.			6
431	0					31	F	Classical/ hypermobility overlap		1		7
534		0				34	F	Classical/ hypermobility overlap	Generalised hypermobility with easy bruising, atrophic scars, slow wound healing, increased skin extensibility,			9
537		0				30	F	Classical/ hypermobility overlap				8
577						22	F	Classical/ hypermobility overlap				8
717			0			23	F	Classical/ hypermobility overlap	Hypermobility with easy bruising, skin hyperextensibility.			7-8 out of 9
803	0					28	F	Classical/ hypermobility overlap	Joint hypermobility and skin hyperextensibility along with osteopaenia & multiple fractures. Kyphoscoliotic type excluded on preliminary urine cross-link analysis.			8
1002		0		TNXB: 0		53	F	Classical/ hypermobility overlap	Generalized joint hypermobility with skin involvement and positive family history as well as gastroparesis and gastrointestinal transit problems.			7

44		31	F	Vascular / Hypermobility overlap	Vascular EDS facies, hypermobile, joint discomfort	1	0	5
73		12	M	Vascular	Borderline Vascular / Hypermobility EDS: hypermobility with vascular phenotype and family history of cerebrovascular event	2		5
372		40	F	Vascular	Atypical case of marked acrogeria and skin fragility			
482		28	F	Vascular / Hypermobility overlap	Borderline Vascular / Hypermobility EDS: generalised joint hypermobility with skin thinning and tissue fragility; marfanoid skeletal features with complex family history of variable connective tissue disease.			6
484		39	F	Vascular	Mixed connective tissue phenotype with features of vascular and hypermobility EDS and cerebral haemorrhage.			5
570		48	M	Vascular / Hypermobility overlap	Hypermobility EDS phenotype, although there are some facial features reminiscent of Vascular EDS			6
798		25	F	Vascular / Hypermobility overlap	Borderline Vascular / Hypermobility EDS: Clinically, overlap between vascular and hypermobile EDS with cerebral haemorrhage.			5
50	0	37	F	Hypermobility / BJHS		2	0	5
61		35	F	Hypermobility / BJHS				
64		12	F	Hypermobility / BJHS		4		5
65		60	F	Hypermobility / BJHS	Sheehan syndrome, femoral rupture in pregnancy.			3
69		<i>PL0D1: 0</i>	14	F	Hypermobility / BJHS	Hypermobility EDS with accompanying features of kyphoscoliosis.	2	6
70		10	M	Hypermobility / BJHS		2		4
74		50	F	Hypermobility / BJHS	Hypermobility syndrome with family history of aneurysms.			
98	0	<i>PL0D1: 0</i>	61	M	Hypermobility / BJHS	Borderline: Hypermobility EDS with marfanoid features and multifocal vascular aneurysm.		8

100	0	0		54	F	Hypermobility / BJHS	Borderline: Generalized joint hypermobility, skin involvement, cerebral aneurysm.	2	7
107		0	<i>FBN1: 0, ACTA2: 0, MYH11: 0, TGFB1: 0, TGFB2: 0</i>	47	M	Hypermobility / BJHS	Borderline: Hypermobility with aortopathy.		4
379	0	0	<i>TNXB: 0</i>	58	F	Hypermobility / BJHS	Marfanoid Hypermobility type with familial recurrent pneumothorax and family history of cerebral aneurysm.		0
381				34	F	Hypermobility / BJHS			
389		0		47	F	Hypermobility / BJHS	Complex of Hypermobility EDS with familial cardiovascular defects / aortopathy and early-onset osteoporosis.		
406		0		43	F	Hypermobility / BJHS	Uncomplicated hypermobility EDS with family history of aneurysm.		4
408			<i>TNXB: 0</i>		F	Hypermobility / BJHS			4
409	0			46	F	Hypermobility / BJHS	Hypermobility EDS with aortic dilatation		
428		0		67	F	Hypermobility / BJHS	Borderline: Overlap between Classical and hypermobility EDS with early onset osteoarthritis and gum recession.		
495		0		41	F	Hypermobility / BJHS	Borderline: Hypermobility EDS with significant tissue fragility presenting multiple severe signs of pelvic floor weakness.		6
533				34	F	Hypermobility / BJHS			9
535				4	M	Hypermobility / BJHS	Hypermobility with upper GI dysmotility.		
536				43	M	Hypermobility / BJHS	Mild connective tissue phenotype with familial dilated cardiomyopathy and multiple pneumothoraces.		1
576		0	<i>FBN1: 0</i>	17	M	Hypermobility / BJHS	Hypermobility with Marfanoid features.		9
578		0		37	M	Hypermobility / BJHS	Initial diagnosis: Hypermobility EDS / BJHS; later rosettes on EM, suggested possible Classical / Hypermobility overlap.		

594			11	F	Hypermobility / BJHS		7
621			22	F	Hypermobility / BJHS		6
623			54	F	Hypermobility / BJHS	Hypermobility, family history of sudden cardiac death, mitral valve prolapse.	
630			36	F	Hypermobility / BJHS		7
631			51	F	Hypermobility / BJHS		8
635			41	F	Hypermobility / BJHS		7
639			38	F	Hypermobility / BJHS	Hypermobility EDS with marfanoid habitus.	5
649			26	M	Hypermobility / BJHS		3
650	0		36	F	Hypermobility / BJHS		7
669	0		29	F	Hypermobility / BJHS		7
670			36	F	Hypermobility / BJHS	Extreme generalised hypermobility with pelvic floor weakness.	8
673	0	0	57	M	Hypermobility / BJHS	Hypermobility with marfanoid features.	3
676		0	35	F	Hypermobility / BJHS		5
681			53	F	Hypermobility / BJHS	Hypermobility and congenital kyphoscoliosis.	
761		<i>PLOD1: 0</i>	22	M	Hypermobility / BJHS	Borderline: Hypermobility with marfanoid features.	6
764		0 <i>COL9A3: 0</i>	10	M	Hypermobility / BJHS	Borderline – other: Extreme connective tissue phenotype – overlap between classical and kyphoscoliotic type EDS.	9
767			54	F	Hypermobility / BJHS	Hypermobility with mitral valve prolapse and family history of cerebral aneurysm.	5
769			22	F	Hypermobility / BJHS	Borderline: Hypermobility with recurrent fracture, brachydactyly and dysautonomia	3

778			22	F	Hypermobility / BJHS	Hypermobility with family history of cerebrovascular accident.	7
781			40	F	Hypermobility / BJHS	Hypermobility with intracranial haemorrhage and bleeding tendency.	5
806			16	M	Hypermobility / BJHS		
821			3	M	Hypermobility / BJHS		8
825	0	<i>PLOD1: 0, TNXB: 0</i>	3	F	Hypermobility / BJHS	Unusual form of Hypermobility EDS III with features overlapping with other subtypes and probably compound heterozygote inheritance.	
826			17	F	Hypermobility / BJHS		7
827	0		29	M	Hypermobility / BJHS	Hypermobility EDS with marfanoid habitus.	6
829		0	2	M	Hypermobility / BJHS	Mild connective tissue phenotype with some extensive pretibial bruising and ultrastructural evidence of collagen disruption (?classical EDS)	0
872		<i>FBN1: 0</i>	5	F	Hypermobility / BJHS		8
888	0		16	F	Hypermobility / BJHS		5
891			33	F	Hypermobility / BJHS	Familial Hypermobility with unusual feature of skin thinning and variable marfanoid features co-segregating.	4
922	0		37	F	Hypermobility / BJHS		6
1083			4	F	Hypermobility / BJHS		9
1085			31	F	Hypermobility / BJHS		3
1089			22	F	Hypermobility / BJHS	Hypermobility with family history of marfanoid habitus and aortic aneurysm.	4
1108			44	F	Hypermobility / BJHS		7
1297			15	M	Hypermobility / BJHS	Soft stretchy skin and joint hypermobility along with multiple exostoses and vertebral artery dissection.	4

1338				13	F	Hypermobility / BJHS	Hypermobility with kyphosis.			8
88	0		<i>COL3A1: 0</i>	12	F	Complex EDS	Borderline (other):Connective tissue phenotype with features of Vascular and Periodontitis EDS.			7
357	0			12	M	Complex EDS	Vascular and Periodontitis EDS: acrogeria, easy bruising, marked generalised periodontal recession.			
682	0			45	F	Complex EDS	indeterminate: Early periodontal disease / BJHS.			6
718	0	0		32	F	Complex EDS	Indeterminate: Complex EDS phenotype overlap of Classical / Vascular / Hypermobility EDS.			5
820		0		3	F	Complex EDS	Borderline other: Mostly Arthrochalasia EDS, but with some features of Kyphoscoliosis EDS and minor features of Classical EDS			
823				6	M	Complex EDS	Borderline other: Very hypermobile with features of number of different overlapping EDS subtypes.			8
890	0			55	F	Complex EDS	Indeterminate: a rare Ehlers-Danlos Syndrome subtype.			4
1092	0			20	F	Complex EDS	Borderline other: skin bruisability, skin thinning.			
1109		0	<i>TNXB: 0</i>	54	F	Complex EDS	Borderline other: bilateral congenitally dislocated hips, scoliosis and pelvic tilt.			
812	0	0	<i>PLOD1: 0 ,FKBP14: 0, CHST14: 0</i>	2	F	Kyphoscoliotic EDS				
1283				31	M	Kyphoscoliotic EDS	Type VI: severe EDS combination of early onset scoliosis operated upon at the age of 8, osteotomies of his hip, stabilisation of one of his knees	1	0	
810				15	M	Complex EDS	Indeterminate: Complex phenotype including overlap between marfanoid Hypermobility, Classical and Kyphoscoliotic EDS.			8
479	0			24	F	Other HDCT	Indeterminate: possibility of chromosomal imbalance, Stickler syndrome, a possibility of neuromuscular disorder.			9
568				4	F	Other HDCT	Indeterminate, Urinary cross link normal.			
620			<i>PLOD1: 0</i>	21	F	Other HDCT	indeterminate: Ehlers-Danlos Syndrome/myopathy overlap, urinary cross link normal.			5
628				49	F	Other HDCT	Indeterminate: borderline between an EDS variant and an acquired cutis laxa.			5
654				47	F	Other HDCT	Indeterminate			5

45	0	0		52	f	Other HDCT(vascular)	Indeterminate: hypermobility with carotid dissection.			
16			0	51	m	Other HDCT (vascular)	Other HDCT: hypermobility with aortopathy and family history of aortic aneurysm.	2		4
33		0		45	f	Other HDCT (vascular)	Features of Marfan and EDS and coronary artery dissection and family history of vascular disease.	1	0	9
35	0	0		32	f	Other HDCT (vascular)	Indeterminate: Joint hypermobility, atrophic scars, carotid dissection.	2	0	
40	0	0	TGFB1: 0, TGFB2: 0	54	M	Other HDCT (vascular)	Indeterminate: multiple aneurysms, slightly soft skin.	3	0	
60		0		48	M	Other HDCT (vascular)	Indeterminate: soft extensible skin, striae, bilateral carotid dissection.	1		
72		0	0	53	M	Other HDCT (vascular)	Indeterminate: Joint hypermobility, skin hyperextensibility, carotid dissection and family history of aortic aneurysms.			
99		0		60	M	Other HDCT (vascular)	Indeterminate: non-specific connective tissue features with carotid dissection.			0
385		0		34	F	Other HDCT (vascular)	Hypermobility with mitral valve prolapse and family history of cerebral and aortic aneurysm.			
403		0		41	F	Other HDCT (vascular)	Hypermobility with carotid dissection.			
421				9	F	Other HDCT (vascular)	Indeterminate: Complex multisystem familial connective tissue phenotype, including generalised hypermobility, camptodactyly, skin fragility and aortopathy.	3		8
425		0		51	F	Other HDCT (vascular)	Unspecified: Mild connective tissue phenotype, aortic dilatation, family history of hypermobility.			3
446		0		49	M	Other HDCT (vascular)	Unspecified: Non-specific mild connective tissue phenotype with vascular event.			4
453		0		48	F	Other HDCT (vascular)	Indeterminate: Non specific, mild connective tissue phenotype with hypermobility, carotid dissection.			4
474	0	0		63	F	Other HDCT (vascular)	Indeterminate: Non-specific connective tissue phenotype with thin skin, easy bruising, spontaneous epidural haemorrhage.			0
532		0		41	M	Other HDCT (vascular)	Indeterminate: Mild connective tissue phenotype with aortopathy and polydactyly and hip dysplasia.			2

564	0	0	0	<i>FBN1: 0, TGFBFR1: 0, TGFBFR2: 0</i>	24	M	Other HDCT (vascular)	EDS hypermobility/OI overlap: EDS hypermobility with aortic dilatation some similarities to classical EDS, a compound heterozygosity of his father's HOCM genes with his mother's hypermobile one, urinary test normal.	8
567		0			53	M	Other HDCT (vascular)	Indeterminate HDCT: mild hypermobility and connective tissue phenotype with iliofemoral arterial aneurysms.	4
651		0		<i>GLUT10: 0, TGFBFR1: 0, TGFBFR2: 0, FBLN4: 0, SLC2A10: 0</i>	27	F	Other HDCT (vascular)	Familial Marfanoid hypermobility syndrome with family history of carotid and cerebral aneurysm and early onset varicose veins.	
768		0			54	M	Other HDCT (vascular)	Indeterminate: Mild connective tissue symptoms with marfanoid habitus and multifocal vascular disease.	3
777		0			29	F	Other HDCT (vascular)	Indeterminate: Hypermobility with early onset osteoarthritis and family history of cerebral aneurysm.	7
800		0			60	F	Other HDCT (vascular)	Indeterminate: Non-specific hereditary disorder of connective tissue with multiple vascular haemorrhages and inflammatory arthropathy.	
964					72	F	Other HDCT (vascular)	Other HDCT: Hypermobility with familial cerebral aneurysm/aortic aneurysm in multiple siblings.	7
1093					47	F	Other HDCT (vascular)	Coronary artery dissection	
1185		0			43	F	Other HDCT (vascular)	Hypermobility with an unexpected aneurysm.	

EDS, Ehlers-Danlos syndrome. VUS, variant of uncertain clinical significance. Beighton, score for extent of joint hypermobility (/9). OI, osteogenesis imperfecta. HDCT, Hereditary dis

- Genetic testing by previous Sanger (performed by clinical service, independently of NGS): 1 = alteration identified, 0 =no alteration identified, [blank cells] =not tested
- Segregation: numbers show the no.affected relatives carrying the variant / no. affected not carrying variant ("affected" =any relative sharing at least one EDS phenotype with index)
- Ghent systemic score /20
- Signs of OI: shows the no. and type of signs of OI: a. blue sclera, b. hereditary osteoporosis/fractures, c. presenile conductive hearing loss
- Biochemical abnormalities: shows collagen type harbouring abnormality by SDS-PAGE

f. LM, Light Microscopy: '+'=abnormal; '-' = normal; [blank cells]= not tested

g. EM, Electron Microscopy: '+'=abnormal, '-' = normal, [blank cells]= not tested, '++' = collagen rosettes (only in Classical/COL5A1/2 cases)

Villefranche criteria - No.major criteria(No. of minor criteria)					Ghent [c]	Signs OI [d]	Biochem [e]	LM [f]	EM [g]
Classical	Vascular	Hypermob	Kyphoscol	Other EDS					
3(4)	0(0)	2(2)	0(0)	0(0)	3			+	+
3(5)	0(0)	0	0(0)	0(0)	1		Col III	+	+
2(3)	0(0)	2(0)	0(0)	0(0)	3				-
1(4)	0(0)	2(3)	0(0)	0(0)				-	-
3(2)	1(2)	2(2)	0(0)	0(0)			Col III	+	-
2(1)	0(0)	2(1)	0(0)	0(0)		1-a	normal	-	+
2(2)	0(0)	2(1)	0(0)	0(0)		1-a		+	+
1(2)	0(0)	2(1)	0(0)	0(0)					+
2(3)	0(0)	2(3)	0(0)	0(0)		1-a	Normal		
2(2)	0(0)	2(2)	0(0)	0(0)			Normal		-

0(0)	1(1)	2(2)	0(0)	0(0)	0			-	-
0(0)	2(2)	2(1)	0(0)	0(0)					
0(0)	2(4)	0(0)	0(0)	0(0)	2			+	+
0(0)	1(1)	2(2)	0(0)	0(0)		Normal			-
0(0)	2(4)	1(0)	0(0)	0(0)	2	1-a	Normal		+
0(0)	1(2)	2(1)	0(0)	0(0)	2	1-a	Normal	+	+
0(0)	3(1)	2(1)	0(0)	0(0)					
2(1)	1(0)	1(2)	0(0)	0(0)					-
0(0)	0(0)	2(0)	0(0)	0(0)					+
0(1)	0(0)	2(2)	0(0)	0(0)					-
0(0)	2(0)	1(0)	0(0)	0(0)					
0(0)	0(0)	2(2)	2(0)	0(0)					-
0(1)	0(0)	1(1)	0(0)	0(0)					
1(0)	0(2)	1(1)	0(0)	0(0)					+
0(0)	1(1)	2(1)	0(0)	0(0)	3				-

2(1)	1(0)	2(1)	0(0)	0(0)				+
0(0)	1(1)	2(1)	0(0)	0(0)				+
0(1)	0(0)	2(2)	0(0)	0(0)	5			
1(0)	0(0)	1(2)	0(0)	0(0)				
0(3)	0(0)	2(3)	0(0)	0(0)				-
0(0)	1(1)	1(1)	0(0)	0(0)				
2(1)	0(0)	2(1)	0(0)	0(0)				-
0(0)	0(0)	2(3)	0(0)	0(0)		1-a		
2(3)	0(0)	2(1)	0(0)	Periodontitis (1 criterion)				
1(3)	0(0)	1(3)	0(0)	0(0)	2			-
1(2)	0(0)	2(2)	0(0)	0(0)				-
0(0)	0(0)	1(1)	0(0)	0(0)				
0(0)	0(0)	1(0)	0(0)	0(0)	5	1-a		+
0(0)	0(0)	2(1)	0(0)	0(0)	7			+
0(0)	0(0)	0(0)	0(0)	0(0)				+

1(2)	0(0)	1(1)	0(0)	0(0)					
0(0)	0(0)	2(2)	0(0)	0(0)		1-a			
0(1)	0(0)	1(1)	0(0)	0(0)		1-a		-	
1(2)	0(0)	2(2)	0(0)	0(0)				-	-
0(0)	0(0)	1(1)	0(0)	0(0)				+	-
0(0)	0(0)	1(1)	0(0)	0(0)				+	-
0(0)	0(0)	2(2)	0(0)	0(0)	3	1-a		-	-
0(0)	0(0)	1(0)	0(0)	0(0)					-
0(0)	0(0)	1(0)	0(0)	0(0)				-	-
1(2)	0(0)	2(1)	0(0)	0(0)		1-a		-	-
0(0)	0(0)	2(2)	0(0)	0(0)				-	-
0(1)	0(0)	1(1)	0(0)	0(0)	3	a		+	-
0(0)	0(0)	2(2)	0(0)	0(0)					+
0(0)	0(0)	1(3)	1(0)	0(0)	1			-	-
1(2)	0(0)	2(1)	3(3)	0(0)	3				
2(4)	0(0)	2(1)	3(2)	0(0)	2				+
0(0)	0(0)	2(1)	0(0)	0(0)	1			-	-
0(0)	0(0)	1(3)	0(0)	0(0)					

0(0)	0(0)	2(3)	0(0)	0(0)			-	-
2(0)	1(0)	2(2)	0(0)	0(0)			-	-
0(0)	0(0)	1(1)	1(1)	0(0)			-	-
0(0)	0(0)	2(2)	2(1)	0(0)			-	-
1(4)	0(0)	2(2)	2(0)	0(0)		1-a		+
0(0)	0(0)	2(0)	0(0)	0(0)		1-a		
0(0)	0(0)	1(1)	0(0)	0(0)	2			
0(2)	0(0)	1(1)	0(0)	0(0)			+	+
0(0)	0(0)	1(2)	0(0)	0(0)				
0(0)	0(0)	2(1)	0(0)	0(0)				
0(0)	1(0)	1(3)	0(0)	0(0)	2			
1(1)	0(0)	2(1)	0(0)	0(0)		1-a	-	-
0(0)	0(0)	1(3)	0(0)	Arthrochalasia - 2(0)		1-a		
0(0)	0(0)	1(2)	0(0)	0(0)			-	+
0(0)	0(0)	2(1)	0(0)	0(0)	1	1-a		
0(0)	0(0)	2(1)	0(0)	0(0)				
0(0)	1(0)	1(1)	0(0)	0(0)				

0(0)	0(0)	2(1)	0(0)	0(0)		1-a			
0(0)	3(2)	1(0)	0(0)	Periodontitis - 1(0)		Col III			
0(0)	2(2)	0(0)	0(0)	Periodontitis - 1(0)		1-a	+	+	
0(0)	0(0)	1(2)	0(0)	0(0)		1-a	+	-	
2(2)	3(1)	2(1)	0(0)	0(0)		1-a	+	+	
1(1)	0(0)	0(0)	1(0)	Arthrochalasia - 2(2)			+	+	
1(5)	2(0)	2(2)	2(2)	0(0)	2		-	-	
0(0)	0(0)	0(1)	0(0)	0(0)					
2(1)	0(0)	0(0)	0(0)	0(0)					
2(1)	0(0)	0(0)	0(0)	Arthrochalasia - 0(1)					
0(0)	0(0)	1(1)	3(2)	0(0)	2			-	
0(0)	0(0)	0(0)	2(1)	0(0)					
2(4)	0(0)	2(2)	2(2)	0(0)	2	-			
1(3)	1(0)	2(0)	2(1)	0(0)		Col I	-	-	
0(2)	0(0)	0(0)	1(0)	0(0)				+	
1(2)	0(0)	1(3)	2(2)	0(0)					
2(2)	0(0)	2(1)	0(0)	0(0)			+		
0(0)	0(0)	1(1)	0(0)	0(0)					

1(0)	1(0)	1(1)	0(0)	0(0)		Normal	+	+
2(1)	0(1)	1(3)	0(0)	0(0)	0	Normal	-	+
0(0)	1(0)	1(1)	0(0)	0(0)	8		-	-
0(1)	3(1)	0(0)	0(0)	0(0)		Col III	-	-
0(1)	1(0)	2(1)	0(0)	0(0)	1	Col III	+	+
1(0)	1(0)	0(0)	0(0)	0(0)			+	-
0(0)	1(1)	0(0)	0(0)	0(0)			-	+
0(1)	1(1)	0(0)	0(0)	0(0)				
0(0)	0(0)	2(2)	0(0)	0(0)	2		-	-
0(0)	1(0)	1(0)	0(0)	0(0)			+	+
2(6)	1(3)	2(3)	0(0)	0(0)	2			
2(0)	0(0)	2(1)	0(0)	0(0)		1-a		
0(1)	1(1)	1(0)	0(0)	0(0)		Normal		+
0(0)	1(1)	0(0)	0(0)	0(0)		Normal		+
0(1)	0(1)	0(0)	0(0)	0(0)		Normal	+	+
0(0)	1(0)	0(0)	0(0)	0(0)	2		-	-

2(3)	0(1)	2(1)	0(0)	0(0)	4	1-a		+	+
1(0)	1(0)	1(0)	0(0)	0(0)	1		Normal	+	-
0(0)	0(2)	0(1)	0(0)	0(0)	2				
0(0)	1(0)	0(0)	0(0)	0(0)	2			-	-
0(0)	0(0)	2(3)	0(0)	0(0)	1				
0(0)	1(1)	1(0)	0(0)	0(0)				-	
1(0)	0(1)	2(1)	0(0)	0(0)	2	1-a	Normal	-	-
0(0)	1(0)	0(0)	0(0)	0(0)					
0(0)	0(0)	1(0)	0(0)	0(0)					

order of connective tissue. ASD, atrial septal defect. CNV, copy number variant.

). c. Ghent systemic score /20

Table S8 In silico predictions of missense pathogenic variants and variants of uncertain significance

Patient ID	Gene	Variant	Classification	Coordinates	Max. Freq.	SIFT		Polyphen		MutationTaster		MutationAssessor		LRT		FATHMM		CADD	GERP++	PhyloP	SiPhy
						score	prediction	score	prediction	score	prediction	score	prediction	score	prediction	score	prediction				
636	COL3A1	c.2329G>C: p.G777R	pathogenic	2:189866168	NA	1.00	D	1.00	D	1.00	D	0.87	H	1.00	D	0.61	D	4.003,20.5	5.38	2.69	19.49
824	COL5A1	c.4564G>T: p.G1522C	pathogenic	9:137713952	NA	1.00	D	1.00	D	1.00	D	0.82	H	1.00	U	0.63	D	3.577,18.22	4.70	2.14	17.22
62	COL5A2	c.3445G>T: p.G1149C	pathogenic	2:189907903	NA	1.00	D	1.00	D	1.00	D	0.90	H	1.00	D	0.62	D	4.220,21.9	5.39	2.68	19.52
36	COL1A1	c.643G>A: p.G215S	pathogenic	17:48275146	NA	1.00	D	1.00	D	1.00	D	0.84	H	1.00	D	0.63	D	4.445,23.7	4.80	2.36	17.02
559	COL1A1	c.662G>C: p.G221A	pathogenic	17:48275127	NA	1.00	D	1.00	D	1.00	D	0.87	H	1.00	D	0.63	D	3.700,18.79	4.80	2.36	17.02
37	COL3A1	c.2564G>A: p.G855D	pathogenic	2:189868147	NA	1.00	D	1.00	D	1.00	D	0.80	H	1.00	D	0.59	D	4.275,22.3	5.61	2.65	19.65
42	COL3A1	c.2417C>T: p.P806L	pathogenic	2:189867049	NA	0.96	D	0.06	B	1.00	D	0.62	L	1.00	D	0.54	D	3.877,19.70	5.77	2.73	19.99
46	COL3A1	c.G1771: p.G591R	pathogenic	2:189861900	NA	1.00	D	1.00	D	1.00	D	0.82	H	1.00	D	0.63	D	4.290,22.4	6.03	2.87	20.16
76	COL3A1	c.2771G>A: p.G924D	pathogenic	2:189868817	NA	1.00	D	1.00	D	1.00	D	0.84	H	1.00	D	0.63	D	5.324,34	5.50	2.59	19.41
733	COL3A1	c.2816G>A: p.G939D	pathogenic	2:189868862	NA	1.00	D	0.98	D	1.00	D	0.87	H	1.00	D	0.63	D	3.773,19.16	5.63	2.66	19.69
448	COL3A1	c.4319C>T: p.P1440L	pathogenic	2:189876418	NA	1.00	D	1.00	D	1.00	D	0.78	M	1.00	D	0.49	D	4.798,27.1	5.70	2.69	19.83
66	FBN1	c.3781T>A: p.Y1261N	pathogenic	15:48776072	NA	1.00	D	0.99	D	1.00	D	0.85	H	1.00	D	0.53	D	5.006,29.4	6.17	2.37	16.48
378	FBN1	c.1775G>A: p.G592D	pathogenic	15:48800841	NA	0.99	D	1.00	D	1.00	D	0.74	M	1.00	D	0.43	T	5.285,33.0	5.71	2.85	18.78
893	COL1A1	c.C2980T: p.R994C	Likely Pathogenic	17:48266329	NA	1.00	D	0.99	D	1.00	D	0.79	H	1.00	D	0.49	D	3.479,17.80	3.83	2.00	14.74
814	TGFBR2	c.T1538C: p.V513A	Likely Pathogenic	3:30732925	NA	0.99	D	0.70	P	1.00	D	0.54	N	1.00	N	0.40	T	4.401,23.3	4.73	1.03	13.21
382	SMAD3	c.1218G>C: p.W406C	Likely Pathogenic	15:67482814	NA	0.97	D	1.00	D	1.00	D	0.73	M	1.00	D	0.56	D	4.218,21.9	4.97	2.32	18.25
706	TGFBR1	c.T827C: p.L276P	Likely Pathogenic	9:101904839	NA	1.00	D	1.00	D	1.00	D	0.73	M	1.00	D	0.41	T	4.565,24.7	5.87	2.37	15.56
49	COL3A1	G3511A: p.G1171K	VUS	2:189872854	NA	0.52	T	0.81	P	0.70	D	0.61	L	1.00	D	0.52	D	4.469,23.9	5.51	2.59	19.42
478	COL1A1	c.4315A>G: p.I1439V	VUS	17:48262943	NA	0.92	T	0.34	B	1.00	D	0.67	M	1.00	D	0.44	T	1.873,12.22	4.49	1.89	12.90
828	COL1A1	c.3301G>A: p.E1101K	VUS	17:48265305	NA	0.91	T	1.00	D	1.00	D	0.61	L	1.00	D	0.52	D	5.449,35.0	5.00	2.32	17.08
39	COL1A2	c.2861T>C: p.I954T	VUS	7:94055087	NA	0.46	T	0.00	B	0.00	N	0.44	N	0.72	N	0.52	D	0.057,4.310	-0.42	-0.43	5.62
558	COL1A2	c.1159G>C: p.A387P	VUS	7:94039801	NA													0.023,4.135			
1151	COL1A2	c.C4012T: p.R1338C	VUS	7:94059616	NA	1.00	D	1.00	D	1.00	D	0.74	M	1.00	D	0.44	T	3.598,18.32	5.35	2.89	19.95
38	COL3A1	c.198A>G: p.I66M	VUS	2:189849604	0.00010	0.86	T	0.05	B	1.00	D	0.59	L	1.00	N	0.42	T	3.973,20.3	-4.78	-0.55	14.85
39	COL3A1	c.2044G>A: p.E682K	VUS	2:189864032	NA	0.87	T	1.00	D	1.00	D	0.66	M	1.00	D	0.52	D	4.152,21.5	4.96	2.47	18.61
655	COL3A1	c.3938A>G: p.K1313R	VUS	2:189875018	0.00260	0.95	D	1.00	D	0.86	D	0.58	L	1.00	D	0.43	T	3.731,18.95	5.93	2.26	16.38
66	COL5A1	c.G805A: p.E269K	VUS	9:137620534	NA	0.08	T	0.02	B	0.95	D	0.64	L	0.99	U	0.49	D	1.159,9.720	3.93	1.72	15.92
734	COL5A1	c.3257C>T: p.A1086V	VUS	9:137697059	NA	0.39	T	0.99	D	1.00	D	0.48	N	1.00	U	0.52	D	2.645,14.80	5.19	2.41	18.70
799	COL5A1	c.2497C>T: p.P833S	VUS	9:137676847	0.00020	0.43	T	0.73	P	0.74	D	0.63	L	1.00	U	0.55	D	1.614,11.35	4.39	2.00	15.75
38	COL5A2	c.2228A>C: p.K743T	VUS	2:189923156	0.00010			0.99	D	1.00	D	0.60	L	1.00	D	0.52	D	2.582,14.60	5.56	2.24	16.02
671	COL5A2	c.470C>T: p.P157L	VUS	2:189957133	0.00010			1.00	D	1.00	D	0.65	M	1.00	D	0.54	D	4.745,26.5	5.98	2.84	17.38
804	COL1A1	c.584C>T: p.A195V	VUS	17:48275526	NA	0.90	T	0.08	B	0.76	D	0.59	L	0.72	N	0.53	D	4.187,21.7	4.10	2.55	14.50
629	COL1A2	c.2123G>A: p.R708Q	VUS	7:94049588	0.00080	0.99	D	1.00	D	1.00	D	0.57	L	1.00	D	0.54	D	4.603,25.1	5.84	2.94	20.53
708	COL3A1	c.C2002A: p.P668T	VUS	2:189863424	NA	0.84	T	0.85	P	1.00	D	0.65	M	1.00	D	0.55	D	3.110,16.39	5.93	2.81	19.95
444	COL1A1	c.G3755A: p.R1252H	VUS	17:48264060	0.00010	1.00	D	0.62	P	0.99	D	0.74	M	1.00	D	0.43	T	3.060,16.21	4.03	2.06	15.09
384	COL1A1	c.3466A>G: p.N1156D	VUS	17:48264441	NA	0.67	T	0.54	P	1.00	D	0.44	N	1.00	D	0.50	D	2.782,15.27	3.70	1.67	11.78
475	TGFBR1	214A>G: p.I72L	VUS	9:101891253	0.00030	0.16	T	0.67	P	1.00	D	0.53	N	1.00	D	0.56	D	2.997,16.00	6.08	2.33	15.63
All Pathogenic	mean					1.00		0.92		1.00		0.81		1.00		0.59		4.35+	5.48	2.59	18.79
	s.d.					0.01		0.26		0.00		0.07		0.00		0.07		0.59+	0.46	0.22	1.34
All Likely Pathogenic	mean					0.99		0.92		1.00		0.70		1.00		0.46		4.17+	4.85	1.93	15.44
	s.d.					0.01		0.15		0.00		0.11		0.00		0.07		0.48+	0.84	0.62	2.11
All VUS	mean					0.70		0.67		0.89		0.60		0.97		0.50		3.04+	4.25	2.05	16.11
	s.d.					0.30		0.38		0.24		0.08		0.09		0.05		1.50+	2.63	0.97	3.50
p (pathogenic vs. VUS)*						< 0.0001		0.0005		0.006		< 0.0001		0.07		0.001		0.009		0.05	

VUS, variant of uncertain significance. Genomic co-ordinates are based on GRCh37/hg19 human reference sequence. Max.Freq., maximum reported minor allele frequency in 1000 genomes (phase 2 release) and the NHLBI exome sequencing project data sets. NA, novel variant. s.d., standard deviation.

*p value shows statistical significance at 5% level (two-tailed Mann-Whitney test)

In silico prediction scores are based on ANNOVAR version 2013aug23, full details available at: <http://www.openbioinformatics.org/annovar/> and refer to the following specific ANNOVAR annotations: Polyphen: "LJB23_Polyphen2_HVAR_score", Mutation Taster: "LJB23_MutationTaster_score_converted", Mutation Assessor: "LJB23_MutationAssessor_score_converted", LRT: "LJB23_LRT_score_converted", FATHMM: "LJB23_FATHMM_score_converted"

Predictive functional scores

SIFT, Polyphen, MutationTaster, MutationAssessor, LRT, FATHMM : all scores converted to 0-1 scale, higher number = higher probability of functional significance

Cadd: shown as [raw score, scaled score]. Raw score: higher number = higher likelihood of deleterious variant. Scaled score: phred-like c-score ($-10 \cdot \log_{10}(\text{rank}/\text{total})$) of variant pathogenicity ranked relative to all possible substitutions of the human genome such that, a scaled score >10 relates to the top 10% of variants ranked for pathogenicity, scaled score of >20 relates to the top 1% of ranked variants.

Qualitative predictions

D, deleterious. T, tolerated; [*Mutation Taster* only: A, disease causing automatic, D, disease causing; N, polymorphism; P, polymorphism automatic]

[*Mutation Assessor* only: H(high), M(medium and L(low) probability of functional impact]

Table S9 Summary of genotype-phenotype correlation in Collagen genes in the EDS cohort

Gene	Initial Clinical Diagnosis ^a					Mean Beighton score	Vascular complication ^b	Collagen ^c abnormality	LM/EM ^c abnormality
	Classical	Vascular	HM	Other EDS	Other HDCT				
<u>Pathogenic variants</u>									
<i>COL1A1</i> / <i>COL1A2</i>					3 ^d	5.5	0/3	1/1	1/1
<i>COL3A1</i>	2	11				7.3	5/13	6/7	5/7
<i>COL5A1</i> / <i>COL5A2</i>	7	1	1			6.3	1/9	2/3	4/5
<u>VUS</u>									
<i>COL1A1</i> / <i>COL1A2</i>		2	6		2	5.7	3/10	1/5 ^e	2/9 ^{e, f}
<i>COL3A1</i>	1		3		1	6.0	2/5	0/2	2/3 ^f
<i>COL5A1</i> / <i>COL5A2</i>	1		6			6.0	2/7	0/2	1/3 ^f

EDS, Ehlers-Danlos syndrome. VUS, variant of uncertain clinical significance; No., number of patients with rare variant in corresponding gene; HDCT, Hereditary disorder of connective tissue; LM, light microscopy; EM, electron microscopy.

a. Initial Clinical Diagnosis refers to most applicable classification at first specialist EDS consultation: numbers shows the presenting clinical diagnoses for variants in each group. **b.** Vascular complication: one or more of the following clinical features at presentation: aortic or peripheral arterial aneurysm, dissection or rupture, cerebral aneurysm / subarachnoid haemorrhage, not including atherosclerotic vascular disease (incidence in mutation negative cases = 31.0%). **c.** numerator: no. patients with abnormality / denominator: number tested for abnormality. **d.** All 3 patients had features of osteogenesis imperfecta (Sillence criteria). **e.** One of these patients (ID 629) had some phenotypic features of EDS/OI overlap, broadening of the pro- α 2(I) band (Collagen I) on SDS-PAGE and possible subtle collagen depletion on LM, but incomplete segregation of phenotype in 7 first-degree relatives tested. **f.** These represent two patients with more than one co-existing rare VUS (Patient ID 38 in *COL3A1* & *COL5A1*; Patient ID 39 in *COL3A1*, *COL1A2*; also *TNXB* gene duplication).